=> d his nofile

(FILE 'REGISTRY' ENTERED AT 12:33:59 ON 04 JAN 2010)

L1	4		ABB=ON OR "GIN A, (14A	KGOLIDE	"GINKGOLIDE A"/CN OR ("GINKGOLIDE A, (10B)-(±)-"/CN OR
L2	1	SEA SPE=ON E GINKGOLIDE	ABB=ON	PLU=ON	"GINKGOLIDE B"/CN
L3	1	SEA SPE=ON E GINKGOLIDE	ABB=ON	PLU=ON	"GINKGOLIDE C"/CN
L4	1	SEA SPE=ON E BILOBALIDE	ABB=ON	PLU=ON	"GINKGOLIDE J"/CN
L5	1			PLU=ON	BILOBALIDE/CN
L6	8		ABB=ON	PLU=ON	(L1 OR L2 OR L3 OR L4 OR L5)
	FILE 'CAPL	JS' ENTERED A	AT 12:36	:30 ON 0	4 JAN 2010
Ь7	1223	SEA SPE=ON E GINKGO BII E E3+ALL		PLU=ON	L6
L8	5267		ABB=ON	PLU=ON	GINKGOACEAE/OBI OR GINKGO BILOBA/OB
L9	513	SEA SPE=ON	ABB=ON	PLU=ON	L8 AND L7
L10		SEA SPE=ON		PLU=ON	L7 (L) (PUR OR THU OR PREP)/RL
L11		SEA SPE=ON		PLU=ON	L10 AND L8
L12		SEA SPE=ON		PLU=ON	CHROMATOG?/OBI
L13	30	SEA SPE=ON	ABB=ON		L12 AND L11
L14	675	SEA SPE=ON	ABB=ON	PLU=ON	TERPENE#/OBI (L) (LACTONE#/OBI OR
		TRILACTONE#/	OBI)		
L15	1196	SEA SPE=ON	ABB=ON	PLU=ON	GINKGOLIDE#/OBI OR BILOBALIDE#/OBI
L16	1740	SEA SPE=ON	ABB=ON	PLU=ON	L14 OR L15
L17		SEA SPE=ON		PLU=ON	L16 AND L8
L18	120	SEA SPE=ON	ABB=ON	PLU=ON	L17 AND L12
L19		SEA SPE=ON		PLU=ON	L18 NOT L13
L20	27729	SEA SPE=ON	ABB=ON	PLU=ON	HYDROGENOLYSIS/OBI OR BENZYLATION/O
		BI			
L21	179933	SEA SPE=ON	ABB=ON	PLU=ON	(COLUMN/OBI OR LIQUID/OBI) (L) L12
L22	1	SEA SPE=ON	ABB=ON	PLU=ON	L19 AND L20
L23		SEA SPE=ON			L19 AND L21
-		D SCAN L22 D BIB			
L24	31	SEA SPE=ON	ABB=ON	PLU=ON	L13 OR L22

FILE 'REGISTRY' ENTERED AT 12:45:10 ON 04 JAN 2010

		E ETHYL ACI	ETATE/CN		
L25	1	SEA SPE=ON	ABB=ON	PLU=ON	"ETHYL ACETATE"/CN
		D RN			
L26	975	SEA SPE=ON	ABB=ON	PLU=ON	141-78-6/CRN
L27	682	SEA SPE=ON	ABB=ON	PLU=ON	L26 AND NC<3
		JS' ENTERED			
L28		SEA SPE=ON			
L29					L28 AND L23
L30	0				L28 AND L24
		E COLUMN C	HROMATOGR	APHY/CT	
		E E3+ALL			
		SEA SPE=ON	ABB=ON	PLU=ON	LIQUID CHROMATOGRAPHY/CT
L32	17		ABB=ON	PLU=ON	L31 AND L23
		D SCAN TI			
		E ALKYLATIO	ON/CT		
		E E3+ALL			
					ALKYLAT?/OBI
L34	0	SEA SPE=ON	ABB=ON	PLU=ON	L33 AND L23
L35		SEA SPE=ON	ABB=ON	PLU=ON	SOLVENT?/BI
L36	10	SEA SPE=ON	ABB=ON	PLU=ON	L23 AND L35
L37	25	SEA SPE=ON	ABB=ON	PLU=ON	L32 OR L36
L38	2	SEA SPE=ON	ABB=ON	PLU=ON	L32 AND L35
		D SCAN TI			
L39	33	SEA SPE=ON	ABB=ON	PLU=ON	L38 OR L24
L40	1	SEA SPE=ON	ABB=ON	PLU=ON	L32 AND ALKYL?/BI
L41	34	SEA SPE=ON	ABB=ON		L40 OR L39
L42	4697	SEA SPE=ON	ABB=ON	PLU=ON	NAKANISHI K?/AU
L43	18	SEA SPE=ON	ABB=ON	PLU=ON	JARACZ S?/AU
L44	1992	SEA SPE=ON	ABB=ON	PLU=ON	MALIK S?/AU
L45	5456	SEA SPE=ON	ABB=ON	PLU=ON	ISHII H?/AU
L46	85	SEA SPE=ON	ABB=ON	PLU=ON	DZYUBA S?/AU
L47	12209	SEA SPE=ON	ABB=ON	PLU=ON	(L42 OR L43 OR L44 OR L45 OR L46)
L48	37	SEA SPE=ON	ABB=ON	PLU=ON	L47 AND L6
L49		SEA SPE=ON	ABB=ON	PLU=ON	L48 AND L12
L50	163	SEA SPE=ON	ABB=ON	PLU=ON	L47 AND L12
L51		SEA SPE=ON			L50 AND L16
L52	5	SEA SPE=ON	ABB=ON	PLU=ON	L49 OR L51
L53	2	SEA SPE=ON	ABB=ON	PLU=ON	L52 NOT L41

FILE 'STNGUIDE' ENTERED AT 12:53:31 ON 04 JAN 2010

=> fil reg FILE 'REGISTRY' ENTERED AT 13:07:33 ON 04 JAN 2010 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 JAN 2010 HIGHEST RN 1200115-43-0 DICTIONARY FILE UPDATES: 3 JAN 2010 HIGHEST RN 1200115-43-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> d que 16
L1
             4 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE A"/CN OR
               ("GINKGOLIDE A, (\pm)-"/CN OR "GINKGOLIDE A, (10B)-(\pm)
               -"/CN OR "GINKGOLIDE A, (14A)-"/CN)
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE B"/CN
L2
L3
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE C"/CN
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE J"/CN
L4
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON BILOBALIDE/CN
L5
1.6
             8 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (L1 OR L2 OR L3 OR
               L4 OR L5)
```

=> d 16 rn cn

- L6 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
- RN 148683-79-8 REGISTRY
- CN 9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione, 3-(1,1-dimethylethyl)hexahydro-4,7b-dihydroxy-8-methyl-, (1R,3S,3aS,4R,6aR,7aR,7bR,8R,10aS,11aS)- (9CI) (CA INDEX NAME) OTHER CA INDEX NAMES:

CN Ginkgolide A, (14α) -

OTHER NAMES:

CN 14-Epiginkgolide A

=> d 16 rn cn 2-8

- L6 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
- RN 119502-58-8 REGISTRY
- CN 9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-

```
b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,
     3-(1,1-dimethylethyl)hexahydro-4,7b-dihydroxy-8-methyl-,
     (1R, 3S, 3aS, 4S, 6aR, 7aR, 7bR, 8S, 10aS, 11aR) -rel- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
    Ginkgolide A, (10\beta)-(\pm)-
CN
L6
     ANSWER 3 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
RN
     119460-49-0 REGISTRY
     Ginkgolide A, (\pm) - (9CI) (CA INDEX NAME)
CN
OTHER CA INDEX NAMES:
     9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan, ginkgolide A deriv.
L6
     ANSWER 4 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
RN
     107438-79-9 REGISTRY
CN
     9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,
     3-(1,1-dimethylethyl)hexahydro-2,4,7b-trihydroxy-8-methyl-,
     (1S, 2R, 3S, 3aS, 4R, 6aR, 7aR, 7bR, 8S, 10aS, 11aS) - (CA INDEX NAME)
OTHER CA INDEX NAMES:
     Ginkgolide A, 7-hydroxy-, (7\beta)-
OTHER NAMES:
     9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,
     3-(1,1-dimethylethyl)hexahydro-2,4,7b-trihydroxy-8-methyl-,
     [1S-(1\alpha, 2\alpha, 3\beta, 3aR*, 4\beta, 6a\alpha, 7a\alpha, 7b\alpha,
     8\alpha, 10a\alpha, 11aR*) | -
CN
     BN 52024
     Ginkgolide J
CN
     ANSWER 5 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
L6
RN
     33570-04-6 REGISTRY
CN
     4H,5aH,9H-Furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-
     trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-,
     (3aS, 5aR, 8R, 8aS, 9R, 10aS) - (CA INDEX NAME)
OTHER CA INDEX NAMES:
     4H,5aH,9H-Furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-
CN
     trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-,
     [5aR-(3aS*,5a\alpha,8\beta,8aS*,9\alpha,10a\alpha)]-
CN
     4H,5aH,9H-Furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-
     trione, 9\alpha-tert-butyl-10,10a\beta-dihydro-8\alpha,9-dihydroxy-,
     (-)-(8CI)
OTHER NAMES:
     (−)-Bilobalide
CN
     Bilobalid
CN
     Bilobalide
     ANSWER 6 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
L6
     15291-77-7 REGISTRY
RN
CN
     9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,
     3-(1,1-dimethylethyl)hexahydro-4,7b,11-trihydroxy-8-methyl-,
     (1R, 3S, 3aS, 4R, 6aR, 7aR, 7bR, 8S, 10aS, 11R, 11aR) - (CA INDEX NAME)
OTHER CA INDEX NAMES:
     5H-Dicyclopenta[b,c]furan-3,5a(6H)-diacetic acid,
     6-tert-butyl-3a-carboxyhexahydro-\alpha5a,1,2,3,5,8-hexahydroxy-\alpha3-
     methyl-, tri-\gamma-lactone (8CI)
     Ginkgolide A, 1-hydroxy-, (1\beta)- (8CI)
OTHER NAMES:
```

```
CN
     9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,
     3-(1,1-dimethylethyl)hexahydro-4,7b,11-trihydroxy-8-methyl-,
     [1R-(1\alpha, 3\beta, 3aS*, 4\beta, 6a\alpha, 7a\alpha, 7b\alpha, 8\alpha,
     10a\alpha, 11\beta, 11aR*) | -
CN
     BN 52021
CN
     BN 52051
CN
     Ginkgolide B
L6
     ANSWER 7 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
     15291-76-6 REGISTRY
RN
CN
     9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,
     3-(1,1-dimethylethyl)hexahydro-2,4,7b,11-tetrahydroxy-8-methyl-,
     (1S, 2R, 3S, 3aS, 4R, 6aR, 7aR, 7bR, 8S, 10aS, 11R, 11aR) - (CA INDEX NAME)
OTHER CA INDEX NAMES:
     5H-Dicyclopenta[b,c]furan-3,5a(6H)-diacetic acid,
CN
     6-tert-butyl-3a-carboxyhexahydro-\alpha5a,1,2,3,5,7,8-heptahydroxy-
     \alpha3-methyl-, tri-\gamma-lactone (8CI)
     9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
CN
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,
     3-tert-butylhexahydro-2,4,7b,11-tetrahydroxy-8-methyl- (8CI)
     Ginkgolide A, 1,7-dihydroxy-, (1\beta,7\beta)-
CN
OTHER NAMES:
     9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
CN
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,
     3-(1,1-dimethylethyl)hexahydro-2,4,7b,11-tetrahydroxy-8-methyl-,
     [1R-(1\alpha, 2\alpha, 3\beta, 3aS*, 4\beta, 6a\alpha, 7a\alpha, 7b\alpha,
     8\alpha, 10a\alpha, 11\alpha, 11aR^*) ] -
     BN 52022
CN
CN
     Ginkgolide C
     ANSWER 8 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
L6
RN
     15291-75-5 REGISTRY
CN
     9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,
     3-(1,1-dimethylethyl) hexahydro-4,7b-dihydroxy-8-methyl-,
     (1R, 3S, 3aS, 4R, 6aR, 7aR, 7bR, 8S, 10aS, 11aS) - (CA INDEX NAME)
OTHER CA INDEX NAMES:
     9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,
     3-tert-butylhexahydro-4,7b-dihydroxy-8-methyl- (8CI)
     Ginkgolide A
CN
OTHER NAMES:
     9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,
     3-(1,1-dimethylethyl) hexahydro-4,7b-dihydroxy-8-methyl-,
     [1R-(1\alpha, 3\beta, 3aS^*, 4\beta, 6a\alpha, 7a\alpha, 7b\alpha, 8\alpha,
     10a\alpha, 11aS*)]-
     BN 52020
CN
CN
     [1R-(1\alpha, 3\beta, 3aS*, 4\beta, 6a\alpha, 7a\alpha, 7b\alpha, 8\alpha,
     10a\alpha, 11aS^*) | -3-(1,1-Dimethylethyl) hexahydro-4,7b-dihydroxy-8-methyl-
     9H-1,7a-(epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-
     b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione
=> d que 125 ;d rn cn 125
L25
               1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "ETHYL ACETATE"/CN
```

```
L25 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN
    141-78-6 REGISTRY
   Acetic acid ethyl ester (CA INDEX NAME)
OTHER CA INDEX NAMES:
   Acetic acid, ester with EtOH (7CI)
OTHER NAMES:
CN Acetic acid, ethyl ester
    Acetic ether
CN
CN
    Acetidin
CN Acetoxyethane
CN Ethyl acetate
CN Ethyl ethanoate
CN EtOAc
CN NSC 70930
CN
    Vinegar naphtha
```

=> d que 127

L26 975 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON 141-78-6/CRN L27 682 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L26 AND NC<3

=> fil caplus FILE 'CAPLUS' ENTERED AT 13:09:20 ON 04 JAN 2010 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Jan 2010 VOL 152 ISS 2
FILE LAST UPDATED: 3 Jan 2010 (20100103/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

```
=> d que 141
             4 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE A"/CN OR
L1
               ("GINKGOLIDE A, (\pm)-"/CN OR "GINKGOLIDE A, (10B)-(\pm)
               -"/CN OR "GINKGOLIDE A, (14A)-"/CN)
L2
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE B"/CN
L3
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE C"/CN
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE J"/CN
L4
L5
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON BILOBALIDE/CN
             8 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (L1 OR L2 OR L3 OR
L6
               L4 OR L5)
L7
          1223 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L6
          5267 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON GINKGOACEAE/OBI OR
L8
               GINKGO BILOBA/OBI
L10
           659 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L7 (L) (PUR OR THU OR
               PREP)/RL
           312 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L10 AND L8
L11
L12
        426805 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON CHROMATOG?/OBI
            30 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L12 AND L11
L13
           675 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON TERPENE#/OBI (L)
L14
               (LACTONE#/OBI OR TRILACTONE#/OBI)
L15
          1196 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON GINKGOLIDE#/OBI OR
               BILOBALIDE#/OBI
          1740 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L14 OR L15
L16
L17
           699 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L16 AND L8
           120 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L17 AND L12
L18
            91 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L18 NOT L13
L19
         27729 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON HYDROGENOLYSIS/OBI OR
L20
               BENZYLATION/OBI
L21
        179933 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON (COLUMN/OBI OR
               LIQUID/OBI) (L) L12
L22
             1 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L19 AND L20
            67 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L19 AND L21
L23
            31 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L13 OR L22
L24
         23072 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON LIOUID CHROMATOGRAPHY/C
L31
L32
            17 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L31 AND L23
L35 1008201 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON SOLVENT?/BI
L38
             2 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L32 AND L35
L39
            33 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L38 OR L24
L40
             1 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L32 AND ALKYL?/BI
            34 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L40 OR L39
L41
=> d que 153
L1
             4 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE A"/CN OR
               ("GINKGOLIDE A, (\pm)-"/CN OR "GINKGOLIDE A, (10B)-(\pm)
               -"/CN OR "GINKGOLIDE A, (14A)-"/CN)
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE B"/CN
L2
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE C"/CN
L3
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE J"/CN
L4
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON BILOBALIDE/CN
L5
L6
             8 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (L1 OR L2 OR L3 OR
               L4 OR L5)
L7
          1223 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L6
L8
          5267 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON GINKGOACEAE/OBI OR
               GINKGO BILOBA/OBI
           659 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L7 (L) (PUR OR THU OR
L10
               PREP)/RL
```

						,	
L11	312	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L10 AND L8
L12	426805	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	CHROMATOG?/OBI
L13	30	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L12 AND L11
L14	675	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	TERPENE#/OBI (L)
		(LA	CTONE#/OBI OF	R TRILAC	TONE#/OB	I)	
L15	1196	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	GINKGOLIDE#/OBI OR
		BIL	OBALIDE#/OBI				
L16	1740	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L14 OR L15
L17	699	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L16 AND L8
L18	120	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L17 AND L12
L19	91	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L18 NOT L13
L20	27729	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	HYDROGENOLYSIS/OBI OR
		BEN	ZYLATION/OBI				
L21	179933	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	(COLUMN/OBI OR
		LIQU	JID/OBI) (L)	L12			
L22	1	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L19 AND L20
L23	67	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L19 AND L21
L24	31	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L13 OR L22
L31	23072	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	LIQUID CHROMATOGRAPHY/C
		T					
L32	17	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L31 AND L23
L35	1008201	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	SOLVENT?/BI
L38	2	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L32 AND L35
L39	33	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L38 OR L24
L40	1	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L32 AND ALKYL?/BI
L41	34	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L40 OR L39
L42	4697	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	NAKANISHI K?/AU
L43	18	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	JARACZ S?/AU
L44	1992	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	MALIK S?/AU
L45	5456	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	ISHII H?/AU
L46	85	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	DZYUBA S?/AU
L47	12209	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	(L42 OR L43 OR L44 OR
		L45	OR L46)				
L48	37	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L47 AND L6
L49	3	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L48 AND L12
L50	163	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L47 AND L12
L51	5	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L50 AND L16
L52	5	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L49 OR L51
L53	2	SEA	FILE=CAPLUS	SPE=ON	ABB=ON	PLU=ON	L52 NOT L41

=> d .ca 141 1-34; d .ca 153 1-2

```
L41 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1192569 CAPLUS <u>Full-text</u>
DOCUMENT NUMBER:
                        151:478871
TITLE:
                        Optimization of extraction technique and validation of
                        developed RP-HPLC-ELSD method for determination of
                        terpene trilactones in Ginkgo biloba
                        leaves
AUTHOR(S):
                        Kaur, Pushpinder; Chaudhary, Abha; Singh, Bikram;
                        Gopichand
CORPORATE SOURCE:
                        Natural Plant Products Division, Institute of
                        Himalayan Bioresource Technology, (CSIR), Palampur,
                        176061, India
SOURCE:
                        Journal of Pharmaceutical and Biomedical Analysis
                         (2009), 50(5), 1060-1064
```

CODEN: JPBADA; ISSN: 0731-7085

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English ED Entered STN: 30 Sep 2009

Terpene trilactones are potent and selective antagonists of platelet activating factor. The present study deals with standardization of efficient extraction method and validation of newly developed simple, sensitive, and rapid reversed phase high performance liquid chromatog. method with evaporative light scattering detection (RP-HPLC-ELSD) method for the quant. determination of ginkgolide A (GA), ginkgolide B (GB), ginkgolide C (GC), ginkgolide J (GJ), and bilobalide (BB) within 8 min in Ginkgo biloba leaf extract The anal. was conducted on a Zorbax RP-C18 column with gradient elution of MeOH-water-tetrahydrofuran. The method was validated for accuracy, precession, limit of detection, and quantification. The drift tube temperature of evaporative light scattering detector was set to 90° and nitrogen flow rate was 1.5 standard liter/min (SLM).

CC 64-2 (Pharmaceutical Analysis) Section cross-reference(s): 63

ST ginkgolide detn RP HPLC ELSD Ginkgo biloba

IT Ginkgo biloba

Natural products, pharmaceutical

Reversed phase HPLC

(extraction technique and validation of RP-HPLC-ELSD method for determination of $\ensuremath{\mbox{\sc determination}}$

terpene trilactones in Ginkgo biloba leaves)

IT Terpenes

RL: ANT (Analyte); PUR (Purification or recovery); ANST (Analytical study); PREP (Preparation)

(lactones, trilactones; extraction technique and validation of RP-HPLC-ELSD method for determination of terpene trilactones in Ginkgo biloba leaves)

IT Liquid chromatographic detectors

(light-scattering, evaporative; extraction technique and validation of RP-HPLC-ELSD method for determination of terpene trilactones in Ginkgo biloba leaves)

IT 15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C 15291-77-7P, Ginkgolide B 33570-04-6P, Bilobalide 107438-79-9P, Ginkgolide J

RL: ANT (Analyte); POR (Purification or recovery); ANST (Analytical study); PREP (Preparation)

(extraction technique and validation of RP-HPLC-ELSD method for determination of $\ensuremath{\mbox{\sc determination}}$

terpene trilactones in Ginkgo biloba leaves)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2009:1146703 CAPLUS Full-text

DOCUMENT NUMBER: 152:6020

TITLE: Separation and purification of bilobalide and

ginkgolides A, B and C from Ginkgo

biloba leaves by high-speed counter-current

chromatography

AUTHOR(S): Su, Jing; Tan, Feng; Li, Lianqiang; Xie, Jun; Feng,

Wei; Chen, Bin

CORPORATE SOURCE: Key Laboratory of Eco-environments in Three Gorged

Reservoir Region (Ministry of Education), Key Laboratory of Plant Ecology and Resources in Three Gorges Reservoir Region, School of Life Science,

Southwest University, Chongqing, 400715, Peop. Rep.

China

SOURCE: Zhongcaoyao (2008), 39(11), 1644-1648

CODEN: CTYAD8; ISSN: 0253-2670

PUBLISHER: Zhongcaoyao Zazhi Bianjibu

DOCUMENT TYPE: Journal LANGUAGE: Chinese ED Entered STN: 21 Sep 2009

Bilobalide and ginkgolides A, B and C from Ginkgo biloba leaves were separated and purified. Firstly, the extract of G. biloba leaves was purified by extraction of acetic ether, D-101 macroporous resin and Al2O3 (pH 4) to obtain the crude extract of lactones. Then, the crude extract was further purified by high-speed counter-current chromatog. (HSCCC) to prepare the monomers of bilobalide and ginkgolides A, B and C. The crude extract of lactones with the purity of 44.98% was obtained by extraction with 25% alc., acetic ether, D-101 macroporous resin and Al2O3 (pH 4). When the crude extract was further purified by HSCCC, the different purities of bilobalide and ginkgolides A, B and C were got. The maximal purities of bilobalide and ginkgolides A, B and C were 98.3%, 98.9%, 98.8% and 98.4%, resp. This method, which is simple and rapid, provides a new way to sep. and purify the lactones from G. biloba leaves.

CC 11-1 (Plant Biochemistry)
 Section cross-reference(s): 9

IT Ginkgo biloba

Leaf

(separation and purification of bilobalide and ginkgolides A, B and C from Ginkgo biloba leaves by high-speed counter-current chromatog.)

IT Lactones

RL: BSU (Biological study, unclassified); BIOL (Biological study) (separation and purification of bilobalide and ginkgolides A, B and C from Ginkgo biloba leaves by high-speed counter-current chromatog.)

IT 15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C 15291-77-7P, Ginkgolide B 33570-04-6P, Bilobalide

RL: BSU (Biological study, unclassified); FUR (Purification or

recovery); BIOL (Biological study); PREP (Preparation)

(separation and purification of bilobalide and ginkgolides A, B and C from Ginkgo biloba leaves by high-speed counter-current chromatog.)

L41 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2009:816643 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 151:254321

TITLE: Metabolite profiling of plant extracts by ultra-high-pressure liquid chromatography at

elevated temperature coupled to time-of-flight mass

spectrometry

AUTHOR(S): Grata, Elia; Guillarme, Davy; Glauser, Gaetan;

Boccard, Julien; Carrupt, Pierre-Alain; Veuthey,

Jean-Luc; Rudaz, Serge; Wolfender, Jean-Luc

CORPORATE SOURCE: School of Pharmaceutical Sciences, University of

Lausanne, University of Geneva, Geneva, 1211, Switz.

SOURCE: Journal of Chromatography, A (2009), 1216(30),

5660-5668

CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English ED Entered STN: 08 Jul 2009

Nizal Chandrakumar 10/579,162 AΒ Detailed metabolite profiling of crude plant exts., mandatory for both quality control and metabolomics purposes, requires high-resolution separation and sensitive detection with a reasonable sample throughput. In this respect, the use of ultra-high-pressure liquid chromatog. (UHPLC) working at high temperature (HT) and coupled to time-of-flight mass spectrometry (TOF-MS) was evaluated in the present study in terms of achievable peak capacities for given anal. times. Prior to the anal. of complex mixts., the effects of TOF-MS detection on peak capacity were evaluated, and a loss of 15-30% compared to UV was observed due to the addnl. band broadening generated by this detector. Exts. from a model plant Arabidopsis thaliana and from a widely used phytochem. preparation Ginkgo biloba, as well as a standard mixture of representative natural products (NPs), were analyzed. As expected from the theory, the increase in mobile phase temperature of \leq 90 °C for the profiling of exts. containing metabolites spread over a large polarity range (e.g., Arabidopsis thaliana) generated similar peak capacities to those obtained at room temperature, but with a 2- to 3-fold reduction in anal. time, demonstrating the power of this approach for such applications. On the other hand, for the anal. of more polar exts. (e.g., Ginkgo biloba), the use of higher temperature was not beneficial, as it induced a significant decrease in retention, and thus resolving power, because of the increase in elution strength. The use of HT-UHPLC-TOF-MS raised the question of NP stability under high temperature conditions. This work demonstrated that no apparent degradation was evidenced at high temperature for a representative mixture of NPs and also for the different metabolites detected in the selected plant CC 64-2 (Pharmaceutical Analysis) ΙΤ Arabidopsis thaliana Decomposition Decomposition kinetics Ginkgo biloba Natural products, pharmaceutical Polarity Thermal stability (metabolite profiling of plant exts. by UPLC at elevated temperature coupled to TOF mass spectrometry) 50-55-5P, Reserpine 117-39-5P, Quercetin 149-91-7P, Gallic acid, ΙT 153-18-4P, Rutin 305-01-1P, Esculetin 476-66-4P, Ellagic analvsis

acid 497-76-7P, Arbutin 520-18-3P, Kaempferol 521-62-0P, Frangulin A 531-75-9P, Esculin 1415-73-2P, Aloin 11021-13-9P, Ginsenoside Rb2 14101-04-3P, Franqulin B 15291-76-6P 22888-70-6P, Silibinin 25429-38-3P, Coumaric acid 94492-24-7P, 2'-Acetylacteoside RL: ANT (Analyte); PRP (Properties); PUR (Purification or recovery); ANST (Analytical study); PREP (Preparation)

(metabolite profiling of plant exts. by UPLC at elevated temperature coupled

to TOF mass spectrometry)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS 33

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN 2009:694898 CAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: 151:235418

TITLE: Liquid chromatography/atmospheric pressure

> chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral

administration of its phospholipidic complex

Rossi, Rossana; Basilico, Fabrizio; Rossoni, Giuseppe; AUTHOR(S):

Riva, Antonella; Morazzoni, Paolo; Mauri, Pier Luigi CORPORATE SOURCE: Institute for Biomedical Technologies, Proteomics and

Metabolomics Unit, CNR, Segrate, Milan, 20090, Italy

SOURCE: Journal of Pharmaceutical and Biomedical Analysis

(2009), 50(2), 224-227

CODEN: JPBADA; ISSN: 0731-7085

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English ED Entered STN: 09 Jun 2009

Standardized exts. of Ginkgo biloba L. leaves are widely used in clin. AΒ practice for the symptomatic treatment of mild to moderate dementia syndromes, cerebral insufficiency and for the enhancement of cognitive function. The main active components present in G. biloba exts. are flavonol-glycosides and terpene-lactones. In recent investigations, the sesquiterpene trilactone bilobalide has been described to exert an interesting neuroprotective effect when administered systemically to exptl. animals. Oral administration of terpene-lactones either as standardized exts. or purified products is characterized by a low bioavailability. While preparing phospholipidic complex of G. biloba exts. or bilobalide, plasma levels of terpenes and sesquiterpene increase. In the present study, phospholipidic complex of bilobalide (IDN 5604) has been administered orally to rats and bilobalide levels have been determined in plasma and brain by means of a validated method based on liquid chromatog. coupled to atmospheric pressure chemical ionization ion trap mass spectrometry (LC/APCI-ITMS). Due to its sensitivity (about 3 pmol/mL) and specificity, LC/APCI-ITMS method proved to be a very powerful tool for pharmacokinetic studies of Ginkgo terpene-lactones. The results of the present study clearly confirm the improvement of oral bioavailability of bilobalide administered as phospholipidic complex and, for the first time, demonstrate the detection of significative amts. of bilobalide in brain. This last finding agrees with the neuroprotective activity observed for bilobalide.

CC 1-1 (Pharmacology)

Section cross-reference(s): 63

ST liq chromatog atm pressure spectrometry bilobalide phospholipid complex Phytosome

(atmospheric pressure chemical; liquid chromatog./atmospheric pressure chemical

ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex)

IT Blood analysis

Blood plasma

Brain

Drug bioavailability

Ginkgo biloba

Liquid chromatography

Oral drug delivery systems

Pharmacokinetics

(liquid chromatog./atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex)

IT Sesquiterpenes

RL: ANT (Analyte); PKT (Pharmacokinetics); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(liquid chromatog./atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex)

IT 33570-04-6, Bilobalide

RL: ANT (Analyte); PKT (Pharmacokinetics); TAU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(liquid chromatog./atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex)

IT 153049-42-4, IDN 5604

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(liquid chromatog./atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2009:506604 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 150:523480

TITLE: Method for separating and extracting ginkgolide b from

Ginkgo biloba leaves

INVENTOR(S): Sun, Lili; Luo, Zenggui; Tang, Jiangming; Li, Zhenzhi PATENT ASSIGNEE(S): Guilin Zhenda Bio-Tech Co., Ltd., Peop. Rep. China SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 7pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101412725	A	20090422	CN 2007-10050245	20071015
PRIORITY APPLN. INFO.:			CN 2007-10050245	20071015

ED Entered STN: 28 Apr 2009

The title method comprises (1) extracting ginkgo biloba leaves with 60-80%, 30-55%, and 10-25% ethanol as sequence at 50-70°C, combining extracting liquid, reclaiming ethanol to obtain concentrated extracting liquid; (2) extracting concentrated extracting liquid with Et acetate for 3 times, reclaiming organic phase, concentrating to obtain extract gum; (3) diluting, loading on selective polar non-porous adsorption resin column ADS-15, ADS-17, or ADS-F8, eluting with 50-70% ethanol, reclaiming ethanol, crystallizing with 50-80% ethanol to obtain ginkgolide compds.; (4) loading ginkgolide compds. on silica gel column, eluting with n-hexane and Et acetate (9:1-2:8) mixed solution, collecting eluting liquid rich in ginkgolide B; (5) reclaiming solvent of eluting liquid, and crystallizing with ethanol to obtain ginkgolide B. This invention has simple technol., low production cost, high product purity, and is fit for com. process.

CC 63-5 (Pharmaceuticals)

ST solvent extn chromatog ginkgolide Ginkgo biloba

IT Chromatography

Ginkgo biloba

Solvent extraction

(method for separating and extracting ginkgolide b from Ginkgo biloba leaves)

IT 64-17-5, Ethanol, uses 110-54-3, n-Hexane, uses 141-78-6, Ethyl acetate, uses

RL: NUU (Other use, unclassified); USES (Uses) (method for separating and extracting ginkgolide b from Ginkgo

biloba leaves)
IT 15291-77-79, Ginkgolide b

RL: PUR (Purification or recovery); PREP (Preparation) (method for separating and extracting ginkgolide b from Ginkgo

biloba leaves)

L41 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:506596 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 150:523458

TITLE: Method for extraction of ginkgolides compound from

ginkgo biloba leaves

INVENTOR(S): Sun, Lili; Luo, Zenggui; Tang, Jiangming; Li, Zhenzhi Guilin Zhenda Bio-Tech Co., Ltd., Peop. Rep. China PATENT ASSIGNEE(S): Faming Zhuanli Shenging Gongkai Shuomingshu, 6pp. SOURCE:

CODEN: CNXXEV

DOCUMENT TYPE: Patent Chinese LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101412724	A	20090422	CN 2007-10050241	20071015
PRIORITY APPLN. INFO.:			CN 2007-10050241	20071015

ED Entered STN: 28 Apr 2009

The method comprises extracting Ginkgo biloba leaves with 8-10-fold 60-80% AΒ ethanol, 6-8-fold 30-55% ethanol and 5-7-fold 10-25% ethanol in turn at 50-70°C each for 1-3 h, merging the extract liquid, recovering ethanol, diluting with water, extracting with Et acetate thrice, concentrating, diluting with water, purifying on selective nonporous adsorbent resin (such as ADS-15, ADS-17 or ADS-F8) column with 50-70% ethanol as eluent, recovering ethanol, and recrystg. with 50-80% ethanol to obtain the title compound containing ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J and bilobalide. method has the advantages of high yield, simple extraction process, low cost, high purity in >60%, and suitability for industrialized production

CC 63-4 (Pharmaceuticals)

ST ginkgolide ginkgo biloba solvent extn chromatog

ΙT

Chromatography

Ginkgo biloba Solvent extraction

> (method for extraction of ginkgolides compound from ginkgo biloba leaves)

64-17-5, Ethanol, uses 141-78-6, Ethyl acetate, uses ΙT

RL: NUU (Other use, unclassified); USES (Uses)

(method for extraction of ginkgolides compound from ginkgo biloba leaves)

15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C

15291-77-7P, Ginkgolide B 33570-04-6P, Bilobalide

107438-79-9P, Ginkgolide J

RL: PUR (Purification or recovery); PREP (Preparation)

(method for extraction of ginkgolides compound from ginkgo biloba leaves)

L41 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2009:506595 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 150:523479

TITLE: Method for extracting ginkgolide c from ginkgo

biloba leaf

INVENTOR(S): Sun, Lili; Luo, Zenggui; Tang, Jiangming; Li, Zhenzhi Guilin Zhenda Bio-Tech Co., Ltd., Peop. Rep. China PATENT ASSIGNEE(S): SOURCE: Faming Zhuanli Shenging Gongkai Shuomingshu, 7pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

ED Entered STN: 28 Apr 2009

AB The title method comprises (1) performing repeated extraction on Ginkgo biloba leaves with ethanol orderly from low concentration to high concentration, combining extractive liquors, and recovering alc.; (2) extracting with Et acetate, and recovering solvent to obtain extract; (3) separating on selective polar nonporous adsorbent resin column with ethanol as eluent, recovering ethanol, and crystallizing in ethanol to obtain ginkgolides; (4) separating ginkgolides on silica gel column with hexane-Et acetate (9:1-2:8, volume/volume) as eluent; and (5) recovering solvent and crystallizing in ethanol. The inventive method has the advantages of simple process, low production cost, high purity, and suitability for mass production

CC 63-5 (Pharmaceuticals)

ST solvent extn chromatog ginkgolide ginkgo biloba

IT Chromatography

Ginkgo biloba

(method for extracting ginkgolide c from ginkgo biloba leaf)

IT 64-17-5, Ethanol, uses 110-54-3, Hexane, uses 141-78-6, Ethyl acetate, uses

RL: NUU (Other use, unclassified); USES (Uses) (method for extracting ginkgolide c from ginkgo biloba leaf)

IT 15291-76-6P, Ginkgolide c

RL: PUR (Purification or recovery); PREF (Preparation) (method for extracting ginkgolide c from ginkgo biloba leaf)

L41 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2009:506569 CAPLUS $\underline{\text{Full-text}}$

DOCUMENT NUMBER: 150:523478

TITLE: Method for extracting and separating ginkgolide j from

Ginkgo biloba leaves

INVENTOR(S): Sun, Lili; Luo, Zenggui; Tang, Jiangming; Li, Zhenzhi PATENT ASSIGNEE(S): Guilin Zhenda Bio-Tech Co., Ltd., Peop. Rep. China SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 7pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

CN 101412723 A 20090422 CN 2007-10050240 20071015

PRIORITY APPLN. INFO:: CN 2007-10050240 20071015

ED Entered STN: 28 Apr 2009

AB The method comprises (1) extracting Ginkgo biloba leaves with different concns. of ethanol at 50-70°C, combining, recovering ethanol to obtain concentrated extracted solution; (2) adding Et acetate, extracting, recovering organic phase, concentrating; (3) diluting, passing through selective polar non-porous adsorbent resin column, eluting with ethanol, recovering ethanol

from eluent, crystallizing with ethanol to obtain ginkgolides; (4) purifying on silica gel column, eluting with the mixture of n-hexane and Et acetate, collecting eluent; and (5) collecting solvent in eluent, and crystallizing with ethanol to obtain ginkgolide J. The method is simple and easy in industrial production, and has low preparation cost. The product has high purity.

CC 63-5 (Pharmaceuticals)

ST solvent extn chromatog ginkgolide Ginkgo biloba

IT Chromatography

Ginkgo biloba

Solvent extraction

(method for extracting and separating ginkgolide j from Ginkgo biloba leaves)

IT 64-17-5, Ethanol, uses 141-78-6, Ethyl acetate, uses

RL: NUU (Other use, unclassified); USES (Uses)

(method for extracting and separating ginkgolide j from Ginkgo biloba leaves)

IT 107438-79-9P, Ginkgolide j

RL: PUR (Purification or recovery); PREP (Preparation) (method for extracting and separating ginkgolide j from Ginkgo biloba leaves)

L41 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2009:429568 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 152:378

TITLE: Simultaneous determination of plasma ginkgolide A and

B by gas chromatography-mass spectrometry and the pharmacokinetics in beagle dogs

AUTHOR(S): Wu, Qiong-shi; Di, Bin; Wen, Hong-liang; Cheng,

Ming-chuan; Liu, Wen-ying

CORPORATE SOURCE: Department of Pharmacy, Hainan Provincial People's

Hospital, Haikou, 570311, Peop. Rep. China

SOURCE: Zhongguo Xinyao Zazhi (2009), 18(4), 365-368,359

CODEN: ZXZHA6; ISSN: 1003-3734

PUBLISHER: Zhongguo Xinyao Zazhi Youxian Gongsi

DOCUMENT TYPE: Journal LANGUAGE: Chinese ED Entered STN: 10 Apr 2009

- AB The objective of the paper is to develop a method for the simultaneous determination of ginkgolide A and B in plasma, and investigate the pharmacokinetics in beagle dogs. Methyltestosterone (mt) was selected as the internal standard Chromatog. anal. was achieved after solid-phase extraction and derivatization with bis (trimethylsilyl) trifluoroacetamide. The assay linear calibration range was 1-80μg·L-1 for both ginkgolide A and ginkgolide B. The limit of quantitation was 1 μg·L-1 for both ginkgolide A and B. The extraction recoveries were over 85%. Both the intra-day and inter-day coeffs. of variation were below 10%. The method was applied to the determination of ginkgolide A and B in plasma samples from 5 male beagle dogs after a single oral administration of ginkgo tablets (Yinxingye Pian). This method is simple, rapid and sensitive; no interferences from endogenous substances in the analyte can be detected. This is an important method in the study of pharmacokinetics for ginkgolide A and B.
- CC 1-2 (Pharmacology)
- IT Mass spectrometry

(gas chromatog. combined with; simultaneous determination of plasma ginkgolide A and B by gas chromatog.-mass spectrometry and pharmacokinetics in beagle dogs)

IT Gas chromatography

(mass spectrometry combined with; simultaneous determination of plasma

ginkgolide A and B by gas chromatog.-mass spectrometry and pharmacokinetics in beagle dogs)

IT Blood plasma

Ginkgo biloba

Pharmacokinetics

(simultaneous determination of plasma ginkgolide A and B by gas chromatog.-mass spectrometry and pharmacokinetics in beagle dogs) $\frac{1}{2} \left(\frac{1}{2} \right) \left$

IT Extraction

(solid-phase; simultaneous determination of plasma ginkgolide ${\tt A}$ and ${\tt B}$ by gas

chromatog.-mass spectrometry and pharmacokinetics in beagle dogs)

IT 15291-75-5, Ginkgolide A 15291-77-7, Ginkgolide B RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(simultaneous determination of plasma ginkgolide A and B by gas chromatog.-mass spectrometry and pharmacokinetics in beagle dogs)

L41 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2009:375002 CAPLUS Full-text

DOCUMENT NUMBER: 150:431502

TITLE: Method for separating and purifying ginkgolides and

 $\label{localide} \mbox{bilobalide monomer from Chinese medicine Ginkgo}$

INVENTOR(S): Zhang, Li; Yang, Bing; Dong, Weizhen; Xia, Ke

PATENT ASSIGNEE(S): Chendu Push Biotechnology Co., Ltd., Peop. Rep. China SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 10pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101392000	A	20090325	CN 2008-10046162	20080925
PRIORITY APPLN. INFO.:			CN 2008-10046162	20080925

ED Entered STN: 31 Mar 2009

The title method comprises of: (1) weighing ginkgo leaf, adding 30-50 volume% AΒ ethanol solution, stirring for dissoln. at 40-60 °C, standing for 2 h, pouring supernatant out, adding petroleum ether (boiling range of 60-90 °C), extracting for three times, recovering petroleum ether, and discarding remnant, removing ginkgoic acid, (2) vacuum-concentrating water phase obtained in step 1 at 60 °C to recover organic reagent, adding Et acetate to water solution, extracting for three times, combining Et acetate phases, backextracting with water for two times, and vacuum-concentrating at 60 °C to obtain total terpene lactones, (3) dissolving in 80 volume% methanol, and performing microfiltration, (4) high-efficiency separating methanol solution of total terpene lactones via an HPLC column to resp. collect solns. of ginkgolides A, B, C and J and bilobalide monomer, and (5) vacuum-concentrating at 50-60 °C to recover methanol, adsorbing with AB-8 macroporous resin, desorbing with 95% ethanol, vacuum-concentrating, and vacuum-drying with coexistence of phosphorus pentoxide to obtain ginkgolides A, B, C and J and bilobalide monomer with purity more than 98%. The method has the advantages of high production amount, good product quality, high yield and low cost, and is suitable for industrialized production

CC 63-4 (Pharmaceuticals)

IT Preparative liquid chromatography

(high-performance reversed-phase; method for separating and purifying

 $$\operatorname{ginkgolides}$$ and bilobalide monomer from Chinese medicine Ginkgo) IT $% \operatorname{Ginkgo}$ biloba

Natural products, pharmaceutical

(method for separating and purifying ginkgolides and bilobalide monomer from $% \left(1\right) =\left(1\right) +\left(1\right$

Chinese medicine Ginkgo)

IT 15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C 15291-77-7P, Ginkgolide B 33570-04-6P, Bilobalid 107438-79-9P, Ginkgolide J

RL: ANT (Analyte); PUR (Purification or recovery); TAU (Therapeutic use); ANST (Analytical study); BIOL (Biological study);

PREP (Preparation); USES (Uses)

(method for separating and purifying ginkgolides and bilobalide monomer

from

Chinese medicine Ginkgo)

L41 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2009:231907 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 150:406783

TITLE: Chemical analysis and quality control of

Ginkgo biloba leaves, extracts, and

phytopharmaceuticals

AUTHOR(S): van Beek, Teris A.; Montoro, Paola

CORPORATE SOURCE: Laboratory of Organic Chemistry, Natural Products

Chemistry Group, Wageningen University, Wageningen,

6703 HB, Neth.

SOURCE: Journal of Chromatography, A (2009), 1216(11),

2002-2032

CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English ED Entered STN: 26 Feb 2009

Entered STN: 26 Feb 2009 A review. The chemical anal. and quality control of Ginkgo leaves, exts., AΒ phytopharmaceuticals and some herbal supplements is comprehensively reviewed. The review is an update of a similar, earlier review in this journal. Since 2001 over 3000 papers on Ginkgo biloba have appeared, and about 400 of them pertain to chemical anal. in a broad sense and are cited herein. The more important ones are discussed and, where relevant, compared with the best methods published prior to 2002. In the same period over 2500 patents were field on Ginkgo and the very few related to anal. are mentioned as well. Important constituents include terpene trilactones, i.e. ginkgolide A, B, C, J and bilobalide, flavonol glycosides, biflavones, proanthocyanidins, alkylphenols, simple phenolic acids, 6-hydroxykynurenic acid, 4-0methylpyridoxine and polyprenols. In the most common so-called "standardized" Ginkgo exts. and phytopharmaceuticals several of these classes are no longer present. About 130 new papers deal with the anal. of the terpene trilactones. They are mostly extracted with MeOH or water or mixts. thereof. Supercrit. fluid extraction and pressurized water extraction are also possible. Sample clean-up is mostly by liquid-liquid extraction with Et acetate although no sample clean-up at all in combination with LC/MS/MS is gaining in importance. Separation and detection can be routinely carried out by RP-HPLC with ELSD, RI or MS, or by GC/FID or GC/MS after silylation. Hydrolysis followed by LC/MS allows the simultaneous anal. of terpene trilactones and flavonol aglycons. No quant. procedure for all major flavonol glycosides has yet been published because they are not com. available. The quantitation of a few available glycosides was carried out but does not serve a real purpose. After acidic hydrolysis to the aglycons quercetin, kaempferol, and isorhamnetin and separation by HPLC, quantitation is straightforward and yields by recalcn. an estimation of the original total flavonol glycoside content. A profile of the

genuine flavonol glycosides can detect poor storage or adulteration. Although the toxicity of Ginkgo alkylphenols upon oral administration has never been undoubtedly proven, most suppliers limit their content in exts. to 5 ppm and dozens of papers on their anal. were published. One procedure in which a methanolic extract is directly injected on a C8 HPLC column appears superior in terms of sensitivity (<5 ppm), separation, simplicity, and validation and will be incorporated in the European Pharmacopoeia. Alternatively GC/MS and ELISA methods can be used. A sharp contrast to the plethora of papers on terpene trilactones, flavonol glycosides, and ginkgolic acids forms the low number of papers on biflavones, proanthocyanidins, simple phenolics, simple acids, and other constituents that make up the remaining 70% of Ginkgo standardized exts. More research in this direction is clearly needed. For the anal. of Ginkgo proanthocyanidins (7%) for instance, no reliable assays are yet existing. Finally the growing literature on pharmacokinetic and fingerprinting studies of Ginkgo is briefly summarized.

CC 64-0 (Pharmaceutical Analysis)
 Section cross-reference(s): 63

ST review Ginkgo biloba quality control analysis std

IT Pharmacopeias

(European; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Phenols, analysis

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(alkyl; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Flavones

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(biflavones; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Gas chromatography

Natural products, pharmaceutical

Quality control

Reversed phase HPLC

(chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Proanthocyanidins

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(chemical anal. and quality control of Ginkgo biloba

leaves, exts., and phytopharmaceuticals)

IT Liquid chromatography

(combined with tandem mass spectrometry; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Glycosides

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(flavonoid; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Terpenes, analysis

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(lactones; chemical anal. and quality control of Ginkgo

biloba leaves, exts., and phytopharmaceuticals)

IT Ginkgo biloba

(leaf; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Tandem mass spectrometry

(liquid chromatog., combined with; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

ΙT Carboxylic acids, analysis

> RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(phenolic; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

ΙT Alcohols, analysis

Isoprenoids

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(polyprenols; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

ΤT Extraction

(supercrit.; chemical anal. and quality control of Ginkgo

biloba leaves, exts., and phytopharmaceuticals)

THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD OS.CITING REF COUNT: 6

(6 CITINGS)

REFERENCE COUNT: 589 THERE ARE 589 CITED REFERENCES AVAILABLE FOR

THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L41 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2008:1414342 CAPLUS Full-text

DOCUMENT NUMBER: 150:11255

Quality control method of Chinese medicine TITLE:

Xinshuningpian

INVENTOR(S): Huang, Xiamin; Feng, Qianling; Chen, Ying; Mai, Yanxia PATENT ASSIGNEE(S): Guangzhou Qixing Pharmaceutical Co., Ltd., Peop. Rep.

China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 12pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent Chinese LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101306081	A	20081119	CN 2008-10029027	20080626
PRIORITY APPLN. INFO.:			CN 2008-10029027	20080626

Entered STN: 25 Nov 2008 ED

The title method comprises of: (1) identifying total flavone glycosides of Ginkgo biloba leaf in Xinshuningpian by TLC, (2) identifying terpene lactones of Ginkgo biloba by TLC, (3) identifying stachydrine hydrochloride by TLC, (4) identifying Herba Siegesbeckia by TLC, and (5) determining puerarin content by HPLC. The inventive quality control method has improved specificity and stability, and ensures the effectiveness of Xinshuningpian.

CC 64-2 (Pharmaceutical Analysis)

ΙΤ Ginkgo biloba

HPLC

ΙT

Leonurus japonicus Pharmaceutical tablets Quality control

Siegesbeckia orientalis

Solvent extraction

TLC (thin layer chromatography)

(quality control method of Chinese medicine Xinshuningpian) 3681-99-0, Puerarin 4136-37-2, Stachydrine hydrochloride

```
15291-75-5, Ginkgolide A
                               15291-76-6, Ginkgolide C
     15291-77-7, Ginkgolide B
     RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical
     study); BIOL (Biological study); USES (Uses)
        (quality control method of Chinese medicine Xinshuningpian)
L41 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:382924 CAPLUS Full-text
DOCUMENT NUMBER:
                        149:61863
                        Study on the technology for extraction and isolation
TITLE:
                         of ginkgolides
                         Li, Baomin; Song, Yabing; Yuan, Cheng; Lu, Jianan;
AUTHOR(S):
                         Liu, Yonglin; Sun, Hong; Zong, Zhimin; Xiao, Hongbin
CORPORATE SOURCE:
                         School of Chemical Engineering, China University of
                        Mining and Technology, Xuzhou, 221008, Peop. Rep.
SOURCE:
                        Huagong Shikan (2007), 21(12), 21-24
                        CODEN: HUSHFT; ISSN: 1002-154X
                        Huagong Shikan Zazhishe
PUBLISHER:
DOCUMENT TYPE:
                        Journal
LANGUAGE:
                        Chinese
   Entered STN: 28 Mar 2008
ED
     Ginkqolide A, B, C and bilobalide (GA, GB, GC and BB for short) had different
     polarities and could by dissolved in different organic solvents. EGB was
     dissolved by acetone, Et acetate and Et alc. in turn and then treated them
     with column chromatog., and GA, GB, GC and BB valuable components in medicine
     could be got, whose concns. were over 80% and they could be separated one by
     one.
CC
     63-4 (Pharmaceuticals)
    Chromatography
     Dissolution
     Extraction
      Ginkgo biloba
     HPLC
     Purity
     TLC (thin layer chromatography)
        (study on the technol. for extraction and isolation of ginkgolides)
     15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C
     15291-77-7P, Ginkgolide B 33570-04-6P, Bilobalide
     RL: PUR (Purification or recovery); THU (Therapeutic
     use); BIOL (Biological study); PREP (Preparation); USES
        (study on the technol. for extraction and isolation of ginkgolides)
OS.CITING REF COUNT: 1
                               THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
                               (1 CITINGS)
L41 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:
                         2007:1484134 CAPLUS Full-text
DOCUMENT NUMBER:
                         148:128060
TITLE:
                        Method for extracting Ginkgo extracts with low content
                         of ginkgolic acid
INVENTOR(S):
                        Yuan, Ganjun; Liu, Junbao; Chen, Zhibin; Tu, Rong;
                         Huang, Hongqian; Su, Qiuling
PATENT ASSIGNEE(S):
                        Hainan Medical College, Peop. Rep. China
SOURCE:
                        Faming Zhuanli Shenqing Gongkai Shuomingshu, 9pp.
                        CODEN: CNXXEV
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101091730	А	20071226	CN 2006-10093940	20060623
PRIORITY APPLN. INFO.:			CN 2006-10093940	20060623

ED Entered STN: 31 Dec 2007

AΒ The process consists of the following steps: (1) extracting Ginkgo biloba leaves with 25-95% ethanol or 30-100% methanol, concentrating, diluting with water, adjusting pH lee than 5 with inorg. acid or organic acid, and filtering, (2) loading on a macroporous absorbent resin column, and eluting with water-containing ethanol or methanol, (3) extracting eluent with lowpolarity organic solvent, concentrating, and drying to obtain Ginkgo biloba exts. (GBE) with low content of ginkgolic acid. The GBE with low content of ginkgolic acid can also be obtained by concentrating the eluate in step 2, drying as raw material, dissolving with 0-95% ethanol or 0-100% methanol, extracting with low-polarity organic solvent, concentrating, and drying, or by concentrating the eluate in step 2, drying as raw material, dissolving with 0-95% ethanol or 0-100% methanol, adsorbing on macroporous adsorbent resin column, eluting with 30-90% methanol or ethanol, concentrating, and drying. The contents of total flavones of Ginkgo, ginkgolides and ginkgolic acid are 28-40%, 6-14% and & 5 ppm, resp.

CC 63-4 (Pharmaceuticals)

IT Ginkgo biloba

Liquid chromatography Solvent extraction Solvent naphtha

(method for extracting Ginkgo exts. with low content of ginkgolic acid)

IT 15291-75-5P, Ginkgolide A 15291-77-7P, Ginkgolide B RL: PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(method for extracting Ginkgo exts. with low content of ginkgolic acid)

L41 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2007:1081728 CAPLUS Full-text

DOCUMENT NUMBER: 147:455299

TITLE: Immunoadsorption chromatography method for

extracting ginkgolide B

INVENTOR(S): Yu, Zhou

PATENT ASSIGNEE(S): Nanchang University, Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 5pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101041661 PRIORITY APPLN. INFO.:	A	20070926	CN 2007-10051805 CN 2007-10051805	20070402 20070402

ED Entered STN: 27 Sep 2007

AB The title method comprises the steps of: (1) extracting gingkgo leaves with 90% ethanol (3 times of the gingkgo leaves) for 3 times, and concentrating with a rotary evaporator to remove ethanol and obtain the extract, and (2) loading the extract on an immune affinity chromatog. column, washing with phosphate buffer solution for 3 times, and eluting with methanol to obtain ginkgolide B.

CC 63-4 (Pharmaceuticals)

Section cross-reference(s): 9, 28

Nizal Chandrakumar 10/579,162 ST Ginkgo leaf ginkgolide B immunoadsorption chromatog prepn ΙT Ovalbumin RL: NUU (Other use, unclassified); USES (Uses) (as protein carrier; immunoadsorption chromatog. method for extracting ginkgolide B) ΙT Albumins, uses RL: NUU (Other use, unclassified); USES (Uses) (bovine, as protein carrier; immunoadsorption chromatog. method for extracting ginkgolide B) ΙT Ginkgo biloba Immunoaffinity chromatography Leaf (immunoadsorption chromatog, method for extracting ginkgolide B) Antibodies and Immunoglobulins ТТ RL: NUU (Other use, unclassified); USES (Uses) (monoclonal, to ginkgolide B; immunoadsorption chromator. method for extracting ginkgolide B) Glass beads ΤТ RL: NUU (Other use, unclassified); USES (Uses) (porous, porus; immunoadsorption chromatog, method for extracting ginkgolide B) 9004-34-6, Cellulose, uses ΤT RL: NUU (Other use, unclassified); USES (Uses) (as solid carrier; immunoadsorption obromatog, method for extracting ginkgolide B) 9003-05-8, Polyacrylamide 9012-36-6, Sepharose 9014-76-0, Sephadex ΙT RL: NUU (Other use, unclassified); USES (Uses) (immunoadsorption chromatog, method for extracting ginkgolide B) 15291-77-7P, Ginkgolide b ΙT RL: PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (immunoadsorption chromatog, method for extracting ginkgolide B) L41 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2007:675848 CAPLUS <u>Full-text</u> DOCUMENT NUMBER: 147:125785 TITLE: Manufacture and application of traditional Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases Yu, Wenfeng INVENTOR(S): Beijing Qiyuanyide Medicine Institute, Peop. Rep. PATENT ASSIGNEE(S): China

SOURCE: Faming Zhuanli Shenging Gongkai Shuomingshu, 12pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent Chinese LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE A 20070620 CN 2005-10134201 20051212 CN 2005-10134201 20051212 CN 1981794 PRIORITY APPLN. INFO.: ED Entered STN: 22 Jun 2007

AB The title medicinal composition is composed of (by%) total saponins of Panax ginseng 1-99, ginkgolides 99-1, and adjuvants. The medical composition can be prepared into injections, infusions, injection powders, tablets, capsules, granules, dripping pills, pills, oral solns., soft capsules, etc. The medical composition can be used for preparing drugs for treating ischemic cerebral

```
apoplexy, coronary heart disease, angina pectoris, heart failure, apoplexy
     sequela, hepatorenal syndrome, pulmonary heart disease, diabetes mellitus and
     its complication, etc.
CC
     63-6 (Pharmaceuticals)
     Section cross-reference(s): 1
ΙT
     Angina pectoris
     Anticoagulants
     Brain ischemia
     Cardiovascular agents
     Cardiovascular disease
     Cerebrovascular disease
     Coronary artery disease
     Diabetes mellitus
     Dripping pills
     Freeze drying
       Ginkgo biloba
     Heart failure
     Liquid chromatography
     Myocardial ischemia
     Natural products, pharmaceutical
     Panax ginseng
     Pharmaceutical capsules
     Pharmaceutical granules
    Pharmaceutical injections
     Pharmaceutical liposomes
     Pharmaceutical liposomes
     Pharmaceutical powders
     Pharmaceutical tablets
     Platelet aggregation inhibitors
     Precipitation (chemical)
     Pulverization
     Solvent extraction
     Stroke
        (manufacture and application of traditional Chinese medicinal composition
for
        treating cardiovascular and cerebrovascular diseases)
     15291-75-5DP, Ginkgolide A, derivs., ginkgolides
     RL: PAC (Pharmacological activity); PUR (Purification or recovery)
     ; THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
        (manufacture and application of traditional Chinese medicinal composition
for
        treating cardiovascular and cerebrovascular diseases)
L41 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN
                         2007:675842 CAPLUS Full-text
ACCESSION NUMBER:
DOCUMENT NUMBER:
                         147:125781
TITLE:
                         Manufacture and application of traditional Chinese
                         medicinal composition for treating cardiovascular and
                         cerebrovascular diseases
INVENTOR(S):
                         Yu, Wenfeng
PATENT ASSIGNEE(S):
                         Beijing Qiyuanyide Medicine Institute, Peop. Rep.
SOURCE:
                         Faming Zhuanli Shenqing Gongkai Shuomingshu, 12pp.
                         CODEN: CNXXEV
DOCUMENT TYPE:
                         Patent
LANGUAGE:
                         Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

		111	zai Chandrak	umar 10/3/9,102	
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PRIC ED	CN 1981777 ORITY APPLN. INFO.: Entered STN: 22 Ju	А	20070620		
AB	The title medicina notoginseng 1-99, and adjuvants. Thinfusions, injectipills, oral solns. for preparing drug disease, angina pe	l compototal fe medicon powd, soft s for t ctoris,	lavones and al composit: ers, tablet: capsules, ereating ischeart fails	omposed of (by%) total ginkgolides of Ginkgolides of Ginkgolides, can be prepared in s, capsules, granules to. The medical compose hemic cerebral apoples ure, apoplexy sequelations and interest mellitus and interest of the sequelations.	o biloba leaf 99-1, nto injections, dripping pills, osition can be used xy, coronary heart, hepatorenal
CC	63-6 (Pharmaceutica Section cross-refer		. 1		
ΙT	Flavones	ence (s)	• 1		
				PUR (Purification or rstudy); PREP (Preparat	
		nese med	dicinal comp	and application of cosition for treating	cardiovascular and
ΙT	Ginkgo biloba	arbeabe	,		
0000		re and	application	of traditional Chine	se medicinal
COMP	osition for treating car	diovaso	cular and ce	erebrovascular disease	:s)
ΙT	Angina pectoris	arovasc	Jarar ana Jo	.10010100000000	<i>-</i> ,
	Anticoagulants				
	Brain ischemia	i			
	Cardiovascular ager Cardiovascular dise				
	Cerebrovascular dise				
	Coronary artery dis				
	Diabetes mellitus				
	Dripping pills				
	Freeze drying				
	Heart failure	. No			
	Liquid chromatograp Myocardial ischemia				
	Natural products, p		eutical		
	Panax notoginseng				
	Pharmaceutical caps				
	Pharmaceutical gran				
	Pharmaceutical injection Pharmaceutical lipo				
	Pharmaceutical lipo				
	Pharmaceutical powd				
	Pharmaceutical tabl	ets			
	Platelet aggregation		oitors		
	Precipitation (chem	nical)			
	Pulverization Solvent extraction				
	Stroke				
		d applic	cation of tr	aditional Chinese med	icinal composition
for	Amaret Jure 11	1			
ΙT	treating cardiov 15291-75-5DP, Ginko			ovascular diseases)	
т т				PUR (Purification or r	ecovery)
	; THU (Therapeutic				~

(Preparation); USES (Uses)

(Ginkgo biloba leaf; manufacture and application of traditional Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases)

L41 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2007:597593 CAPLUS Full-text

DOCUMENT NUMBER: 147:101987

TITLE: New formulations of traditional Chinese medicine

containing troxerutin and Ginkgo

biloba flavonoids for treating cardiovascular

and cerebrovascular diseases

INVENTOR(S): Yu, Wenfeng

PATENT ASSIGNEE(S): Beijing Qiyuanyide Medicine Institute, Peop. Rep.

China

SOURCE: Faming Zhuanli Shenging Gongkai Shuomingshu, 14pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1969892	A	20070530	CN 2005-10115004	20051123
PRIORITY APPLN. INFO.:			CN 2005-10115004	20051123

ED Entered STN: 04 Jun 2007

The invention provides new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases. The pharmaceutical composition is composed of (by weight part) troxerutin 1, and Ginkgo biloba leaf flavonoids 0.1-50 or lactones 0.01-50 or mixture of lactones and flavonoids 0.1-30. The pharmaceutical composition can be manufactured into injections, oral prepns., etc. The pharmaceutical composition is used for treating coronary heart disease, angina pectoris, miocardial infarction, arrhythmia, cerebral thrombosis, senile dementia, thrombophlebitis, capillary bleeding, diabetes mellitus and complications, hepatorenal syndrome, etc. The manufacturing and quality control methods are also disclosed. The pharmaceutical composition has advantages of high purity, definite constituent, controllable quality, enhanced therapeutic effect, reliable security and stable efficacy.

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 64

IT Flavonoids

Lactones

RL: ANT (Analyte); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Ginkgo biloba; new formulations of traditional

Chinese medicine containing troxerutin and Ginkgo biloba

flavonoids for treating cardiovascular and cerebrovascular diseases)

IT Charcoal

RL: NUU (Other use, unclassified); USES (Uses)

(activated; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for

treating cardiovascular and cerebrovascular diseases)

IT Antiarteriosclerotics

(antiatherosclerotics; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases)

IT Pharmaceutical excipients

(disintegrants; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) ΙT Pharmaceutical tablets (effervescent tablets; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) Glycosides ΤТ RL: ANT (Analyte); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses) (flavonoid; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) Freeze-dried drug delivery systems ΤТ Pharmaceutical injections (freeze-dried injectable drug delivery systems; new formulations of traditional Chinese medicine containing troxerutin and Giokgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) ΙT Infusion drug delivery systems (i.v. infusions; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) Pharmaceutical injections TΤ (i.v. injections; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) Terpenes ΙT RL: ANT (Analyte); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses) (lactones; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) Pharmaceutical microparticles TΤ (microtablets; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) ΙT Anti-Alzheimer's agents Antiarrhythmics Anticonvulsants Antidiabetic agents Cardiovascular agents Dripping pills Flocculation Freeze drving Ginkgo biloba Liquid chromatography Oral drug delivery systems Pharmaceutical capsules Pharmaceutical films Pharmaceutical granules Pharmaceutical liposomes Pharmaceutical powders Pharmaceutical tablets Platelet aggregation inhibitors Quality control

Sedimentation (separation)

Solvent extraction

Stability (new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) ΙT Oral drug delivery systems Pharmaceutical solutions (oral solns.; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) TΤ Drug interactions (pharmacodynamic; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) Drying ΤТ (spray; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) ΙT Pharmaceutical tablets (sublingual tablets; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) ΙT Inflammation Vein, disease (thrombophlebitis, treatment of; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) Alzheimer disease TΤ Angina pectoris Atherosclerosis Cardiac arrhythmia Coronary artery disease Diabetes mellitus Hemostatics Myocardial infarction Thrombolytics (treatment of; new formulations of traditional Chinese medicine containing troxerutin and Giokgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) ΙT 7085-55-4, Troxerutin RL: ANT (Analyte); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) ΙT 64-17-5, Ethanol, uses RL: NUU (Other use, unclassified); USES (Uses) (new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases) 50-70-4, Sorbitol, biological studies 56-40-6, Glycine, biological TΤ 57-55-6, Propylene glycol, biological studies 59-23-4, Galactose, biological studies 69-65-8, Mannitol 9003-39-8, Polyvinylpyrrolidone 9004-54-0, Dextran, biological studies 9004-64-2, Hydroxypropylcellulose RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases)

L41 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2007:339577 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 146:408191

TITLE: Method for extracting active ingredients from

Ginkgo biloba leaf by using two

resin columns

INVENTOR(S): Zhang, Liming; Lu, Fuping; Wang, Yan

PATENT ASSIGNEE(S): Liaoning Dasheng Pharmaceutical Co., Ltd., Peop. Rep.

China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 8pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1931199	A	20070321	CN 2006-10200908	20060925
CN 100418543	С	20080917		
PRIORITY APPLN. INFO.:			CN 2006-10200908	20060925

ED Entered STN: 26 Mar 2007

The title method comprises pretreating ADS-17 and ADS-F8 resins with waterethanol-hydrochloric acid method, extracting Ginkgo biloba leaves with ethanol solution under refluxing and stirring at 68-72°, performing adsorption and clarification of the extractive solution with ZTC-II clarifier B for 30-50 min and then ZTC-II clarifier A for 30-50 min at 38-42°, filtering or centrifuging, adding water and standing for 8-12 h, filtering or centrifuging to remove fat-soluble substances, purifying with ADS-17 chromatog. column, separating ketone and ester with ADS-F8 chromatog. column, detecting content of ginkgolic acid by HPLC to make sure its concentration is below 5 μ g/g, and manufacturing into the final product. The method has the advantages of reasonable process, high extraction rate, and high content of active ingredients, definite therapeutic effect and convenient administration.

CC 63-4 (Pharmaceuticals)

IT Adsorption

Ginkgo biloba

HPLC

Liquid chromatography

Quality control

Solvent extraction

(method for extracting active ingredients from Ginkgo biloba leaf by using two resin columns)

IT 64-17-5, Ethanol, uses 7647-01-0, Hydrochloric acid, uses

RL: NUU (Other use, unclassified); USES (Uses)

(method for extracting active ingredients from ${\tt Ginkgo}$

biloba leaf by using two resin columns)

IT 481-46-9P, Ginkgetin 22910-60-7P, Ginkgolic acid 33570-04-6P, Bilobalide

RL: PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(method for extracting active ingredients from Ginkgo biloba leaf by using two resin columns)

IT 256463-70-4, ADS 17 926021-63-8, ADS-F 8

RL: TEM (Technical or engineered material use); USES (Uses) (method for extracting active ingredients from Ginkgo biloba leaf by using two resin columns)

L41 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2006:1272234 CAPLUS Full-text DOCUMENT NUMBER: 146:149217 TITLE: Quantitative determination of ginkgolides by liquid chromatography-electrospray mass spectrometry AUTHOR(S): Zhou, Xin; Zhang, Xueqin; Yuan, Mu; Wang, Daoping CORPORATE SOURCE: The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550002, Peop. Rep. China SOURCE: Zhongguo Zhongyao Zazhi (2005), 30(24), 1915-1918 CODEN: ZZZAE3; ISSN: 1001-5302 Zhongguo Zhongyao Zazhishe PUBLISHER: DOCUMENT TYPE: Journal LANGUAGE: Chinese Entered STN: 06 Dec 2006 EDAΒ A method based on liquid chromatoq, coupled with electrospray mass spectrometry (LC-ESI-MS) for the anal. of terpenoids in ginkgo laminae was reported. The anal. was performed on Zorbax RX-C18 (2.1 mm x 150 mm) column with methanol-water (with gradient elution) as mobile phase at a flow rate 0.25~mL/min and column temperature 25° . The anal. was carried out in the selected ion monitoring mode. Ginkgolides (GA, GB, and CC) and bilobalide were quant. detected by external standardization. The linear range was 4.04-101.2 ng, detection limit 1.47 x 10-3-0.320 μ g/mL, and RSD 2.50-4.73%. LC-ESI-MS shows highly enhanced sensitivity as compared with other methods. CC 64-2 (Pharmaceutical Analysis) ΙΤ Ginkqo biloba Natural products, pharmaceutical (ginkgolides determination by liquid chromatog.-electrospray mass spectrometry) Mass spectrometry ΙΤ (liquid chromatog. combined with; ginkgolides determination by liquid chromatog.-electrospray mass spectrometry) ΙT Liquid chromatography (mass spectrometry combined with; ginkgolides determination by liquid chromatog.-electrospray mass spectrometry) 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C ΙT 15291-77-7, Ginkgolide B 33570-04-6, Bilobalide RL: ANT (Analyte); NPO (Natural product occurrence); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (ginkgolides determination by liquid chromatog, -electrospray mass spectrometry) OS.CITING REF COUNT: THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD 1 (1 CITINGS) L41 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2006:1215169 CAPLUS Full-text DOCUMENT NUMBER: 146:517243 Determination of ginkgolides in Ginkgo TITLE: biloba by capillary gas chromatography Liu, Hong-mei; Zhou, Qing-xia; Yang, Wen-ling AUTHOR(S): CORPORATE SOURCE: College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, Hebei, 050018, Peop. Rep. China Hebei Keji Daxue Xuebao (2006), 27(3), 209-213 SOURCE: CODEN: HKDXFY; ISSN: 1008-1542 Hebei Keji Daxue Xuebao Bianjibu PUBLISHER: DOCUMENT TYPE: Journal LANGUAGE: Chinese ED Entered STN: 20 Nov 2006

Nizal Chandrakumar 10/579,162 AΒ The optimum conditions of chromatograph separation were selected for the ginkgolides: bilobalide (BB), ginkgolide A (GA), ginkgolide J (GJ), ginkgolide B (GB) and ginkgolide C (GC). Selecting squalane (SQ) as an internal standard, the weight correction factors of ginkgolides were confirmed by measurement and theor. calcn. The contents of the five ginkgolides were determined by internal standard method. The average recoveries of the method for BB, GA, GB and GC were 92.8%, 93.2%, 92.4% and 94.4%, and RSD were 2.9%, 1.6%, 2.2%, 1.9% and 1.9% resp. 9-3 (Biochemical Methods) CC Section cross-reference(s): 64 ginkgolide capillary gas chromatog Ginkgo ST Flame ionization detectors ΙT Gas chromatography Ginkgo biloba (determination of ginkgolides in Ginkgo biloba by capillary gas chromatog.)

ΙT 7631-86-9, Silicon dioxide, analysis RL: AMX (Analytical matrix); ANST (Analytical study) (determination of ginkgolides in Ginkgo biloba by capillary gas chromatog.)

ΙT 15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C 15291-77-7P, Ginkgolide B 33570-04-6P, Bilobalide 107438-79-9P, Ginkgolide J

RL: ANT (Analyte); PUR (Purification or recovery); ANST (Analytical study); PREP (Preparation)

(determination of ginkgolides in Ginkgo biloba by capillary gas chromatog.)

67-56-1, Methanol, analysis 67-64-1, Acetone, analysis ΙT 68-12-2, N, N-Dimethylformamide, analysis 75-77-4, Trimethylchlorosilane, analysis 108-88-3, Toluene, analysis 110-54-3, n-Hexane, analysis 111-01-3, 7727-37-9, Nitrogen, Squalane 141-78-6, Ethyl acetate, analysis analysis 25561-30-2, Bis(trimethylsilyl)trifluoroacetamide RL: ARU (Analytical role, unclassified); ANST (Analytical study) (determination of ginkgolides in Ginkgo biloba by capillary qas chromatog.)

OS.CITING REF COUNT: THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD 1 (1 CITINGS)

L41 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN 2006:1164539 CAPLUS Full-text ACCESSION NUMBER:

145:511322 DOCUMENT NUMBER:

Quality control method for injection containing gingko TITLE:

and Salvia miltiorrhiza

INVENTOR(S): Yu, Wenvona

Guiyang Yunyan Xichuang Medicinal Technology PATENT ASSIGNEE(S):

Development Co., Ltd., Peop. Rep. China

SOURCE: Faming Zhuanli Shenging Gongkai Shuomingshu, 82pp.

CODEN: CNXXEV

Patent DOCUMENT TYPE: LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
CN 1853674	 A	20061101	CN 2006-10200071	_	20060124
CN 1033674 CN 101156893	A	20081101	CN 2000-10200071 CN 2007-10201880		20060124
CN 101136693 CN 101156894	A A	20080409	CN 2007-10201885		20060124
PRIORITY APPLN. INFO.:	A	20000409	CN 2007-10201883 CN 2005-10003011	Д	20050124
FRIORITI AFFLIN. INCO.:			CN 2005-10003011 CN 2006-10200071		20050207
			CN 2000-102000/1	$A_{\mathcal{S}}$	20000124

ED Entered STN: 07 Nov 2006

AB The method comprises fingerprint spectrum testing, identifying the ingredient of gingko, gingko extract, total flavonoids, and total terpene lactones, measuring the ingredient of Salvia miltiorrhiza extract or its sodium salt, protocatechuic aldehyde, lithosperman B or its magnesium salt, tanshinone IIA, quercetin, and kaempferide. Compared with existing technol., the claimed method is more effective, more accurate, and more stable.

CC 63-4 (Pharmaceuticals)

IT Ginkgo biloba

HPLC

Natural products, pharmaceutical

Quality control Salvia miltiorrhiza Spectrophotometry

TLC (thin layer chromatography)

(quality control method for injection containing gingko and Salvia miltiorrhiza)

IT 50-99-7, D-Glucose, biological studies 117-39-5, Quercetin 139-85-5, Protocatechuic aldehyde 480-19-3, Isorhamnetin 486-66-8, Daidzein 520-18-3, Kaempferol 568-72-9, Tanshinone IIA 9004-32-4, Sodium carboxymethyl cellulose 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B 22910-60-7, Ginkgolic acid 33570-04-6, Bilobalide 40644-73-3 98112-96-0, Lithosperman B 122021-74-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (quality control method for injection containing gingko and Salvia

L41 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2006:907292 CAPLUS $\underline{\text{Full-text}}$

DOCUMENT NUMBER:

miltiorrhiza)

145:342646

TITLE: Quality control of ginkgo orally disintegrating tablet

INVENTOR(S): Ye, Xiangwu; Zhang, Mei
PATENT ASSIGNEE(S): Guizhou Yibai Pharmaceutical Co., Ltd., Peop. Rep.

China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 26pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1823852	A	20060830	CN 2005-10003342	20051229
CN 100520404	С	20090729		
PRIORITY APPLN. INFO.:			CN 2005-10003342	20051229

ED Entered STN: 06 Sep 2006

AB The patent relates to quality control which has good precision, sensitivity and stability to ensure that the product is safe, even, stable, effective, controllable, etc. The tablet is comprised of Ginkgo biloba extract and pharmaceutic adjuvant at a ratio of 1-10:10-1. The pharmaceutic adjuvant is selected from Et cellulose, mannite, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, microcryst. cellulose, aspartame, silica gel, and magnesium stearate, etc. The quality control comprises observing character, checking content according to pharmacopoeia method, and identifying flavonol glycosides and terpene lactones and determining the content of them. The differentiation process consists of grinding the product, adding 10-50% HCl and methanol (1-9:9-1), reflux extracting, filtering, adding distilled water, volatilizing partial solution,

extracting with ether for 1-6 times, washing with water 1-5 times, evaporating to dryness, adding methanol to the residue as sample for test, weighing Ginkgo biloba extract and preparing the solution of Ginkgo biloba extract, determining with thin-layer chromatog. (TLC) with toluene, Et acetate, acetone and formic acid (1-20:0.1-50.1-5:0.05-0.5) as developing agent and developing, air drying, spraying 1-10% ethanol solution of aluminum chloride, and observing the color; dotting terpene lactone solution for test and check solution on the same silica gel thin-layer plate with toluene, Et acetate, acetone and formic acid (5-20:1-10:1-10:0.1-1) as as developing agent and developing at 20%, air drying, fumigating with acetic anhydride steam, heating at 140-160%, cooling, viewing, and determining The content of flavonol glycosides and terpene lactones in the tablets is determined by HPLC scanning from 200 nm to 500 nm on C18 column with methanol-0.01-0.1 mol potassium dihydrogen phosphate (1-9:9-1) as mobile phase.

CC 64-2 (Pharmaceutical Analysis)
 Section cross-reference(s): 63

IT Cardiovascular agents

Ginkqo biloba

HPLC

Natural products, pharmaceutical

Quality control

TLC (thin layer chromatography)

(quality control of orally disintegrating tablets containing Ginkgo exts.)

IT 117-39-5, Quercetin 480-19-3, Isorhamnetin 491-54-3, Kaempferide 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C

15291-77-7, Ginkgolide B

RL: AMX (Analytical matrix); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); ANST

(Analytical study); BIOL (Biological study); PROC (Process); USES (Uses) (quality control of orally disintegrating tablets containing Ginkgo exts.)

L41 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2006:815138 CAPLUS Full-text

DOCUMENT NUMBER: 145:299230

TITLE: Ginkgo leaf orally disintegrating tablet and its

preparation and quality control methods

INVENTOR(S): Chen, Fagui; Wang, Tianxing; Xu, Lijun

PATENT ASSIGNEE(S): Zhejiang Dade Pharmaceutical Group Co., Ltd., Peop.

Rep. China

SOURCE: Faming Zhuanli Shenging Gongkai Shuomingshu, 36pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1813826	A	20060809	CN 2005-10200764	20051205
CN 100381115	С	20080416		
PRIORITY APPLN. INFO.:			CN 2005-10200764	20051205
ED E 1 0 EM 1 7 7	0000			

ED Entered STN: 17 Aug 2006

AB The title orally disintegrating tablet (1000 tablets) is composed of ginkgo leaf extract 80, microcrystal cellulose 183, crosslinked polyvinylpyrrolidone 35, low substituted hydroxypropylmethyl cellulose 75, aspartame 7, menthol 0.1 g, wherein each tablet contains total flavonoids 19.2 and terpene 4.8 mg. The title orally disintegrating tablet is prepared by mixing ginkgo leaf extract, microcrystal cellulose, low substituted hydroxypropylmethyl cellulose, crosslinked polyvinylpyrrolidone with aspartame, pelletizing with 95% ethanol, drying, spraying menthol ethanol solution, sealing for 10 h and tableting.

The total flavonoids in the disintegrating tablet are identified by TLC with Et acetate-butanol-methanol-water(5:3:1:1) as developing agent and ginkgo leaf extract as control; terpene is identified by TLC with ginkgolide A, ginkgolide B, ginkgolide C and bilobalide as control and toluene:ethyl acetate: acetone:methanol(10:5:5:0.6) as developing agent. The total flavonoids content in the disintegrating tablet are determined by HPLC on octadecyl silane column at 360 nm with methanol-0.4% phosphoric acid(50:50) as mobile phase and quercetin-kaempferol-isorhamnetin as control; terpene in the disintegrating tablet is determined by HPLC on octadecyl silane column with methanol-tetrahydrofuran-water(25:10:65) as mobile phase and ginkgolide A-ginkgolide B-ginkgolide C-bilobalide as control. The flavonoids peak area ratio and disintegration time are also checked. The inventive product disintegrates and acts more quickly than the existed orally disintegrating tablet.

CC 63-4 (Pharmaceuticals)
IT Cytoprotective agents

Dissolution

Ginkgo biloba

HPLC Leaf

Natural products, pharmaceutical

Quality control

TLC (thin layer chromatography)

(ginkgo leaf orally disintegrating tablet and its preparation and quality control methods)

IT 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B 33570-04-6, Bilobalide

RL: ANT (Analyte); NPO (Natural product occurrence); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(ginkgo leaf orally disintegrating tablet and its preparation and quality control methods)

L41 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2005:1319245 CAPLUS Full-text

DOCUMENT NUMBER: 144:40971

TITLE: Simultaneous quantification of terpenelactones and

flavonol aglycones in hydrolyzed Ginkgo

biloba extract by liquid

chromatography with inline ultraviolet and evaporative light scattering detection

AUTHOR(S): Gray, Dean E.; Messer, Dale; Porter, Andrew; Ferguson,

Sherry; Harris, Roger K.; Clark, Alice P.; Algaier, Joseph W.; Overstreet, J. Diane; Smith, Cynthia S.

CORPORATE SOURCE: Midwest Research Institute, Kansas City, MO,

64110-2299, USA

SOURCE: Journal of AOAC International (2005), 88(6), 1613-1620

CODEN: JAINEE; ISSN: 1060-3271

PUBLISHER: AOAC International

DOCUMENT TYPE: Journal LANGUAGE: English ED Entered STN: 19 Dec 2005

AB The authors report here a liquid chromatog. (LC) method with inline UV/evaporative light scattering (UV/ELS) detection for the simultaneous quantification of the terpenelactones and flavonol aglycons in a single sample of hydrolyzed Ginkgo biloba extract (GBE). The sample is hydrolyzed by a rapid and convenient oven heating method for 1 h at 90°C with 10% hydrochloric acid. The 1 h hydrolysis was found to be equivalent to the 2.25 h reflux treatment for dry powder extract, where total flavonol glycosides were 28.4 and 28.1%, resp. Acceptable precision was achieved for total terpenelactones

[relative standard deviation (RSD) = 4.8%] by ELS detection, and total flavonol aglycons (RSD = 2.3%) by UV detection. The anal. range was 1.5 to 7.3% (weight/weight) for the individual terpenelactones (ELS) and 2.5 to 15.0% (weight/weight) for the individual glycosides (UV) calculated from the aglycons quercetin, kaempferol, and isorhamnetin. This improved method allows for the 1st time high throughput sample preparation coupled with the quantification of the predominant compds. generally used for quality control of GBE in a single assay.

CC 64-2 (Pharmaceutical Analysis)

Section cross-reference(s): 63

- ST terpenelactone flavonol aglycon detn Ginkgo biloba liq chromatog stability
- IT Hydrolysis

(acid; quantification of terpenelactones and flavonol aglycons in hydrolyzed Ginkgo biloba extract by LC)

IT Ginkgo biloba

(extract; quantification of terpenelactones and flavonol aglycons in hydrolyzed Ginkgo biloba extract by LC)

IT Terpenes, analysis

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(lactones; quantification of terpenelactones and flavonol aglycons in hydrolyzed Giokgo biloba extract by LC)

IT Antioxidants

(natural; quantification of terpenelactones and flavonol aglycons in hydrolyzed Ginkgo biloba extract by LC)

IT Cytoprotective agents

Nervous system agents

(neuroprotective agents; quantification of terpenelactones and flavonol aglycons in hydrolyzed Ginkgo biloba extract by LC)

IT Anti-ischemic agents

Anticoagulants

Liquid chromatography

Quality control

Stability

(quantification of terpenelactones and flavonol aglycons in hydrolyzed Ginhqo biloba extract by LC)

IT Flavonoids

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(quantification of terpenelactones and flavonol aglycons in hydrolyzed Ginkgo biloba extract by LC)

IT 117-39-5, Quercetin 480-19-3, Isorhamnetin 520-18-3, Kaempferol 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C

15291-77-7, Ginkgolide B 33570-04-6, Bilobalide

RL: ANT (Analyte); CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); ANST

(Analytical study); BIOL (Biological study); PROC (Process); USES (Uses) (quantification of terpenelactones and flavonol aglycons in hydrolyzed Ginkgo biloba extract by LC)

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2005:1061219 CAPLUS Full-text

DOCUMENT NUMBER: 143:455133

TITLE: Preparative isolation of tempene

trilactones from Ginkgo

biloba leaves

AUTHOR(S): Lai, Shih-Ming; Chen, I-Wen; Tsai, Ming-Jyi

CORPORATE SOURCE: Department of Chemical Engineering, National Yunlin

University of Science and Technology, Yunlin, 640,

Taiwan

SOURCE: Journal of Chromatography, A (2005), 1092(1), 125-134

CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English ED Entered STN: 04 Oct 2005

This study investigated and compared some techniques for the preparative AΒ isolation of terpene trilactones, including ginkgolides (GA and GB, etc.) and bilobalide (BB), from Ginkgo biloba leaves. The crude Ginkgo biloba L. exts. (GBE) were prepared using an extractor with solvent refluxing operated under an optimal extraction condition. The extraction yield was 20-23% and the purity of terpene trilactones was about 1.0-1.4 wt%. Before the isolation operations, the exts. were dissolved in de-ionized water. The isolation procedures included the method of liquid-liquid extraction and the method of column chromatog. For the method of liquid-liquid extraction using Et acetate as the organic solvent operated under the optimal extraction conditions, the purity, concentration ratio, and yield of terpene trilactones were 13.5-18.0%, 15-16, and >99%. For the method of column chromatog., XAD-7HP, XAD-4, and C-18 adsorbents with different polarities were used as the packing materials. Only for the XAD-7HP column, a part of more polar impurities was efficiently separated with the majority of terpene trilactones by a proper step-gradient elution, which resulted in an efficient isolation: the purity, concentration ratio, and yield of terpene trilactones were .apprx.20, .apprx.15, and .apprx.80%. In comparison, the XAD-7HP column achieved the highest purity, but at the expense of the yield of terpene trilactones; on the contrary, the liquid-liquid extraction method, achieving the highest yield but with a slightly lower purity, proved to be superior to the method of column chromatog. in the current isolation stage.

CC 9-3 (Biochemical Methods)

ST terpene trilactone Gingko leaf liq chromatog; liq extn terpene trilactone Gingko leaf

IT Extraction

(liquid-liquid; preparative isolation of terpene trilactones from Ginkgo biloba leaves)

IT Ginkgo biloba

HPLC

Leaf

Liquid chromatography

(preparative isolation of terpene trilactones from Ginkgo biloba leaves)

IT Tempenes, preparation

RL: PUR (Purification or recovery); PREP (Preparation) (trilactores; preparative isolation of terpene

trilactones from Ginkgo biloba leaves)

IT 141-78-6, Ethyl acetate, uses 220455-89-0, Amberlite XAD 7HP

RL: NUU (Other use, unclassified); USES (Uses)

(preparative isolation of tempene trilactones from

Ginkgo biloba leaves)

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

(4 CITINGS)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:644914 CAPLUS Full-text DOCUMENT NUMBER: 143:216806 TITLE: Development of a Ginkgo biloba fingerprint chromatogram with UV and evaporative light scattering detection and optimization of the evaporative light scattering detector operating conditions van Nederkassel, A. M.; Vijverman, V.; Massart, D. L.; AUTHOR(S): Vander Heyden, Y. CORPORATE SOURCE: Department of Analytical Chemistry and Pharmaceutical Technology, Pharmaceutical Institute, Vrije Universiteit Brussel-VUB, Brussels, 1090, Belg. Journal of Chromatography, A (2005), 1085(2), 230-239 SOURCE: CODEN: JCRAEY; ISSN: 0021-9673 Elsevier B.V. PUBLISHER: DOCUMENT TYPE: Journal LANGUAGE: English ΕD Entered STN: 25 Jul 2005 AΒ A fingerprint chromatogram of a standardized Ginkgo biloba extract is developed on a monolithic silica column using a ternary gradient containing water, iso-propanol and THF. For the detection, UV and evaporative light scattering (ELS) detectors are used, the latter allowing detection of the poor UV absorbing compds. as ginkgolides (A-C and J) and bilobalide in the extract The complementary information between the UV and ELS fingerprint is evaluated. The ELS detector used in this study can operate in an impactor on' or off' mode. For each mode, the operating conditions such as the nebulizing gas flow rate, the drift tube temperature, and the gain are optimized by use of 3-level screening designs to obtain the best signal-to-noise (S/N) ratio in the final ELS fingerprint chromatogram. In both impactor modes, very similar S/N ratios are obtained for the nominal levels of the design. However, optimization of the operating conditions resulted, for both impactor modes, in a significant increase in S/N ratios compared to the initial evaluated conditions, obtained from the detector software. CC 64-2 (Pharmaceutical Analysis) Ginkgo biloba fingerprint chromatogram HPLC evaporative light scattering ΙT HPLC (Ginkgo biloba fingerprint chromatogram with UV and evaporative light scattering detection) ΙT Ginkgo biloba (development of a Ginkgo biloba fingerprint chromatogram with UV and evaporative light scattering detection and optimization of the evaporative light scattering detector operating conditions) Liquid chromatographic detectors ΙT (light-scattering; Ginkgo biloba fingerprint chromatogram with UV and evaporative light scattering detection) ΤТ 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B 33570-04-6, Bilobalide 107438-79-9, Ginkgolide J RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (Ginkgo biloba fingerprint chromatogram with UV and evaporative light scattering detection) OS.CITING REF COUNT: 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)

THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

27

REFERENCE COUNT:

L41 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2005:507012 CAPLUS $\underline{\text{Full-text}}$

DOCUMENT NUMBER: 143:353291

TITLE: Extraction of terpene lactone from Ginkgo

biloba leaves

INVENTOR(S): Dai, Baixiong; Gong, Ting; Qian, Jun

PATENT ASSIGNEE(S): Sanjiangyuan Pharmaceutical Co., Ltd., Suizhou City,

Peop. Rep. China

SOURCE: Faming Zhuanli Shenging Gongkai Shuomingshu, No pp.

given

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1530363	А	20040922	CN 2003-119744	20030311
CN 1301988	С	20070228		
PRIORITY APPLN. INF	0.:		CN 2003-119744	20030311

ED Entered STN: 14 Jun 2005

AB The title extraction process includes: (1) pulverizing Ginkgo biloba leaves, (2) extracting the powders by ethanol at 75-85ÅC, (3) concentrating the extract, (4) adding water into the extract and filtrating, (5) loading the filtrate on a macroporous resin chromatog. column and eluting it by ethanol, (6) concentrating the eluate and extracting it by Et acetate, and (7) concentrating the extract and drying to obtain the product. The product can be used for treating senile dementia, cardiovascular diseases and cerebrovascular diseases. This process is low cost, low environment pollution, and is suitable for industrial production

IC ICM C07D311-30

ICS A61P025-28; A61P009-10

- CC 63-4 (Pharmaceuticals)
- IT Brain, disease

(cerebrovascular; extraction of terpene lactone from Ginkgo biloba leaves)

IT Cardiovascular system, disease

Ginkgo biloba

Human

Liquid chromatography

Solvent extraction

(extraction of terpene lactone from Ginkgo biloba leaves)

IT Mental and behavioral disorders

(senile psychosis; extraction of terpene lactone from Ginkgo biloba leaves)

IT 64-17-5, Ethanol, uses 127-09-3, Sodium acetate 141-78-6, Ethyl acetate, uses 676466-31-2, HPD 100

RL: NUU (Other use, unclassified); USES (Uses)

(extraction of terpene lactone from Ginkgo biloba leaves)

IT 15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C 15291-77-7P, Ginkgolide B 33570-04-6P, Bilobalide RL: PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(extraction of terpene lactone from Ginkgo biloba leaves)

L41 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2005:451255 CAPLUS Full-text

DOCUMENT NUMBER: 142:487413

TITLE: Separation of ginkgolides and bilobalide from

Ginkgo biloba using column

chromatography

INVENTOR(S): Nakanishi, Koji; Jaracz, Stanislav; Malik, Shahid;

Ishii, Hideki; Dzyuba, Sergei V.

PATENT ASSIGNEE(S): The Trustees of Columbia University In the City of New

York, USA

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.			KIND DATE			APPLICATION NO.				DATE						
WC	2005	0468	29		A2	_	2005			WO 2	004-	 US37	412			0041	
WC	2005	0468	29		А3		2005	1110									
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
		AZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	ΙT,	LU,	MC,	NL,	PL,	PT,	RO,
		SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	G₩,	ML,	MR,
		ΝE,	SN,	TD,	ΤG												
US	3 2008	0108	837		A1		2008	0508		US 2	007-	5791	62		2	0070	905
PRIORIT	TY APP	LN.	INFO	.:						US 2	003-	5198	40P		P 2	0031	112
										WO 2	004-	US37	412	1	₩ 2	0041	109

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT OTHER SOURCE(S): MARPAT 142:487413

ED Entered STN: 27 May 2005

The subject invention provides a method for separating a terpene trilactone AΒ from Ginkqo biloba plant material or from an extract of Ginkqo biloba comprising a mixture of terpene trilactones. The process comprises the steps of: (a) subjecting the Ginkgo biloba plant material or the extract to column chromatog. with an appropriate solvent system to produce at least a first fraction containing the terpene trilactone bilobalide, a second fraction eluted after the first fraction containing the terpene trilactones ginkgolide A and ginkgolide B, and a third fraction eluted after the second fraction containing at least a preponderance of the terpene trilactones ginkgolide C and ginkgolide J; and (b) alkylating the terpene trilactone ginkgolide B of the second fraction so as to produce a first mixture including terpene trilactone ginkgolide A and alkylated terpene trilactone ginkgolide B; or alkylating the terpene trilactone ginkgolide C of the third fraction so as produce a second mixture including terpene trilactone ginkgolide J and alkylated terpene trilactone ginkgolide C, so as to thereby isolate a terpene trilactone. For example, the enriched extract of Ginkgo biloba (4.0 g) in min. amount of Et acetate was loaded on silica gel (100 g) column. The column was slowly eluted with Et acetate/hexanes solvent mixts. The fraction collected at 45% Et acetate/hexanes contained bilobalide (0.4 g). The fractions collected at 50% Et acetate/hexanes contained small amts. of impure bilobalide and ginkgolide A then mixture ginkgolide A/ginkgolide B. The fractions collected at 55% Et acetate/hexanes contained ginkgolide

IC

CC

ST

ΙT

ΤТ

ΙT

ΙT

ΙT

A/qinkqolide B (1.1 q). The fractions collected at 60% Et acetate/hexanes contained mixture of ginkgolide C/ginkgolide J (0.4 g) with small amts. of ginkgolide A and ginkgolide B. To a ginkolide mixture (1.08 g, ginkgolide B 25% weight/weight, ginkgolide A 74% weight/weight) was added potassium carbonate 879 mg, DMF 11 mL, benzyl bromide 756 mL. The mixture was stirred and quenched with 1M HCl (18 mL) and solution was extracted with Et acetate and dried with magnesium sulfate. The product mixture was suspended in chloroform (10 mL), filtered to obtain 605 mg of ginkgolide A as white powder. The filtrate was concentrated and purified by gradient column chromatog. (30 -50 % Et acetate/hexanes) to obtain 326 mg of benzylated ginkgolide B and 134 mg of ginkgolide A. Catalytic hydrogenation of 322 mg of benzylated ginkgolide B yielded 257 mg of ginkolide B. ICM B01D 63-4 (Pharmaceuticals) Section cross-reference(s): 30 terpene lactone benzylation liq chromatog hydrogenolysis; ginkgolide bilobalide benzylation liq chromatog hydrogenolysis Terpenes, biological studies RL: NPO (Natural product occurrence); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses) (lactones; separation of terpene lactones from Ginkgo biloba using column chromatog.) Benzylation Ginkgo biloba Hydrogenolysis Liquid chromatography (separation of ginkgolides and bilobalide from Ginkgo biloba using column chromatog.) 15291-76-6P, Ginkgolide C 15291-77-7P, Ginkgolide B RL: NPO (Natural product occurrence); FUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use) ; BIOL (Biological study); OCCU (Occurrence); PREP (Preparation) ; USES (Uses) (separation of ginkgolides and bilobalide from Ginkgo biloba using column chromatog.) 15291-75-5P, Ginkgolide A 33570-04-6P, Bilobalide 107438-79-9P, Ginkgolide J RL: NPO (Natural product occurrence); PUR (Purification or recovery); TAU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses) (separation of ginkgolides and bilobalide from Ginkgo biloba using column chromatog.) 534-17-8, Cesium carbonate 584-08-7, Potassium carbonate RL: NUU (Other use, unclassified); USES (Uses) (separation of ginkgolides and bilobalide from Ginkgo biloba using column chromatog.) 100-39-0, Benzyl bromide 106-95-6, Allyl bromide, reactions P-Methoxy-benzylbromide 4392-24-9, Cinnamyl bromide 17690-16-3, Benzyloxymethyl bromide RL: RCT (Reactant); RACT (Reactant or reagent) (separation of ginkgolides and bilobalide from Ginkgo biloba using column chromatog.) 170288-58-1P 502421-88-7P 852046-13-0P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (separation of ginkgolides and bilobalide from Ginkgo biloba using column chromatog.) OS.CITING REF COUNT: THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD 1 (1 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L41 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN 2004:886401 CAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: 142:62866 TITLE: Isolation of ginkgolides A, B, C, J and bilobalide from G. biloba extracts Jaracz, Stanislav; Malik, Shahid; Nakanishi, Koji AUTHOR(S): CORPORATE SOURCE: Department of Chemistry, Columbia University, NY, 10027, USA Phytochemistry (Elsevier) (2004), 65(21), 2897-2902 SOURCE: CODEN: PYTCAS; ISSN: 0031-9422 PUBLISHER: Elsevier B.V. Journal DOCUMENT TYPE: LANGUAGE: English Entered STN: 26 Oct 2004 AΒ Ginkgolides A, B, C and J, together with bilobalide, are unique terpenoid components of the Ginkgo biloba tree. Due to similar chemical properties, their separation is quite tedious. We have developed an efficient and rapid protocol for separation of individual ginkgolides and bilobalide from G. biloba exts. The procedure takes advantage of enhanced susceptibility of ginkgolides B and C to benzylation and the ease of separation of these products from ginkgolides A and J which do not react. The protocol is applicable to the previously reported enriched exts. prepared from G. biloba leaves. A single chromatog. step prior to benzylation provides bilobalide and mixture of ginkgolides A, B, C, and J. After benzylation, the individual ginkgolides are separated by chromatog. 64-2 (Pharmaceutical Analysis) CC Section cross-reference(s): 30, 63 ST bilobalide ginkgolide Ginkgo benzylation chromatog hydrogenolysis ΙT Ginkgo biloba Liquid chromatography (isolation of ginkgolides and bilobalide from Ginkgo biloba exts. by benzylation, chromatog. and hydrogenolysis) 15291-75-5, Ginkgolide A 33570-04-6, Bilobalide TT 107438-79-9, Ginkgolide J RL: ANT (Analyte); ANST (Analytical study) (isolation of ginkgolides and bilobalide from Ginkgo biloba exts. by benzylation, chromatog, and hydrogenolysis) 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B RL: ANT (Analyte); RCT (Reactant); ANST (Analytical study); RACT (Reactant or reagent) (isolation of ginkgolides and bilobalide from Ginkgo biloba exts. by benzylation, chromatog. and hydrogenolysis) ΙΤ 100-39-0, Benzyl bromide RL: RCT (Reactant); RACT (Reactant or reagent) (isolation of ginkgolides and bilobalide from Ginkgo biloba exts. by benzylation, chromatog. and hydrogenolysis) 170288-58-1P, 10-O-Benzyl-ginkgolide B 502421-88-7P, TΤ 10-O-Benzyl-ginkgolide C RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (isolation of ginkgolides and bilobalide from Ginkgo biloba exts. by benzylation,

chromatog. and hydrogenolysis)

OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS

RECORD (12 CITINGS)

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2004:485409 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 141:179751

TITLE: A Method for Extraction and Quantification of Ginkgo

Terpene Trilactones

AUTHOR(S): Ding, Chen; Chen, Erqin; Zhou, Weijia; Lindsay, Robert

С.

CORPORATE SOURCE: Department of Food Science, University of Wisconsin

Madison, Madison, WI, 53711, USA

SOURCE: Analytical Chemistry (2004), 76(15), 4332-4336

CODEN: ANCHAM; ISSN: 0003-2700

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English ED Entered STN: 17 Jun 2004

A method was developed for the extraction and quantification of pharmacol. AΒ active terpene trilactones (ginkgolides, bilobalide) from the tissues of Ginkgo biloba L. and pharmaceutical ginkgo products by RP-HPLC, based on the theory of terpene trilactones ionization. Four ginkgolides (GA, GB, GC, GJ) and bilobalide (BB) from both the ginkgo leaves and com. available ginkgo exts. were quant. extracted by using this method. The recovery rate of the method was 97.5-100% with RSD of 1.2-2.8%. The detection limit was 0.05-0.1 μg , and the linear range was 0.1-12 μg . This detection limit represents a marked improvement over previously reported methods, suggesting the new method is a viable technique for routine anal. of ginkgo terpene trilactones in natural and com. samples. The method reported by van Beek et al. in 1991 was used as a reference method to monitor the accuracy of extraction and anal. in this study. SSI-MS technique was used to identify isolated target components. Carbohydrase treatment and solubility of terpene trilactones in various solvents were also discussed.

CC 64-2 (Pharmaceutical Analysis)

IT Mass spectrometry

(liquid chromatog. combined with; method for extraction and quantification of Ginkgo terpene trilactones)

IT Liquid chromatography

(mass spectrometry combined with; method for extraction and quantification of Ginkgo terpene trilactones)

IT Extraction

Ginkgo biloba

Leaf

Reversed phase HPLC

рН

(method for extraction and quantification of Ginkgo terpene trilactones)

IT 15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C 15291-77-7P, Ginkgolide B 33570-04-6P, Bilobalide

107438-79-9P, Ginkgolide J

RL: ANT (Analyte); PUR (Purification or recovery); ANST

(Analytical study); PREP (Preparation)

(method for extraction and quantification of Ginkgo terpene trilactones) OS.CITING REF COUNT: $\,\,$ 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD

(6 CITINGS)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2003:598252 CAPLUS Full-text DOCUMENT NUMBER: 140:70227 TITLE: Liquid chromatography/atmospheric pressure chemical ionization ion trap mass spectrometry of terpene lactones in plasma of animals AUTHOR(S): Mauri, Pierluigi; Minoggio, Markus; Iemoli, Loredana; Rossoni, Giuseppe; Morazzoni, Paolo; Bombardelli, Ezio; Pietta, Piergiorgio CORPORATE SOURCE: Istituto Tecnologie Biomediche-CNR, Segrate, Milan, 20090, Italy Journal of Pharmaceutical and Biomedical Analysis SOURCE: (2003), 32(4-5), 633-639CODEN: JPBADA; ISSN: 0731-7085 Elsevier Science B.V. PUBLISHER: DOCUMENT TYPE: Journal LANGUAGE: English ΕD Entered STN: 05 Aug 2003 Liquid chromatog./atmospheric pressure chemical ionization ion trap mass AΒ spectrometry (LC/APCI-ITMS) was applied to evaluate the bioavailability of two different forms (free and complexed with soy phospholipids) of pure bilobalide and ginkgolide B in rats after acute administration. The same technique was used to measure the levels of ginkgolide A, B and bilobalide in plasma of quinea pigs fed Ginkqo biloba extract enriched in terpene lactones after chronic administration. The ratio RP/RA increased two to four times after the administration in the phytosomic form, where RP and RA represent the percentage ratio between the concentration of each terpene lactone in plasma and in the administered form, resp. 1-2 (Pharmacology) CC Section cross-reference(s): 11, 63 ΙT Bronchodilators Drug bioavailability Ion trap mass spectrometry Liquid chromatography (LC APCI ITMS of Ginkgo terpene lactones in plasma) Ginkqo biloba ΙΤ (ginkgoterpene enriched extract; LC APCI ITMS of Ginkgo terpene lactones in plasma) 15291-75-5P, Ginkgolide A 15291-77-7DP, Ginkgolide TТ B, complexed with soy phospholipids 15291-77-7P, Ginkgolide B 33570-04-6DP, Bilobalide, complexed with soy phospholipids 33570-04-6P, Bilobalide RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PKT (Pharmacokinetics): PUR (Purification or recovery): THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses) (LC APCI ITMS of Ginkgo terpene lactones in plasma) OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS) REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L41 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2003:118417 CAPLUS Full-text DOCUMENT NUMBER: 138:150364 TITLE: Method for isolating terpene trilactones (ginkgolides, bilobalide) from leaves and pharmaceutical powders of Ginkgo biloba Lichtblau, Dirk; Berova, Nina; Berger, John; INVENTOR(S):

Nakanishi, Koji

PATENT ASSIGNEE(S): The Trustees of Columbia University in the City of New

York, USA

SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S.

Ser. No. 903049, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030031736	A1	20030213	US 2002-194089	20020711
US 6590109	В2	20030708		
AT 343393	T	20061115	AT 2002-748132	20020711
US 20040077883	A1	20040422	US 2003-615346	20030707
US 6844451	В2	20050118		
US 20050136136	A1	20050623	US 2005-36409	20050114
PRIORITY APPLN. INFO.:			US 2001-903049 B2	20010711
			US 2002-194089 A1	20020711
			US 2003-615346 A1	20030707

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 14 Feb 2003

AB A method of isolating terpene trilactones from Ginkgo biloba plant material or extract comprising the steps of suspending the plant material or extract in either water or an aqueous solution of an oxidation reagent; extracting the terpene trilactones using an acceptable extraction agent; separating the organic layer from the aqueous layer; washing the organic layer with an acceptable aqueous salt or hydroxide solution, which may be an alkaline solution; and drying the organic layer to form a dried extract containing terpene trilactones. Further purification by treatment with or filtration over activated charcoal, by treatment with or filtration over alumina and by recrystn. with an acceptable solvent or solvent mixture leads to exts. with a content of terpene trilactones higher than 50%. Unwanted levels of ginkgolic acids are reduced to acceptable levels by reversed phase chromatog.

IC ICM C07D311-78

ICS C07D498-14; A61K035-78

INCL 424752000; 549280000

CC 11-1 (Plant Biochemistry)

Section cross-reference(s): 63

ST terpene trilactone extn Ginkgo biloba; ginkgolide extn Ginkgo; bilobalide extn Ginkgo

IT Ginkgo biloba

(extraction of terpene trilactones (ginkgolides, bilobalide) from leaves and

pharmaceutical powders of Ginkgo biloba)

IT Oxidizing agents

(for extraction of terpene trilactones (ginkgolides, bilobalide) from leaves

and pharmaceutical powders of Ginkgo biloba)

IT Reversed phase chromatography

(for isolating terpene trilactones (ginkgolides, bilobalide) from Ginkgo biloba)

IT Terpenes, biological studies

RL: NPO (Natural product occurrence); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)

(lactones; extraction of terpene trilactones (ginkgolides, bilobalide) from leaves and pharmaceutical powders of Ginkgo biloba)

IT Catalysts

(metal or non metal; for destroying excess of oxidation reagent in organic

layer during extraction of terpene trilactones (ginkgolides, bilobalide) from leaves and pharmaceutical powders of Ginkgo biloba)

IT Extraction

(of terpene trilactones (ginkgolides, bilobalide) from leaves and pharmaceutical powders of Ginkgo biloba)

IT 15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C 15291-77-7P, Ginkgolide B 33570-04-6P, Bilobalide 107438-79-9P, Ginkgolide J

RL: NPO (Natural product occurrence); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)

(extraction of terpene trilactones (ginkgolides, bilobalide) from leaves and

pharmaceutical powders of Ginkgo biloba)

IT 22910-60-7 111047-30-4 496811-17-7

RL: NPO (Natural product occurrence); REM (Removal or disposal); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(extraction of terpene trilactones (ginkgolides, bilobalide) from leaves and

pharmaceutical powders of Ginkgo biloba)

IT 64-19-7, Acetic acid, reactions 144-55-8, Sodium bicarbonate, reactions 497-19-8, Sodium carbonate, reactions 584-08-7, Potassium carbonate 1310-58-3, Potassium hydroxide, reactions 1310-73-2, Sodium hydroxide, reactions 7647-01-0, Hydrochloric acid, reactions 7664-38-2, Phosphoric acid, reactions 7664-93-9, Sulfuric acid, reactions 7697-37-2, Nitric acid, reactions 7722-84-1, Hydrogen peroxide, reactions 7757-83-7, Sodium sulfite 7772-98-7, Sodium thiosulfate 12125-02-9, Ammonium chloride, reactions 16721-80-5, Sodium hydrosulfide RL: RGT (Reagent); RACT (Reactant or reagent)

(extraction of terpene trilactones (ginkgolides, bilobalide) from leaves and

pharmaceutical powders of Ginkgo biloba)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L41 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1999:355742 CAPLUS $\underline{\text{Full-text}}$

DOCUMENT NUMBER: 131:9615

TITLE: Methods for preparation of bioginkgo

INVENTOR(S): Zhang, De Cheng; Yu, Zhenghun; Cooper, Raymond; Chang,

Michael

PATENT ASSIGNEE(S): Pharmanex, Inc., USA SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT	NO.			KIN	D :	DATE			APPL	ICAT	ION 1	NO.		D	ATE	
WO 9926643 A1 19990603					0603	WO 1998-US25165					19981123					
W:	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,
	DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IS,	JP,	ΚE,
	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,
	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,
	TT,	UA,	UG,	UZ,	VN,	YU,	ZW									
RW:	GH,	GM,	KE,	LS,	MW,	SD,	SZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,	ES,
	FΙ,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,

```
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    AU 9919022
                     A
                               19990615 AU 1999-19022
                                                                  19981123
    EP 1033994
                        A1
                               20000913
                                          EP 1998-963768
                                                                  19981123
        R: AT, BE, DE, DK, ES, FR, GB, IT, NL, SE, PT, IE, FI
    JP 2003514761
                        T 20030422
                                          JP 2000-521845
                                                                  19981123
    JP 4249388
                         В2
                               20090402
PRIORITY APPLN. INFO.:
                                           US 1997-66867P P 19971125
                                           WO 1998-US25165
                                                              W 19981123
    Entered STN: 10 Jun 1999
ED
     The invention relates to a novel process for producing novel exts. of Ginkgo
AΒ
     biloba leaves. The invention further relates to a process which produces
     novel exts. of Ginkgo biloba with an increased amount of one of the major
     lactones and having an improved biol. activity. Further, the disclosed
     process allows for a controlled method to produce a desired ratio of flavone
     glycosides to lactones in the end product. The invention also discloses new
     exts. from Ginkgo biloba, particularly for oral application. The leaves of
     Ginkgo biloba are collected during the months of August through Oct. from 3-5
     yr of tree age in the Shandong province of China.
IC
    ICM A61K035-78
    ICS A61K031-70
CC
    63-4 (Pharmaceuticals)
    ginkgo biloba ext purifn dietary supplement
ST
    Ginkgo biloba
ΤT
    Nutrients
        (extraction and purification of Ginkgo biloba leaves for use
       as dietary supplements)
ΙT
    Lactones
    RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PUR
    (Purification or recovery); THU (Therapeutic use); BIOL (Biological
    study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
        (extraction and purification of Ginkgo biloba leaves for use
       as dietary supplements)
    Glycosides
    RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PUR
     (Purification or recovery); THU (Therapeutic use); BIOL (Biological
    study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
        (flavonoid, oxo; extraction and purification of Ginhgo biloba
       leaves for use as dietary supplements)
    Polyamides, analysis
ΙΤ
    RL: ARU (Analytical role, unclassified); ANST (Analytical study)
        (stationary phase for column chromatog.; extraction and purification of
       Ginkgo biloba leaves for use as dietary supplements)
IΤ
    15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C
    15291-77-7P, Ginkgolide B
    RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
    PUR (Purification or recovery); THU (Therapeutic use);
    BIOL (Biological study); OCCU (Occurrence); PREP (Preparation);
    USES (Uses)
        (extraction and purification of Ginkgo biloba leaves for use
        as dietary supplements)
ΙT
    22910-60-7, Ginkgolic acid
    RL: REM (Removal or disposal); PROC (Process)
        (extraction and purification of Ginkgo biloba leaves for use
        as dietary supplements)
    64-17-5, Ethanol, uses 141-78-6, Acetic acid ethyl ester, uses
ΙT
    RL: NUU (Other use, unclassified); USES (Uses)
        (solvent; extraction and purification of Ginkgo biloba leaves
       for use as dietary supplements)
OS.CITING REF COUNT: 1
                              THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
                              (1 CITINGS)
```

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L53 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2009:1457148 CAPLUS Full-text Method for isolating terpene trilactones (ginkgolides,

bilobalide) from leaves and pharmaceutical

powders of Ginkgo biloba

INVENTOR(S): Lichtblau, Dirk; Berova, Nina; Berger, John;

Nakanishi, Koji

PATENT ASSIGNEE(S): Columbia University, USA

SOURCE: U.S. Pat. Appl. Publ., Cont. of U.S. Ser. No. 194,089.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040077883	A1	20040422	US 2003-615346	20030707
US 6844451	В2	20050118		
US 20030031736	A1	20030213	US 2002-194089	20020711
US 6590109	В2	20030708		
US 20050136136	A1	20050623	US 2005-36409	20050114
PRIORITY APPLN. INFO.:			US 2001-903049	B2 20010711
			US 2002-194089	A1 20020711
			US 2003-615346	A1 20030707

ED Entered STN: 24 Nov 2009

AΒ A method of isolating terpene trilactones (ginkgolide A (GA), ginkgolide B (GB), ginkgolide C (GC), ginkgolide J (GJ) and bilobalide (BB)) from leaves and pharmaceutical powders of Ginkgo biloba (G. biloba) comprises the steps of suspending leaves or pharmaceutical powders of Ginkgo biloba in either water or an aqueous solution of an oxidation reagent hydrogen peroxide and an acid selected from acetic acid, hydrochloric acid, nitric acid, phosphoric acid and sulfuric acid; extracting the terpene trilactones using an acceptable extraction agent selected from lower acetates such as Et acetate, lower ketones, lower ether such as diethylether, lower alcs. and benzenes; separating the organic layer from the aqueous layer; washing the organic layer with an acceptable aqueous salt such as sodium bicarbonate, sodium sulfite, sodium chloride, sodium thiosulfate or hydroxide solution, which may be an alkaline solution, or with water; and drying the organic layer to form a dried extract containing terpene trilactones. Further purification by treatment with or filtration over activated charcoal, by treatment with or filtration over alumina and by recrystn. with an acceptable solvent or solvent mixture leads to exts. with a content of terpene trilactones higher than 50%. Unwanted levels of ginkgolic acids are reduced to acceptable levels by reversed phase chromatog.

IC ICM C07D493-14

INCL 549275000; 549276000

ST g biloba leaf ext; ginkgo biloba leaf ext; terpene trilactone; ttl; ginkgolides a; ga; ginkgolides b; gb; ginkgolides c; gc; ginkgolides j; gj; bilobalide; bb; recrystn; chromatog; reversed phase chromatog; ethyl acetate extn; diethylether extn; water extn

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

L53 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1358096 CAPLUS <u>Full-text</u>

TITLE: Method for isolating terpene trilactores (ginkgolides,

bilobadide) from leaves and pharmaceutical powders of

ginkgo biloba/Method for extracting

qinkgolides and bilobadide from Ginkgo biloba

leaves

INVENTOR(S): Lichtblau, Dirk; Berova, Nina; Berger, John;

Nakanishi, Koji

PATENT ASSIGNEE(S): The Trustees of Columbia University, USA

SOURCE: U.S. Pat. Appl. Publ., Cont. U.S. Ser. No. 615,346.

Abandoned CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050136136	A1	20050623	US 2005-36409	20050114
US 20030031736	A1	20030213	US 2002-194089	20020711
US 6590109	B2	20030708		
US 20040077883	A1	20040422	US 2003-615346	20030707
US 6844451	B2	20050118		
PRIORITY APPLN. INFO.:			US 2001-903049	B2 20010711
			US 2002-194089	A1 20020711
			US 2003-615346 .	A1 20030707

ED Entered STN: 05 Nov 2009

AΒ A method for extracting terpene trilactones (ginkgolides A,B,C,J and bilobalide) from Ginkgo biloba plant material (e.g. leaf) or extract comprises the steps of: suspending the plant material or extract in either water or an aqueous solution of an oxidation reagent (such as 3-chloroperbenzoic acid (MCPBA), MnO2, or hydrogen peroxide), wherein the aqueous solution may further comprise acid selected from acetic acid, hydrochloric acid, nitric acid, phosphoric acid and sulfuric acid; extracting the terpene trilactones using an acceptable extraction agent selected from lower acetates (such as Et acetate), lower ketones, lower ether, lower alcs. and benzenes; separating the organic layer from the aqueous layer; washing the organic layer at least once with an acceptable aqueous salt or hydroxide solution selected from ammonium chloride, sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, sodium thiosulfate, sodium sulfite and sodium hydrosulfide, which may be alkaline solution; contacting the organic layer with a metal or nonmetal catalyst to destroy excess oxidation reagent in the organic layer; and drying the organic layer to form a dried extract containing terpene trilactones. Further purification by treatment with or filtration over activated charcoal, by treatment with or filtration over alumina and by recrystn. with an acceptable solvent or solvent mixture leads to exts. with a content of terpene trilactones higher than 50%. Unwanted levels of ginkgolic acids are reduced to acceptable levels by reversed phase chromatog. The method provides higher purity and higher yields; decreases time for the extraction process thus helping to save energy; maintains the natural distribution of the terpene trilactone levels and gives high recovery of trilactones.

IC ICM C07D493-14 ICS A61K035-78

INCL 424752000; 549275000; 549297000

ST ginkgo biloba leaf; ginkgo biloba leaf ext; terpene trilactone; ginkgolide; ginkgolide a; ginkgolide b; ginkgolide c; ginkgolide j; bilobalide; ethyl acetate extn; recrystn; reversed phase chromatog; chromatog

=>

=> fil hcap FILE 'HCAPLUS' ENTERED AT 17:21:49 ON 27 OCT 2009 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Oct 2009 VOL 151 ISS 18

FILE LAST UPDATED: 26 Oct 2009 (20091026/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d que 135
            14 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (100-39-0/BI OR
               106-95-6/BI OR 107438-79-9/BI OR 15291-75-5/BI OR 15291-76-6/BI
                OR 15291-77-7/BI OR 170288-58-1/BI OR 17690-16-3/BI OR
               2746-25-0/BI OR 33570-04-6/BI OR 4392-24-9/BI OR 502421-88-7/BI
                OR 534-17-8/BI OR 584-08-7/BI)
L3
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON 852046-13-0/BI
L4
            15 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L2 OR L3
L6
          4569 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON GINKGO BILOBA+PFT,NT/C
               Т
L7
          2201 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON TERPENES+PFT,NT/CT(L)?
               LACTON?
L8
           184 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L7 AND L6
L9
       1075549 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON SEPARATION+PFT,NT/CT
L10
            83 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L9 AND L8
            49 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L10 AND ?CHROMATOG?
L12
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE A"/CN
L13
             1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE B"/CN
L14
```

L15	1	SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE C"/CN
L16	1	SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "GINKGOLIDE J"/CN
L17	4	SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (L13 OR L14 OR L15
		OR L16)
L18	8	SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (107438-79-9/CRN OR
		15291-75-5/CRN OR 15291-76-6/CRN OR 15291-77-7/CRN)
L19	12	SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L17 OR L18
L20	97	SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L19(L)PUR/RL
L22	1	SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L4 AND K/ELS
L23	120	SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON 584-08-7/CRN OR L22
L24	1	SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON DIMETHYLFORMAMIDE/CN
L26	4742	SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L24 OR 68-12-2/CRN
L28	1	SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "BENZYL BROMIDE"/CN
L29	118	SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L28 OR 100-39-0/CRN
L30	117	SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L20 OR L19(L)(?ISOLAT?
		OR ?PURIF?)
L31	4	SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L30 AND (L23 OR L26
		OR L29)
L33	40	SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L30 AND ?CHROMATOG?
L34	4	SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L31 AND L33
L35	51	SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L34 OR L12

=> d 135 ibib abs hitind tot

L35 ANSWER 1 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2009:459053 HCAPLUS Full-text

DOCUMENT NUMBER: 151:273173

TITLE: Determination of the content of terpene lactone in

Yinqu Capsule

AUTHOR(S): Shao, Wenhao; Zhang, Xiantao; Gu, Yan; Zhang, Yazhao

CORPORATE SOURCE: Nanjing Hailing Traditional Chinese Medicine

Pharmaceutical Technology Research Co., Ltd., Nanjing,

210049, Peop. Rep. China

SOURCE: Zhongchengyao (2009), 31(2), S4-S5

CODEN: ZHONBS; ISSN: 1001-1528

PUBLISHER: Guojia Shipin Yaopin Jiandu Guanliju, Xinxi Zhongxin

Zhongchengyao Xinxizhan

DOCUMENT TYPE: Journal LANGUAGE: Chinese

AB The content of terpene lactone in Yinqu Capsule was determined by HPLC on Alltima C18 (4.6 mm × 250 mm, 5 μm). The mobile phase was methanol-water (30:70). Evaporative light-scattering detector (ELSD) was used for determination of terpene lactone. The temperature of drift tube was 110°, and the flow rate of carrier gas was 2.8 L/min. Bilobalide, ginkgolide A, ginkgolide B and ginkgolide C were used as reference substances. The regression equations for bilobalide, ginkgolide A, ginkgolide B and ginkgolide C were Y = 1.6137X +4.5278 (r = 0.9996), Y = 1.587X +4.4118 , Y = 1.6341X +4.3623 (r = 0.9999), and Y = 1.576X +4.5002 (r = 0.99965), and the linear ranges were 1.160-23.20, 1.50-30.00, 0.77-15.40, and 0.73-14.6 μg. This method is simple and the result is accurate.

CC 64-1 (Pharmaceutical Analysis)

IT Ginkgo biloba

HPLC

Light scattering

Monascus

Pharmaceutical capsules

Quality control

(determination of content of terpene lactone in Yinqu Capsule by high performance liquid chromatog.)

IT Lactones

Terpenes

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(determination of content of terpene lactone in Yinqu Capsule by high performance liquid chromatog.)

L35 ANSWER 2 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2009:375002 HCAPLUS Full-text

DOCUMENT NUMBER: 150:431502

TITLE: Method for separating and purifying ginkgolides and

bilobalide monomer from Chinese medicine Ginkgo

INVENTOR(S): Zhang, Li; Yang, Bing; Dong, Weizhen; Xia, Ke

PATENT ASSIGNEE(S): Chendu Push Biotechnology Co., Ltd., Peop. Rep. China SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 10pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101392000	A	20090325	CN 2008-10046162	20080925
PRIORITY APPLN. INFO.:			CN 2008-10046162	20080925

The title method comprises of: (1) weighing ginkgo leaf, adding 30-50 volume% AΒ ethanol solution, stirring for dissoln. at 40-60 °C, standing for 2 h, pouring supernatant out, adding petroleum ether (boiling range of 60-90 $^{\circ}$ C), extracting for three times, recovering petroleum ether, and discarding remnant, removing ginkgoic acid, (2) vacuum-concentrating water phase obtained in step 1 at 60 °C to recover organic reagent, adding Et acetate to water solution, extracting for three times, combining Et acetate phases, backextracting with water for two times, and vacuum-concentrating at 60 $^{\circ}\mathrm{C}$ to obtain total terpene lactones, (3) dissolving in 80 volume% methanol, and performing microfiltration, (4) high-efficiency separating methanol solution of total terpene lactones via an HPLC column to resp. collect solns. of ginkgolides A, B, C and J and bilobalide monomer, and (5) vacuum-concentrating at 50-60 $^{\circ}\text{C}$ to recover methanol, adsorbing with AB-8 macroporous resin, desorbing with 95% ethanol, vacuum-concentrating, and vacuum-drying with coexistence of phosphorus pentoxide to obtain ginkgolides A, B, C and J and bilobalide monomer with purity more than 98%. The method has the advantages of high production amount, good product quality, high yield and low cost, and is suitable for industrialized production

CC 63-4 (Pharmaceuticals)

IT Preparative liquid chromatography

(high-performance reversed-phase; method for separating and purifying ginkgolides and bilobalide monomer from Chinese medicine Ginkgo)

IT Terpenes, biological studies

RL: ANT (Analyte); PUR (Purification or recovery); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(lactones; method for separating and purifying ginkgolides and bilobalide monomer from Chinese medicine Ginkgo)

IT Ginkgo biloba

Natural products, pharmaceutical

(method for separating and purifying ginkgolides and bilobalide monomer from $% \left(1\right) =\left(1\right) +\left(1\right$

Chinese medicine Ginkgo)

ΙΤ Reversed phase HPLC

(preparative; method for separating and purifying ginkgolides and bilobalide

monomer from Chinese medicine Ginkgo)

L35 ANSWER 3 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2009:231907 HCAPLUS Full-text

DOCUMENT NUMBER: 150:406783

TITLE: Chemical analysis and quality control of Ginkgo biloba

leaves, extracts, and phytopharmaceuticals

van Beek, Teris A.; Montoro, Paola AUTHOR(S):

CORPORATE SOURCE: Laboratory of Organic Chemistry, Natural Products Chemistry Group, Wageningen University, Wageningen,

6703 HB, Neth.

SOURCE: Journal of Chromatography, A (2009), 1216(11),

2002-2032

CODEN: JCRAEY; ISSN: 0021-9673

Elsevier B.V. PUBLISHER:

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

A review. The chemical anal. and quality control of Ginkgo leaves, exts., AΒ phytopharmaceuticals and some herbal supplements is comprehensively reviewed. The review is an update of a similar, earlier review in this journal. Since 2001 over 3000 papers on Ginkgo biloba have appeared, and about 400 of them pertain to chemical anal. in a broad sense and are cited herein. The more important ones are discussed and, where relevant, compared with the best methods published prior to 2002. In the same period over 2500 patents were field on Ginkgo and the very few related to anal. are mentioned as well. Important constituents include terpene trilactones, i.e. ginkgolide A, B, C, J and bilobalide, flavonol glycosides, biflavones, proanthocyanidins, alkylphenols, simple phenolic acids, 6-hydroxykynurenic acid, 4-0methylpyridoxine and polyprenols. In the most common so-called "standardized" Ginkgo exts. and phytopharmaceuticals several of these classes are no longer present. About 130 new papers deal with the anal. of the terpene trilactones. They are mostly extracted with MeOH or water or mixts. thereof. Supercrit. fluid extraction and pressurized water extraction are also possible. Sample clean-up is mostly by liquid-liquid extraction with Et acetate although no sample clean-up at all in combination with LC/MS/MS is gaining in importance. Separation and detection can be routinely carried out by RP-HPLC with ELSD, RI or MS, or by GC/FID or GC/MS after silylation. Hydrolysis followed by LC/MS allows the simultaneous anal. of terpene trilactones and flavonol aglycons. No quant. procedure for all major flavonol glycosides has yet been published because they are not com. available. The quantitation of a few available glycosides was carried out but does not serve a real purpose. After acidic hydrolysis to the aglycons quercetin, kaempferol, and isorhamnetin and separation by HPLC, quantitation is straightforward and yields by recalcn. an estimation of the original total flavonol glycoside content. A profile of the genuine flavonol glycosides can detect poor storage or adulteration. Although the toxicity of Ginkgo alkylphenols upon oral administration has never been undoubtedly proven, most suppliers limit their content in exts. to 5 ppm and dozens of papers on their anal. were published. One procedure in which a methanolic extract is directly injected on a C8 HPLC column appears superior in terms of sensitivity (<5 ppm), separation, simplicity, and validation and will be incorporated in the European Pharmacopoeia. Alternatively GC/MS and ELISA methods can be used. A sharp contrast to the plethora of papers on terpene trilactones, flavonol glycosides, and ginkgolic acids forms the low number of papers on biflavones, proanthocyanidins, simple phenolics, simple acids, and other constituents that make up the remaining 70% of Ginkgo standardized exts. More research in this direction is clearly needed.

the anal. of Ginkgo proanthocyanidins (7%) for instance, no reliable assays are yet existing. Finally the growing literature on pharmacokinetic and fingerprinting studies of Ginkgo is briefly summarized.

CC 64-0 (Pharmaceutical Analysis)

Section cross-reference(s): 63

IT Gas chromatography

Natural products, pharmaceutical

Quality control

Reversed phase HPLC

(chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Liquid chromatography

(combined with tandem mass spectrometry; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Terpenes, analysis

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(lactones; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Ginkgo biloba

(leaf; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Tandem mass spectrometry

(liquid chromatog., combined with; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

IT Extraction

(supercrit.; chemical anal. and quality control of Ginkgo biloba leaves, exts., and phytopharmaceuticals)

OS.CITING REF COUNT:

THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

(4 CITINGS)

REFERENCE COUNT:

THERE ARE 589 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L35 ANSWER 4 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2009:176910 HCAPLUS Full-text

4

589

TITLE: GC determination of terpene lactones in gingko leaf

extracts with capillary chromatographic column

AUTHOR(S): Liu, Hong-mei; Zhou, Qing-xia; Yang, Wen-ling

CORPORATE SOURCE: College of Chemistry and Pharmaceutical Engineering,

Hebei University of Science and Technology, Shijiazhuang, 0050018, Peop. Rep. China

SOURCE: Lihua Jianyan, Huaxue Fence (2008), 44(10), 982-985

CODEN: LJHFE2; ISSN: 1001-4020

PUBLISHER: Lihua Jianyan Huaxue Fence Bianjibu

DOCUMENT TYPE: Journal LANGUAGE: Chinese

- AB Chromatog. conditions for separation of terpenes (named in abbreviation as GA, GB, GC, GJ and BB) from exts. of gingko leaves with capillary column were studied, and the terpenes were satisfactorily separated Squalane was used as internal standard in the determination. The relative mass correction factors were calculated theor. and also determined exptl. Tests for recovery of BB, GA, GB and GC were made by addition of stds. to a sample of known terpene contents and analyzed by the proposed method, and values of recovery obtained were 95.2%, 95.5%, 94.6% and 96.1% resp.
- CC 64 (Pharmaceutical Analysis)
- ST terpene lactone gingko leaf ext capillary gas chromatog
- IT INDEXING IN PROGRESS
- IT Capillary gas chromatography Ginkgo biloba

Leaf

(GC determination of terpene lactones in gingko leaf exts. with capillary chromatog. column)

15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7 ΤТ , Ginkgolide B 33570-04-6, Bilobalide 107438-79-9, Ginkgolide J RL: ANT (Analyte); ANST (Analytical study)

(GC determination of terpene lactones in gingko leaf exts. with capillary chromatog. column)

67-56-1, Methanol 67-64-1, Acetone 75-77-4, Trimethylchlorosilane 111-01-3, Squalane 141-78-6, Ethyl acetate 1333-74-0, Hydrogen 7727-37-9, Nitrogen 25561-30-2, Bis(trimethylsilyl)trifluoroacetamide RL: ARU (Analytical role, unclassified); ANST (Analytical study)

(GC determination of terpene lactones in gingko leaf exts. with capillary chromatog. column)

L35 ANSWER 5 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2009:97523 HCAPLUS Full-text

DOCUMENT NUMBER: 151:322531

Determination of total flavonol glycosides and terpene TITLE:

lactones in Ginkgo biloba extract sustained release

microspheres by HPLC

Su, Mingwu; Yang, Xin; Zhao, Jun AUTHOR(S):

CORPORATE SOURCE: Hubei College of TCM, Wuhan, 430065, Peop. Rep. China

Zhongguo Yaoshi (Wuhan, China) (2008), 11(12), SOURCE:

1460-1462

CODEN: ZYWCAH; ISSN: 1008-049X Yaowu Liuxingbingxue Zazhishe

DOCUMENT TYPE: Journal Chinese LANGUAGE:

The objective of this paper is to determine the total flavonol glycosides and terpene lactones in the Ginkgo biloba extract sustained release microspheres. The HPLC method was adopted and the Aglient C18 column (250 mm \times 4.6 mm , 5 μ m) was used with methanol-0.4% phosphate (52:48) and methanol-waters (35:65) as a mobile phase resp., the flow rate was 1.0 mL/min-1. The results show that the ginkgetins and the gingko terpene lactones could be completely separated from each other, and had good linear relationship. It was concluded that the method is accurate, reliable, sensitive and reproducible, which can be used for quality control in the Ginkgo biloba extract sustained release microspheres sustained release microspheres.

CC 64-1 (Pharmaceutical Analysis)

ΙT Pharmaceutical microspheres

> (controlled-release; determination of total flavonol glycosides and terpene lactones in Ginkgo biloba extract sustained release microspheres by high performance liquid chromatog.)

Ginkgo biloba ΙT

PUBLISHER:

Reversed phase HPLC

(determination of total flavonol glycosides and terpene lactones in Ginkgo biloba extract sustained release microspheres by high performance liquid chromatog.)

ΙT Glycosides

> RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(flavonoid; determination of total flavonol glycosides and terpene lactones

Ginkgo biloba extract sustained release microspheres by high performance liquid chromatog.)

ΙΤ Terpenes

in

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(lactones; determination of total flavonol glycosides and terpene

Lactones in Ginkgo biloba extract sustained release microspheres
by high performance liquid chromatog.)

IT Controlled-release drug delivery systems

(microspheres; determination of total flavonol glycosides and terpene lactones $% \left(1\right) =\left(1\right) +\left(1\right) +\left($

in Ginkgo biloba extract sustained release microspheres by high performance liquid chromatog.)

IT 117-39-5, Quercetin 480-19-3, Isorhamnetin 481-46-9, Ginkgetin 520-18-3 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B 33570-04-6, Bilobalide

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(determination of total flavonol glycosides and terpene lactones in Ginkgo biloba extract sustained release microspheres by high performance liquid chromatog.)

L35 ANSWER 6 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2007:1165281 HCAPLUS Full-text

DOCUMENT NUMBER: 147:413463

TITLE: Analysis of flavonol aglycones and terpenelactones in

Ginkgo biloba extract: a comparison of

high-performance thin-layer chromatography and column high-performance liquid chromatography

AUTHOR(S): Gray, Dean E.; Messer, Dale; Porter, Andrew; Hefner,

Brian: Logan, Dama: Harris, Pogor K.; Clark, Alico P.;

Brian; Logan, Dama; Harris, Roger K.; Clark, Alice P.;

Algaier, Joseph A.; Overstreet, J. Diane; Smith,

Cynthia S.

CORPORATE SOURCE: Midwest Research Institute, Kansas City, MO, 64110,

USA

SOURCE: Journal of AOAC International (2007), 90(5), 1203-1209

CODEN: JAINEE; ISSN: 1060-3271

PUBLISHER: AOAC International

DOCUMENT TYPE: Journal LANGUAGE: English

Advancements in automated high-performance thin-layer chromatog. (HPTLC) have made it feasible to assess its use for the quant. anal. of marker compds. in botanical prepns. We report here the findings of method comparisons for the terpenelactones and flavonol aglycons by column high-performance liquid chromatog. (HPLC) with evaporative light scattering and UV detection, and HPTLC with a scanning densitometer. For the HPTLC assay of terpenelactones, total bilobalide, ginkgolide A, and ginkgolide B consistently achieved <70% of the total determined using HPLC, regardless of variations to postohromatog. derivatization time and temperature Accuracy testing showed the possibility of a matrix interference. In contrast, a good relationship (95%) was determined between HPTLC and HPLC for determination of total flavonol glycosides (calculated from combined quercetin, kaempferol, and isorhamnetin) from an acid-hydrolyzed Ginkgo biloba L. (GBE) sample. The HPTLC flavonol aglycon method also performed well in terms of accuracy (overall average of 96% recovery for the 3 aglycons) and consecutive plate repeatability (overall percent relative standard deviation of 4.4). It is demonstrated that HPTLC can be a time-saving complement to HPLC for routine anal. of the flavonol glycosides in GBE.

CC 64-2 (Pharmaceutical Analysis) Section cross-reference(s): 63

IT HPLC

(anal. of flavonol aglycons and terpenelactones in Ginkgo biloba extract)

IT Ginkgo biloba

(extract; anal. of flavonol aglycons and terpenelactones in Ginkgo biloba extract)

IT TLC (thin layer chromatography)

(high-performance; anal. of flavonol aglycons and terpenelactones in Ginkgo biloba extract)

IT Terpenes, analysis

RL: ANT (Analyte); ANST (Analytical study) (lactones; anal. of flavonol aglycons and terpenelactones in Ginkgo biloba extract)

IT 117-39-5, Quercetin 480-19-3, Isorhamnetin 520-18-3, Kaempferol

15291-75-5, Ginkgolide A 15291-77-7, Ginkgolide B

33570-04-6, Bilobalide

RL: ANT (Analyte); ANST (Analytical study)

(anal. of flavonol aglycons and terpenelactones in Ginkgo

biloba extract)

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD

(7 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 7 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2007:942838 HCAPLUS Full-text

DOCUMENT NUMBER: 147:330668

TITLE: Characterization of a suite of ginkgo-containing

standard reference materials

AUTHOR(S): Rimmer, Catherine A.; Howerton, Samuel B.; Sharpless,

Katherine E.; Sander, Lane C.; Long, Stephen E.;
Murphy, Karen E.; Porter, Barbara J.; Putzbach,

Karsten; Rearick, Michael S.; Wise, Stephen A.; Wood, Laura J.; Zeisler, Rolf; Hancock, Diane K.; Yen, James

H.; Betz, Joseph M.; NguyenPho, Agnes; Yang, Lu; Scriver, Christine; Willie, Scott; Sturgeon, Ralph; Schaneberg, Brian; Nelson, Christina; Skamarack, Jules; Pan, Meide; Levanseler, Kerri; Gray, Dean; Waysek, Edward H.; Blatter, Anne; Reich, Eike

Waysek, Edward H.; Blatter, Anne; Reich, Eike National Institute of Standards and Technology,

Gaithersburg, MD, 20899-8392, USA

SOURCE: Analytical and Bioanalytical Chemistry (2007), 389(1),

179-196

CODEN: ABCNBP; ISSN: 1618-2642

PUBLISHER: Springer DOCUMENT TYPE: Journal LANGUAGE: English

CORPORATE SOURCE:

As uite of three ginkgo-containing dietary supplement Standard Reference Materials (SRMs) has been issued by the National Institute of Stds. and Technol. (NIST) with certified values for flavonoid aglycons, ginkgolides, bilobalide, and selected toxic trace elements. The materials represent a range of matrixes (i.e., plant, extract, and finished product) that provide different anal. challenges. The constituents have been determined by at least two independent anal. methods with measurements performed by NIST and at least one collaborating laboratory The methods utilized different extns., chromatog. sepns., modes of detection, and approaches to quantitation. The SRMs are primarily intended for method validation and for use as control materials to support the anal. of dietary supplements and related botanical materials.

CC 64-2 (Pharmaceutical Analysis)

IT Dietary supplements

Ginkgo biloba

(characterization of suite of ginkgo-containing standard reference materials)

IT Terpenes, analysis

RL: ANT (Analyte); ANST (Analytical study)

(lactones; characterization of suite of ginkgo-containing standard

reference materials)

ΙT Mass spectrometry

> (liquid chromatog. combined with; characterization of suite of ginkgo-containing standard reference materials)

ΙT Liquid chromatography

> (mass spectrometry combined with; characterization of suite of ginkgo-containing standard reference materials)

OS.CITING REF COUNT: THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD 3

(3 CITINGS)

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 8 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN 2007:659241 HCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER: 147:39511

TITLE: Comparison of the terpene lactones and flavonols

contents in G. biloba commercial samples and the NIST

standard reference materials using LC/UV/MS

Mustafa, Ozcan; Brendan, Mcauley; Pei, Chen AUTHOR(S): CORPORATE SOURCE:

Agricultural Research Service, Beltsville Human

Nutrition Research Center, Food Composition Lab, U.S. Department of Agriculture, Beltsville, MD, 20705, USA

SOURCE: Yaowu Shipin Fenxi (2007), 15(1), 55-62

CODEN: YSFEEP; ISSN: 1021-9498

Bureau of Food and Drug Analysis, Dep. of Health, PUBLISHER:

Executive Yuan

DOCUMENT TYPE: Journal LANGUAGE: English

The leaf extract of Ginkgo biloba has purported value for improving mental AB capacities in Alzheimer's patients. The flavonols and the terpene lactones are considered to be the 2 major groups of active components that influence human health. Almost all the clin. studies regarding G. biloba were using either EGb 761, a proprietary extract of G. Biloba leaves, or an extract prepared according to the standard set by it. Consequently, most of the com. G. biloba products were labeled with their content accordingly. This paper studied the compns. of both flavonols and terpene lactones of 7 com. available G. biloba products and 3 standard reference materials (SRM 3246 G. biloba leaves, SRM 3247 G. biloba extract, and SRM 3248 G. biloba tablet) from the National Institute of Stds. and Technol. (NIST). In this study, a chromatog. method with UV and mass spectroscopic detection was employed for the determination of the compns. of flavonols and the terpene lactones in Ginkgo products using gradient reversed-phase HPLC. MeOH-water (1:1) exts. of terpene lactones and flavonols out of G. biloba products and NIST SRMs were analyzed qual. and quant. While the relative compns. of the flavonol glycosides were similar for the NIST SRMs, those for the com. G. biloba products varied significantly. The relative concns. of terpene lactones were also shown significant differences among products, but not as dramatic as that of flavonols.

CC 64-2 (Pharmaceutical Analysis) Section cross-reference(s): 63

ΙT Reversed phase HPLC

(combined with mass spectrometry; comparison of terpene lactones and flavonols contents in G. biloba com. samples using LC/UV/MS)

ΙT Ginkgo biloba

> (exts.; comparison of terpene lactones and flavonols contents in G. biloba com. samples using LC/UV/MS)

ΤТ Terpenes, analysis

RL: ANT (Analyte); ANST (Analytical study)

(lactones; comparison of terpene lactones and

flavonols contents in G. biloba com. samples using LC/UV/MS)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD

(2 CITINGS)

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 9 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2007:597593 HCAPLUS Full-text

DOCUMENT NUMBER: 147:101987

TITLE: New formulations of traditional Chinese medicine

containing troxerutin and Ginkgo biloba flavonoids for

treating cardiovascular and cerebrovascular diseases

INVENTOR(S): Yu, Wenfeng

PATENT ASSIGNEE(S): Beijing Qiyuanyide Medicine Institute, Peop. Rep.

China

SOURCE: Faming Zhuanli Shenging Gongkai Shuomingshu, 14pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1969892	A	20070530	CN 2005-10115004	20051123
PRIORITY APPLN. INFO.:			CN 2005-10115004	20051123

The invention provides new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases. The pharmaceutical composition is composed of (by weight part) troxerutin 1, and Ginkgo biloba leaf flavonoids 0.1-50 or lactones 0.01-50 or mixture of lactones and flavonoids 0.1-30. The pharmaceutical composition can be manufactured into injections, oral prepns., etc. The pharmaceutical composition is used for treating coronary heart disease, angina pectoris, miocardial infarction, arrhythmia, cerebral thrombosis, senile dementia, thrombophlebitis, capillary bleeding, diabetes mellitus and complications, hepatorenal syndrome, etc. The manufacturing and quality control methods are also disclosed. The pharmaceutical composition has advantages of high purity, definite constituent, controllable quality, enhanced therapeutic effect, reliable security and stable efficacy.

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 64

IT Terpenes

RL: ANT (Analyte); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses) (lactores; new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases)

IT Anti-Alzheimer's agents

Antiarrhythmics
Anticonvulsants
Antidiabetic agents
Cardiovascular agents
Dripping pills
Flocculation

Freeze drying Ginkgo biloba

Human

Liquid chromatography
Oral drug delivery systems
Pharmaceutical capsules

Pharmaceutical films

Pharmaceutical granules

Pharmaceutical liposomes

Pharmaceutical powders

Pharmaceutical tablets

Platelet aggregation inhibitors

Quality control

Sedimentation (separation)

Solvent extraction

Stability

(new formulations of traditional Chinese medicine containing troxerutin and Ginkgo biloba flavonoids for treating cardiovascular and cerebrovascular diseases)

L35 ANSWER 10 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2007:391260 HCAPLUS Full-text

DOCUMENT NUMBER: 146:448775

TITLE: Quality control method of traditional Chinese medical

composition of Astragalus membranaceus and Ginkgo

biloba

INVENTOR(S): Yu, Wenfeng

PATENT ASSIGNEE(S): Beijing Qiyuanyide Medicine Institute, Peop. Rep.

China

SOURCE: Faming Zhuanli Shenging Gongkai Shuomingshu, 67pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1939393	A	20070404	CN 2005-10107822	20050930
PRIORITY APPLN. INF	·O.:		CN 2005-10107822	20050930

- The invention provides a new quality control method of traditional Chinese medical composition of Astragalus membranaceus and Ginkgo biloba. The quality control method comprises determination of flavonoids of Astragalus membranaceus, flavonoids of Ginkgo biloba leaf, saponins of Astragalus membranaceus, and terpenoid lactone of Ginkgo biloba leaf by fingerprint chromatogram, identification of Astragalus membranaceus, Ginkgo biloba leaf, total flavonol glycosides, terpenoid lactone, formononetin, calycosin, and astragaloside, and content determination of total flavonol glycosides, terpenoid lactone, astragaloside, formononetin, calycosin, and total saponins. The method is reliable, stable and novel for quality control of mass production, and provides digitized illustration for ensuring effectivity and security of the composition
- CC 64-2 (Pharmaceutical Analysis)
 Section cross-reference(s): 63
- ST quality control compn Astragalus Ginkgo fingerprint chromatogram HPLC TLC
- IT Terpenes, analysis

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(lactones, Ginkgo biloba; quality control method of

traditional Chinese medical composition of Astragalus membranaceus and Ginkqo biloba)

IT Astragalus membranaceus

Ginkgo biloba

HPLC

Natural products, pharmaceutical

Quality control

TLC (thin layer chromatography)

(quality control method of traditional Chinese medical composition of Astragalus membranaceus and Ginkgo biloba)

L35 ANSWER 11 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2007:391257 HCAPLUS Full-text

DOCUMENT NUMBER: 146:429103

TITLE: Quality control method of traditional Chinese medicine

composition of Astragalus membranaceus and Ginkgo

APPLICATION NO.

DATE

biloba

INVENTOR(S): Yu, Wenfeng

PATENT NO. KIND DATE

Beijing Qiyuanyide Medicine Institute, Peop. Rep. PATENT ASSIGNEE(S):

China

Faming Zhuanli Shenqing Gongkai Shuomingshu, 70pp. SOURCE:

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

	CN 1939392	A	20070404	CN 2005-10	107820	20050930				
PRIC	RITY APPLN. INFO.:			CN 2005-10	107820	20050930				
AB	The invention prov	ides a	quality cont	rol method o	of tradition	al Chinese				
medicine composition of Astragalus membranaceus and Ginkgo biloba. The										
quality control method comprises determination of flavonoids of Astragalus										
	membranaceus, flav	onoids	of Ginkgo b	loba leaf, s	aponins of	Astragalus				
membranaceus and terpenoid lactone of Ginkgo biloba leaf by fingerprint										
	chromatogram, iden	tificat:	ion of Astra	agalus membra	anaceus, Gin	kgo biloba leaf,				
	formononetin, caly	cosin,	total flavo	nol glycoside	es, terpenoi	d lactone and				
	astragaloside, and	content	t determinat	tion of total	L flavonol g	lycosides,				
	terpenoid lactone,	formon	onetin, cal	cosin, astra	agaloside, t	otal saponins and				
	total polysacchari	des. Il	he method is	s reliable, s	stable and n	ovel for quality				
	control of mass pr	oduction	n, and provi	des digitize	ed illustrat	ion for ensuring				
	effectivity and se	curity o	of the compo	sition						

- 64-2 (Pharmaceutical Analysis) Section cross-reference(s): 63
- quality control compn Astragalus Ginkgo chromatogram HPLC TLC ST
- TΤ Terpenes, analysis

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(lactones, Ginkgo biloba; quality control method of

traditional Chinese medicine composition of Astragalus membranaceus and Ginkgo biloba)

Astragalus membranaceus ΤТ

Ginkgo biloba

HPLC

Natural products, pharmaceutical

Quality control

TLC (thin layer chromatography)

(quality control method of traditional Chinese medicine composition of Astragalus membranaceus and Ginkgo biloba)

L35 ANSWER 12 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2007:22369 HCAPLUS Full-text

DOCUMENT NUMBER: 146:236345

Determination of active components of Ginkgo biloba in TITLE:

> human urine by capillary high-performance liquid chromatography/mass spectrometry with on-line

column-switching purification

AUTHOR(S): Ding, Shujing; Dudley, Ed; Chen, Lijuan; Plummer, Sue;

Tang, Jiandong; Newton, Russell P.; Brenton, A. Gareth

CORPORATE SOURCE: Mass Spectrometry Research Unit, University of Wales

Swansea, Swansea, SA2 8PP, UK

SOURCE: Rapid Communications in Mass Spectrometry (2006),

20(24), 3619-3624

CODEN: RCMSEF; ISSN: 0951-4198

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB Ginkgo biloba is one of the most popular herbal nutritional supplements, with terpene lactones and flavonoids being the two major active components. An online purification high-performance liquid chromatog./mass spectrometry method was successfully developed for the quant. determination of flavonoids and terpene lactones excreted in human urine after ingesting the herbal supplement. Satisfactory separation was obtained using a C18 capillary column made inhouse with sample clean-up and pre-concentration achieved using a C18 pre-column with column switching. High selectivity and limits of detection of 1-18 ng/mL were achieved using a selected ion monitoring scan in neg. ion mode; the online solid-phase extraction recovery of the active components in Ginkgo biloba determined in this study was greater than 75%.

CC 64-2 (Pharmaceutical Analysis)

Section cross-reference(s): 1

ST Ginkgo biloba urine analysis liq chromatog mass spectrometry

IT Mass spectrometry

(HPLC combined with, capillary; active components of Ginkgo biloba determination in human urine by capillary high-performance liquid chromatog.-mass spectrometry with online column-switching purification)

IT Ginkgo biloba

Human

Natural products, pharmaceutical

Purification

Urine analysis

(active components of Ginkgo biloba determination in human urine by capillary $\ensuremath{\mathsf{S}}$

 $\label{liquid chromatog.-mass} \mbox{ spectrometry with online column-switching purification)}$

IT Flavonoids

RL: ANT (Analyte); NPO (Natural product occurrence); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(active components of Ginkgo biloba determination in human urine by capillary

high-performance liquid chromatog.-mass spectrometry with online column-switching purification)

IT Terpenes, analysis

RL: ANT (Analyte); NPO (Natural product occurrence); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(lactones; active components of Ginkgo biloba determination in human urine by capillary high-performance liquid chromatog.-mass spectrometry with online column-switching purification)

IT HPLC

chromatog.-mass spectrometry with online column-switching
purification)

```
ΤТ
    Extraction
        (solid-phase; active components of Ginkgo biloba determination in human
urine
        by capillary high-performance liquid chromatog.-mass
        spectrometry with online column-switching purification)
     153-18-4, Rutin 480-19-3, Isorhamnetin 482-35-9,
     Ouercetin-3-\beta-D-glucoside 520-18-3, Kaempferol
                                                       522-12-3,
     Quercetin-3-rhamnoside 5508-58-7, Andrographolide 6151-25-3, Quercetin
                9001-45-0, \beta-Glucuronidase
     dihvdrate
                                             9068-67-1, Sulfatase
     15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7,
     Ginkgolide B
                  33570-04-6, Bilobalide
     RL: ARU (Analytical role, unclassified); ANST (Analytical study)
        (active components of Ginkgo biloba determination in human urine by
capillary
        high-performance liquid chromatog.-mass spectrometry with
        online column-switching purification)
OS.CITING REF COUNT: 8
                              THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
                               (8 CITINGS)
REFERENCE COUNT:
                        18
                               THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
L35 ANSWER 13 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN
                        2006:1215169 HCAPLUS Full-text
ACCESSION NUMBER:
DOCUMENT NUMBER:
                        146:517243
                        Determination of ginkgolides in Ginkgo biloba by
TITLE:
                        capillary gas chromatography
                        Liu, Hong-mei; Zhou, Qing-xia; Yang, Wen-ling
AUTHOR(S):
                        College of Chemical and Pharmaceutical Engineering,
CORPORATE SOURCE:
                        Hebei University of Science and Technology,
                        Shijiazhuang, Hebei, 050018, Peop. Rep. China
                        Hebei Keji Daxue Xuebao (2006), 27(3), 209-213
SOURCE:
                        CODEN: HKDXFY; ISSN: 1008-1542
                        Hebei Keji Daxue Xuebao Bianjibu
PUBLISHER:
                        Journal
DOCUMENT TYPE:
                        Chinese
LANGUAGE:
     The optimum conditions of chromatograph separation were selected for the
     ginkgolides: bilobalide (BB), ginkgolide A (GA), ginkgolide J (GJ), ginkgolide
     B (GB) and ginkgolide C (GC). Selecting squalane (SQ) as an internal
     standard, the weight correction factors of ginkgolides were confirmed by
     measurement and theor. calcn. The contents of the five ginkgolides were
     determined by internal standard method. The average recoveries of the method
     for BB, GA, GB and GC were 92.8%, 93.2%, 92.4% and 94.4%, and RSD were 2.9%,
     1.6%, 2.2%, 1.9% and 1.9% resp.
     9-3 (Biochemical Methods)
CC
     Section cross-reference(s): 64
     ginkgolide capillary gas chromatog Ginkgo
ST
ΤT
    Flame ionization detectors
    Gas chromatography
     Ginkgo biloba
        (determination of ginkgolides in Ginkgo biloba by capillary gas
        chromatog.)
     7631-86-9, Silicon dioxide, analysis
ΙT
     RL: AMX (Analytical matrix); ANST (Analytical study)
        (determination of ginkgolides in Ginkgo biloba by capillary gas
        chromatog.)
ΙT
     15291-75-5P, Ginkgolide A
                                15291-76-6P, Ginkgolide C
     15291-77-7P, Ginkgolide B
                                 33570-04-6P, Bilobalide
     107438-79-9P, Ginkgolide J
     RL: ANT (Analyte); PUR (Purification or recovery); ANST
     (Analytical study); PREP (Preparation)
```

(determination of ginkgolides in Ginkgo biloba by capillary gas chromatog.)

IT 67-56-1, Methanol, analysis 67-64-1, Acetone, analysis 68-12-2, N, N-Dimethylformamide, analysis 75-77-4, Trimethylchlorosilane, analysis 108-88-3, Toluene, analysis 110-54-3, n-Hexane, analysis 111-01-3, Squalane 141-78-6, Ethyl acetate, analysis 7727-37-9, Nitrogen, analysis 25561-30-2, Bis(trimethylsilyl)trifluoroacetamide RL: ARU (Analytical role, unclassified); ANST (Analytical study) (determination of ginkgolides in Ginkgo biloba by capillary gas chromatog.)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L35 ANSWER 14 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2006:1164539 HCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 145:511322

TITLE: Quality control method for injection containing gingko

and Salvia miltiorrhiza

INVENTOR(S): Yu, Wenyong

PATENT ASSIGNEE(S): Guiyang Yunyan Xichuang Medicinal Technology

Development Co., Ltd., Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 82pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
				-	
CN 1853674	A	20061101	CN 2006-10200071		20060124
CN 101156893	А	20080409	CN 2007-10201880		20060124
CN 101156894	A	20080409	CN 2007-10201885		20060124
PRIORITY APPLN. INFO.:			CN 2005-10003011	Α	20050207
			CN 2006-10200071	АЗ	20060124

- AB The method comprises fingerprint spectrum testing, identifying the ingredient of gingko, gingko extract, total flavonoids, and total terpene lactones, measuring the ingredient of Salvia miltiorrhiza extract or its sodium salt, protocatechuic aldehyde, lithosperman B or its magnesium salt, tanshinone IIA, quercetin, and kaempferide. Compared with existing technol., the claimed method is more effective, more accurate, and more stable.
- CC 63-4 (Pharmaceuticals)
- IT Terpenes, biological studies

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(lactones; quality control method for injection containing gingko and Salvia miltiorrhiza)

IT Ginkgo biloba

HPLC

Natural products, pharmaceutical

Quality control

Salvia miltiorrhiza

Spectrophotometry

TLC (thin layer chromatography)

(quality control method for injection containing gingko and Salvia miltiorrhiza)

L35 ANSWER 15 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2006:1043882 HCAPLUS Full-text

DOCUMENT NUMBER: 146:13351

TITLE: Quantitative determination of major active components

in Ginkgo biloba dietary supplements by liquid

chromatography/mass spectrometry

AUTHOR(S): Ding, Shujing; Dudley, Ed; Plummer, Sue; Tang,

Jiandong; Newton, Russell P.; Brenton, A. Gareth

CORPORATE SOURCE: Mass Spectrometry Research Unit, University of Wales

Swansea, Swansea, SA2 8PP, UK

SOURCE: Rapid Communications in Mass Spectrometry (2006),

20(18), 2753-2760

CODEN: RCMSEF; ISSN: 0951-4198

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

A reversed-phase high-performance liquid chromatog./electrospray ionization mass spectrometry (RP-HPLC/ESI-MS) method was developed and validated for the simultaneous determination of ten major active components in Ginkgo biloba extract (bilobalide, ginkgolides A, B, C, quercetin, kaempferol, isorhamnetin, rutin hydrate, quercetin-3- β -D-glucoside and quercitrin hydrate) which were not previously reported to be quantified in a single anal. The ten components exhibit baseline separation in 50 min by C18 chromatog. using a water/1:1 (volume/volume) methanol/acetonitrile gradient. Quantitation was performed using neq. ESI-MS in selected ion monitoring (SIM) mode. Good reproducibility and recovery were obtained by this method. The sensitivity of both UV and different mass spectrometry modes (full scan, selected ion monitoring (SIM), and selected reaction monitoring (SRM)) were compared and both quantitation with and without internal standard were evaluated. The anal. of Ginkgo biloba com. products showed remarkable variations in the rutin and quercetin content as well as the terpene lactone contents although all the products satisfy the conventional quality control method.

CC 64-2 (Pharmaceutical Analysis)

IT Mass spectrometry

(HPLC combined with; quant. determination of major active components in Ginkgo

biloba dietary supplements by liquid chromatog./mass spectrometry)

IT Terpenes, analysis

RL: ANT (Analyte); ANST (Analytical study)

(lactones; quant. determination of major active components in Ginkgo biloba dietary supplements by liquid chromatog./mass spectrometry)

IT HPLC

(mass spectrometry combined with; quant. determination of major active components in Ginkgo biloba dietary supplements by liquid chromatog./mass spectrometry)

IT Dietary supplements

Electrospray ionization mass spectrometry

Ginkgo biloba

Reversed phase HPLC

(quant. determination of major active components in Ginkgo biloba dietary supplements by liquid ${\it chromatog./mass}$ spectrometry)

IT Flavonoids

RL: ANT (Analyte); ANST (Analytical study)

(quant. determination of major active components in Ginkgo biloba dietary supplements by liquid chromatog./mass spectrometry)

IT 117-39-5, Quercetin 480-19-3, Isorhamnetin 482-35-9,

Quercetin-3- β -D-glucoside 520-18-3, Kaempferol 14402-66-5, Quercitrin dihydrate 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B 33570-04-6, Bilobalide 190836-14-7, Rutin hydrate

RL: ANT (Analyte); ANST (Analytical study)

(quant. determination of major active components in Ginkgo biloba dietary supplements by liquid chromatog./mass spectrometry)

OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS

RECORD (18 CITINGS)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 16 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2006:907292 HCAPLUS Full-text

DOCUMENT NUMBER: 145:342646

TITLE: Quality control of ginkgo orally disintegrating tablet

INVENTOR(S): Ye, Xiangwu; Zhang, Mei

PATENT ASSIGNEE(S): Guizhou Yibai Pharmaceutical Co., Ltd., Peop. Rep.

China

SOURCE: Faming Zhuanli Shenging Gongkai Shuomingshu, 26pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1823852	A	20060830	CN 2005-10003342	20051229
CN 100520404	С	20090729		

PRIORITY APPLN. INFO.: CN 2005-10003342 20051229

The patent relates to quality control which has good precision, sensitivity and stability to ensure that the product is safe, even, stable, effective, controllable, etc. The tablet is comprised of Ginkgo biloba extract and pharmaceutic adjuvant at a ratio of 1-10:10-1. The pharmaceutic adjuvant is selected from Et cellulose, mannite, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, microcryst. cellulose, aspartame, silica gel, and magnesium stearate, etc. The quality control comprises observing character, checking content according to pharmacopoeia method, and identifying flavonol glycosides and terpene lactones and determining the content of them. The differentiation process consists of grinding the product, adding 10-50% HCl and methanol (1-9:9-1), reflux extracting, filtering, adding distilled water, volatilizing partial solution, extracting with ether for 1-6 times, washing with water 1-5 times, evaporating to dryness, adding methanol to the residue as sample for test, weighing Ginkgo biloba extract and preparing the solution of Ginkgo biloba extract, determining with thin-layer chromatog. (TLC) with toluene, Et acetate, acetone and formic acid (1-20:0.1-50.1-5:0.05-0.5) as developing agent and developing, air drying, spraying 1-10% ethanol solution of aluminum chloride, and observing the color; dotting terpene lactone solution for test and check solution on the same silica gel thin-layer plate with toluene, Et acetate, acetone and formic acid (5-20:1-10:1-10:0.1-1) as as developing agent and developing at 20°, air drying, fumigating with acetic anhydride steam, heating at $140-160^{\circ}$, cooling, viewing, and determining The content of flavonol glycosides and terpene lactones in the tablets is determined by HPLC scanning from 200 nm to 500 nm on C18 column with methanol-0.01-0.1 mol potassium dihydrogen phosphate (1-9:9-1) as mobile phase.

CC 64-2 (Pharmaceutical Analysis)

Section cross-reference(s): 63

IT Terpenes, analysis

RL: ANT (Analyte); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)

(lactomes; quality control of orally disintegrating tablets containing Ginkgo exts.)

IT Cardiovascular agents Ginkgo biloba

HPLC

Natural products, pharmaceutical

Quality control

TLC (thin layer chromatography)

(quality control of orally disintegrating tablets containing Ginkgo exts.)

L35 ANSWER 17 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2006:682701 HCAPLUS Full-text

DOCUMENT NUMBER: 145:299918

TITLE: Application of reverse-flow micellar electrokinetic

chromatography for the simultaneous determination of flavonols and terpene trilactones in Ginkgo biloba

dosage forms

AUTHOR(S): Dubber, M.-J.; Kanfer, I.

CORPORATE SOURCE: Faculty of Pharmacy, Division of Pharmaceutics, Rhodes

University, Grahamstown, 6139, S. Afr.

SOURCE: Journal of Chromatography, A (2006), 1122(1-2),

266-274

CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

A reverse-flow micellar electrokinetic chromatog. (RF-MEKC) method was AΒ developed for the simultaneous qual. determination of 10 components consisting of the flavonol glycosides, rutin and quercitrin, the flavonol aglycons, isorhamnetin, kaempferol and quercetin, the terpene trilactones, ginkgolides A, B, C and J and the sesquiterpene, bilobalide. This method was used to fingerprint Ginkgo biloba solid oral dosage forms and validated for the quantitation of the marker compds., rutin and quercetin in some com. products. In addition to the usual variables, the influence of some essential background electrolyte (BGE) components such as SDS and β -cyclodextrin concns. were investigated. A polyimide fused-silica square capillary column (75 μ m I.D. \times 360 μ m O.D.) with a total length of 60.0 cm and effective length of 45.0 cm was used for the separation The final BGE consisted of 20 mM phosphoric acid, 40 mM SDS and 12 mM <beta>-cyclodextrin (pH 2.2) using reverse polarity with a voltage of -17.5 kV. Samples were injected electrokinetically at -5 kV for 3 s for the qual. anal. and hydrodynamically at 20 mbar for 0.6 s for the quant. assay. The total run time was 22 min and the limits of detection were 3.13 μ g/mL and 1.88 μ g/mL for rutin and quercetin, resp. Fingerprint profiles of the solid oral dosage forms and the results of the quant. anal. indicated that there were major discrepancies in the marker content between products and illustrates the value of this method for use as a procedure to assess product quality of com. available Ginkgo biloba products.

CC 64-2 (Pharmaceutical Analysis)

IT Ginkgo biloba

Micellar electrokinetic chromatography

(application of reverse-flow micellar electrokinetic ${\it chromatog}$

. for simultaneous determination of flavonols and terpene trilactones in $\ensuremath{\mathsf{Ginkgo}}$

biloba dosage forms)

IT Drug delivery systems

(solids, oral; application of reverse-flow micellar electrokinetic chromatog. for simultaneous determination of flavonols and terpene trilactones in Ginkgo biloba dosage forms)

IT 117-39-5, Quercetin 153-18-4, Rutin 480-19-3, Isorhamnetin 520-18-3, Kaempferol 522-12-3, Quercitrin 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B 33570-04-6, Bilobalide

107438-79-9, Ginkgolide J

RL: ANT (Analyte); NPO (Natural product occurrence); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)

(application of reverse-flow micellar electrokinetic chromatog

. for simultaneous determination of flavonols and terpene trilactones in Ginkqo biloba dosage forms)

IT 151-21-3, Sodium dodecyl sulfate, uses 7585-39-9, β -Cyclodextrin RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (application of reverse-flow micellar electrokinetic chromatog

. for simultaneous determination of flavonols and terpene trilactones in $\ensuremath{\mathsf{Ginkgo}}$

biloba dosage forms)

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD

(8 CITINGS)

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 18 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2006:493217 HCAPLUS Full-text

DOCUMENT NUMBER: 145:130614

TITLE: Quality control method of gingko extract-dipyridamole

injection

INVENTOR(S): Ye, Xiangwu; Jiang, Fan; Tang, Xiujing

PATENT ASSIGNEE(S): Guizhou Yibai Pharmaceutical Co., Ltd., Peop. Rep.

China

SOURCE: Faming Zhuanli Shenging Gongkai Shuomingshu, 46 pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1772013	А	20060517	CN 2005-10200658	20051031
CN 100358539	С	20080102		
PRIORITY APPLN. INFO.:			CN 2005-10200658	20051031

The gingko extract is identified by HCl-Mg reaction, and clarity, pH value, water content, bacteria content, pyrogen, and insol. particle are all checked. The total flavonoids in gingko extract injection is identified by thin layer chromatog. (TLC) with quercetin, isorhamnetin and kaempferol as control and dichloromethane-acetic acid-50-99% ethanol(1-10:1-6:0.2-5) as developing agent. The total terpene lactone in gingko extract injection is identified by thin layer chromatog. (TLC) with ginkgolide A, ginkgolide B, ginkgolide C and Bilobalide as control and toluene-Et acetate-acetone-ethanol(5-20:2-10:2-10:0.5-5) a developing agent. The dipyridamole content in injection is determined by HPLC at 288 nm on C18 column with methanol or acetonitrile-0.05-10% sodium dihydrogen phosphate (1-9:9-1) as mobile phase. Total flavonoids content in injection is determined by HPLC at 360 nm on C18 column with methanol or acetonitrile-0.05-10% phosphoric acid(1-9:9-1) as mobile phase and quercetin, isorhamnetin and kaempferol as control. The total terpene lactone content in injection is determined by HPLC with propanol-tetrahydrofuranwater (0.1-10:3-50:20-150) as mobile phase.

CC 63-2 (Pharmaceuticals)

IT Terpenes, biological studies

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(lactones; quality control method of gingko extract-dipyridamole injection)

IT Ginkgo biloba

HPLC

Quality control

TLC (thin layer chromatography)

(quality control method of gingko extract-dipyridamole injection)

L35 ANSWER 19 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2006:368396 HCAPLUS Full-text

DOCUMENT NUMBER: 145:70236

TITLE: Chromatographic fingerprint analysis-a rational

approach for quality assessment of traditional Chinese

herbal medicine

AUTHOR(S): Xie, Peishan; Chen, Sibao; Liang, Yi-zeng; Wang,

Xianghong; Tian, Runtao; Upton, Roy

CORPORATE SOURCE: Zhuhai Chromap Institute of Herbal Medicine Research,

Zhuhai, 519085, Peop. Rep. China

SOURCE: Journal of Chromatography, A (2006), 1112(1-2),

171-180

CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

Traditional Chinese Herbal Medicine (TCHM) contain multiple botanicals, each AB of which contains many compds. that may be relevant to the medicine's putative activity. Therefore, anal. techniques that look at a suite of compds., including their resp. ratios, provide a more rational approach to the authentication and quality assessment of TCHM. In this paper the authors present several examples of applying chromatog. fingerprint anal. for determining the identity, stability, and consistency of TCHM as well as the identification of adulterants as follows: (1) species authentication of various species of ginseng (Panax ginseng, Panax guinguefolium, Panax notoginseng) and stability of ginseng prepns. using high performance thin-layer chromatog. (HPTLC) fingerprint anal.; (2) batch-to-batch consistency of exts. of Total Glycosides of Peony (TGP), to be used as a raw material and in finished products (TGP powdered extract products), using high performance liquid chromatog. (HPLC) fingerprint anal. with a pattern recognition software interface (CASE); (3) documenting the representative HPLC fingerprints of Immature Fruits of Terminalia chebula (IFTC) through the assessment of raw material, in-process assay of the exts., and the anal. of the finished product (tablets); (4) HPLC fingerprint study demonstrating the consistent quality of total flavonoids of com. exts. of ginkgo (Ginkgo biloba) leaves (EGb) along with detection of adulterations. The exptl. conditions as well as general comments on the application of chromatog. fingerprint anal. are discussed.

CC 64-2 (Pharmaceutical Analysis)

IT Ginkgo biloba

HPLC

Paeonia

Panax ginseng

Panax notoginseng

Panax quinquefolium

Quality control

Terminalia chebula

(chromatog. fingerprint anal. for quality assessment of traditional Chinese herbal medicine)

IT Flavonoids

Ginsenosides

Glycosides

RL: ANT (Analyte); ANST (Analytical study)

(chromatog, fingerprint anal, for quality assessment of

traditional Chinese herbal medicine)

IT Natural products, pharmaceutical

(ginseng; chromatog. fingerprint anal. for quality assessment of traditional Chinese herbal medicine)

ΙT TLC (thin layer chromatography)

> (high-performance; chromatog. fingerprint anal. for quality assessment of traditional Chinese herbal medicine)

ΙT Triterpenes

> RL: ANT (Analyte); ANST (Analytical study) (lactones; chromatog. fingerprint anal. for quality assessment of traditional Chinese herbal medicine)

ΙT

AUTHOR(S):

RL: ANT (Analyte); ANST (Analytical study) (triterpene; chromatog, fingerprint anal, for quality assessment of traditional Chinese herbal medicine)

149-91-7, Gallic acid, analysis 153-18-4, Rutin 11021-13-9, ΙT Ginsenoside Rb2 11021-14-0, Ginsenoside Rc 18942-26-2, Chebulinic acid 22427-39-0, Ginsenoside Rq1 23094-71-5, Chebulagic acid Paeoniflorin 38642-49-8, Benzoylpaeoniflorin 39011-90-0, Albiflorin 41753-43-9, Ginsenoside Rb1 52286-58-5, Ginsenoside Rf 52286-59-6, Ginsenoside Re 52705-93-8, Ginsenoside Rd 78690-50-3, Ginsenoside Ra 80418-24-2, NotoGinsenoside R1 115038-42-1, Ginsenoside F11 891194-26-6, Heteroside A 891194-27-7, Heteroside B RL: ANT (Analyte); ANST (Analytical study)

(chromatog, fingerprint anal, for quality assessment of

traditional Chinese herbal medicine)

THERE ARE 68 CAPLUS RECORDS THAT CITE THIS OS.CITING REF COUNT: 68

RECORD (68 CITINGS)

REFERENCE COUNT: THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 20 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN 2006:263453 HCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER: 144:338343

TITLE: Determination of terpene trilactones in Ginkgo biloba

solid oral dosage forms using HPLC with evaporative

light scattering detection Dubber, M.-J.; Kanfer, I.

CORPORATE SOURCE: Faculty of Pharmacy, Division of Pharmaceutics, Rhodes

University, Grahamstown, 6139, S. Afr.

Journal of Pharmaceutical and Biomedical Analysis SOURCE:

(2006), 41(1), 135-140

CODEN: JPBADA; ISSN: 0731-7085

Elsevier B.V. PUBLISHER:

DOCUMENT TYPE: Journal LANGUAGE: Enalish

A reversed phase high performance liquid chromatog. method with evaporative light scattering detection (RP-HPLC-ELSD) was developed for the quant. determination of the terpene trilactones, ginkgolide A, B, C and J and the sesquiterpene, bilobalide in Ginkgo biloba solid oral dosage forms. Separation was achieved using a minibore Phenomenex Luna (5 μm) C18 column with dimensions 250 mm \times 2.00 mm maintained at a temperature of 45 $^{\circ}\mathrm{C}$. A simple gradient method using a mobile phase of methanol:water and a flow rate of 350 μ l/min facilitated baseline separation of the selected marker compds. within 14 min. The ELSD parameters affecting the detector response were optimized prior to the validation. The limits of detection and quantification were 31.25 and 62.50 ng, resp. The percentage relative errors of the recovery ranged between -3.16 and +1.88 and both intra-day and inter-day percentage standard deviations were all better than 6%. This method was used to assay com. available Ginkgo biloba products and proved to be suitable for the routine anal. of such products for quality control purposes.

Nizal Chandrakumar 10/579,162 CC 64-2 (Pharmaceutical Analysis) ΙT Ginkgo biloba Quality control Reversed phase HPLC (HPLC determination of terpene trilactones in Ginkgo biloba solid oral dosage forms) Terpenes, analysis TΤ RL: ANT (Analyte); ANST (Analytical study) (HPLC determination of terpene trilactones in Ginkgo biloba solid oral dosage forms) 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7 ΙT , Ginkgolide B 33570-04-6, Bilobalide 107438-79-9, Ginkgolide J RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (HPLC determination of terpene trilactores in Ginkgo biloba solid oral dosage forms) OS.CITING REF COUNT: THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD 3 (3 CITINGS) REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L35 ANSWER 21 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN 2006:160292 HCAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: 144:324063 TITLE: LC-MS characterization of terpene lactones in plasma of experimental animals treated with Ginkgo biloba extracts AUTHOR(S): Mauri, Pierluigi; De Palma, Antonella; Pozzi, Francesca; Basilico, Fabrizio; Riva, Antonella; Morazzoni, Paolo; Bombardelli, Ezio; Rossoni, Giuseppe CNR, Istituto Tecnologie Biomediche, Segrate (Milan), CORPORATE SOURCE: 93-20090, Italy Journal of Pharmaceutical and Biomedical Analysis SOURCE: (2006), 40(3), 763-768CODEN: JPBADA; ISSN: 0731-7085 PUBLISHER: Elsevier B.V. DOCUMENT TYPE: Journal LANGUAGE: English Liquid chromatog./atmospheric pressure chemical ionization ion trap mass AΒ spectrometry (LC/APCI-ITMS) was applied to determine the concentration of terpene lactone in plasma of quinea pigs after chronic administration of Ginkgo biloba extract enriched in ginkgoterpenes in free form (IDN 5380) or complexed with soy phosphlipids (IDN 5381). Oral treatment of the animals with ginkgoterpenes resulted to inhibit the bronchoconstriction (ITP) and the concomitant increase of the levels of thromboxane B2 (TXB2) in the circulation caused by histamine (HIST) and platelet activating factor (PAF) in normal guinea pigs or by ovalbumin (OA) in actively sensitized guinea pigs. To compare the protective activities of G. biloba forms (IDN 5380 and IDN 5381), ED50 and dose ratio (DR) values for both parameters (ITP and TXB2) were evaluated. The phytosomic form (IDN 5381) significantly reduced (two- to four-fold as compared to free form, P < 0.001) the HIST, PAF or OA-induced airway changes and TXB2 release. In addition it has been observed that the absence of ginkgolide C (GC) in plasma samples (in human and animals) was due to its rapid methylation.

70

liq chromatog mass spectrometry terpene lactone blood analysis Ginkgo

CC

ST IT 1-1 (Pharmacology)

Blood analysis Bronchodilators Ginkgo biloba

Ion trap mass spectrometry

(LC-MS characterization of terpene lactones in plasma of exptl. animals treated with Ginkqo biloba exts.)

IT Terpenes, biological studies

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(lactones; LC-MS characterization of terpene lactones

in plasma of exptl. animals treated with Ginkgo biloba exts.)

IT Mass spectrometry

(liquid chromatog. combined with; LC-MS characterization of terpene lactones in plasma of exptl. animals treated with Ginkgo biloba exts.)

IT Liquid chromatography

(mass spectrometry combined with; LC-MS characterization of terpene lactones in plasma of exptl. animals treated with Ginkgo biloba exts.)

IT 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B 33570-04-6, Bilobalide

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(LC-MS characterization of terpene lactones in plasma of exptl. animals treated with Ginkgo biloba exts.)

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD

(7 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 22 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2005:1319245 HCAPLUS Full-text

DOCUMENT NUMBER: 144:40971

TITLE: Simultaneous quantification of terpenelactones and

flavonol aglycones in hydrolyzed Ginkgo biloba extract by liquid chromatography with inline ultraviolet and

evaporative light scattering detection

AUTHOR(S): Gray, Dean E.; Messer, Dale; Porter, Andrew; Ferguson,

Sherry; Harris, Roger K.; Clark, Alice P.; Algaier, Joseph W.; Overstreet, J. Diane; Smith, Cynthia S.

CORPORATE SOURCE: Midwest Research Institute, Kansas City, MO,

64110-2299, USA

SOURCE: Journal of AOAC International (2005), 88(6), 1613-1620

CODEN: JAINEE; ISSN: 1060-3271

PUBLISHER: AOAC International

DOCUMENT TYPE: Journal LANGUAGE: English

The authors report here a liquid chromatog. (LC) method with inline UV/evaporative light scattering (UV/ELS) detection for the simultaneous quantification of the terpenelactones and flavonol aglycons in a single sample of hydrolyzed Ginkgo biloba extract (GBE). The sample is hydrolyzed by a rapid and convenient oven heating method for 1 h at 90 °C with 10% hydrochloric acid. The 1 h hydrolysis was found to be equivalent to the 2.25 h reflux treatment for dry powder extract, where total flavonol glycosides were 28.4 and 28.1%, resp. Acceptable precision was achieved for total terpenelactones [relative standard deviation (RSD) = 4.8%] by ELS detection, and total flavonol aglycons (RSD = 2.3%) by UV detection. The anal. range was 1.5 to 7.3% (weight/weight) for the individual terpenelactones (ELS) and 2.5 to 15.0% (weight/weight) for the individual glycosides (UV) calculated from the aglycons guercetin, kaempferol, and isorhamnetin. This improved method allows for the 1st time high throughput sample preparation coupled with the quantification of the predominant compds. generally used for quality control of GBE in a single assay.

CC 64-2 (Pharmaceutical Analysis)

Section cross-reference(s): 63

ST terpenelactone flavonol aglycon detn Ginkgo biloba liq chromatog stability

IT Ginkgo biloba

(extract; quantification of terpenelactones and flavonol aglycons in hydrolyzed Ginkgo biloba extract by LC)

IT Terpenes, analysis

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(lactones; quantification of terpenelactones and

flavonol aglycons in hydrolyzed Ginkgo biloba extract by LC)

IT Anti-ischemic agents

Anticoagulants

Liquid chromatography

Quality control

Stability

(quantification of terpenelactones and flavonol aglycons in hydrolyzed Ginkgo biloba extract by LC)

IT 117-39-5, Quercetin 480-19-3, Isorhamnetin 520-18-3, Kaempferol 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B 33570-04-6, Bilobalide

RL: ANT (Analyte); CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses) (quantification of tempenelactores and flavonol aglycons in

(quantification of texpeneractiones and flavonor agrycons

hydrolyzed Ginkgo biloba extract by LC)

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 23 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2005:1061219 HCAPLUS Full-text

DOCUMENT NUMBER: 143:455133

TITLE: Preparative isolation of terpene trilactones from

Ginkgo biloba leaves

AUTHOR(S): Lai, Shih-Ming; Chen, I-Wen; Tsai, Ming-Jyi

CORPORATE SOURCE: Department of Chemical Engineering, National Yunlin University of Science and Technology, Yunlin, 640,

Tairran

Taiwan

SOURCE: Journal of Chromatography, A (2005), 1092(1), 125-134

CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

AB This study investigated and compared some techniques for the preparative isolation of terpene trilactones, including ginkgolides (GA and GB, etc.) and bilobalide (BB), from Ginkgo biloba leaves. The crude Ginkgo biloba L. exts. (GBE) were prepared using an extractor with solvent refluxing operated under an optimal extraction condition. The extraction yield was 20-23% and the purity of terpene trilactones was about 1.0-1.4 wt%. Before the isolation operations, the exts. were dissolved in de-ionized water. The isolation procedures included the method of liquid-liquid extraction and the method of column chromatog. For the method of liquid-liquid extraction using Et acetate as the organic solvent operated under the optimal extraction conditions, the purity, concentration ratio, and yield of terpene trilactones were 13.5-18.0%, 15-16, and >99%. For the method of column chromatog., XAD-7HP, XAD-4, and C-18 adsorbents with different polarities were used as the packing materials. Only for the XAD-7HP column, a part of more polar impurities was efficiently separated with the majority of terpene trilactones by a proper step-gradient elution, which resulted in an efficient isolation: the purity, concentration

ratio, and yield of terpene trilactones were .apprx.20, .apprx.15, and .apprx.80%. In comparison, the XAD-7HP column achieved the highest purity, but at the expense of the yield of terpene trilactones; on the contrary, the liquid-liquid extraction method, achieving the highest yield but with a slightly lower purity, proved to be superior to the method of column chromatog. in the current isolation stage.

CC 9-3 (Biochemical Methods)

ST terpene trilactone Gingko leaf liq chromatog; liq extn terpene trilactone Gingko leaf

IT Extraction

(liquid-liquid; preparative isolation of terpene trilactones from Ginkgo biloba leaves)

IT Ginkgo biloba

HPLC

Leaf

Liquid chromatography

(preparative isolation of terpene trilactones from Ginkgo biloba leaves)

IT Terpenes, preparation

RL: PUR (Purification or recovery); PREP (Preparation) (trilactones; preparative isolation of terpene

trilactones from Ginkgo biloba leaves)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD

(2 CITINGS)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 24 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2005:780983 HCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 143:474357

TITLE: Adsorption separation of terpene lactones from Ginkgo

biloba L. extract using glass fiber membranes modified

with octadecyltrichlorosilane

AUTHOR(S): Su, I-Fang; Chen, Li-Jen; Suen, Shing-Yi

CORPORATE SOURCE: Department of Chemical Engineering, National Chung

Hsing University, Taichung, 402, Taiwan

SOURCE: Journal of Separation Science (2005), 28(11),

1211-1220

CODEN: JSSCCJ; ISSN: 1615-9306 Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal LANGUAGE: English

AB In this study porous glass fiber membranes were modified by reaction with octadecyltrichlorosilane to form C18 hydrophobic membranes. The contact angle and the CH2 vibration bands at 2855 and 2920 cm-1 found by FTIR measurements verified the successful immobilization of C18 groups on the glass fiber membranes. The resulting C18 hydrophobic membranes were used to adsorb terpene lactones from crude Ginkgo biloba L. exts. In batch adsorption processes, the modified C18 membranes exhibited a better adsorption performance than com. C18 solid phase extraction adsorbents. Different desorption solvents were tested and Et acetate was found to preferentially desorb terpene lactones from the modified C18 membranes. In flow adsorption expts. at 1 mL/min, terpene lactone contents higher than 6 wt% (the standardized content) could be achieved in the elution step using Et acetate.

CC 9-3 (Biochemical Methods)

Section cross-reference(s): 11, 64

IT Adsorption

PUBLISHER:

Ginkgo biloba

(adsorption separation of terpene lactones from Ginkgo biloba using glass fiber membranes modified with octadecyltrichlorosilane)

IT Chromatography

(column and liquid; adsorption separation of terpene lactones from Ginkgo biloba using glass fiber membranes modified with octadecyltrichlorosilane)

IT Terpenes, analysis

RL: ANT (Analyte); ANST (Analytical study)

(lactones; adsorption separation of terpene lactones

from Ginkgo biloba using glass fiber membranes modified with

octadecyltrichlorosilane)

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD

(6 CITINGS)

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 25 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2005:686245 HCAPLUS Full-text

DOCUMENT NUMBER: 143:302429

TITLE: Ginkgolides and bilobalide: Their physical,

chromatographic and spectroscopic properties

AUTHOR(S): van Beek, Teris A.

CORPORATE SOURCE: Laboratory of Organic Chemistry, Natural Products

Chemistry Group, Wageningen University, Wageningen,

6703 HB, Neth.

SOURCE: Bioorganic & Medicinal Chemistry (2005), 13(17),

5001-5012

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Ginkgolides A, B, C, J, K, L and M and bilobalide are rare terpene trilactones that have been isolated from leaves and root bark of the Chinese tree Ginkgo biloba. The structures of the highly oxidized ginkgolides were independently elucidated in the 1960s by the groups of Nakanishi and Sakabe. Later these compds. were found to be potent and selective antagonists of platelet activating factor, which fact triggered much new research. During the past 40 years, much phys., chromatog. and spectroscopic data have been published on these compds. in various, sometimes inaccessible, sources. The published m.ps., solubility in different solvents, ionization consts., chromatog. behavior, specific optical rotations, UV, IR, MS and NMR data, and X-ray studies are summarized and, where necessary, discussed. The literature until Apr. 2005 has been reviewed.

CC 11-0 (Plant Biochemistry)

Section cross-reference(s): 30

IT Terpenes, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (lactones, trilactones; phys., chromatog.

and spectroscopic properties of ginkgolides and bilobalide)

IT Chromatography

Ginkgo biloba

Spectroscopy

(phys., chromatog. and spectroscopic properties of ginkgolides and bilobalide)

IT Natural products

RL: BSU (Biological study, unclassified); BIOL (Biological study) (phys., chromatog. and spectroscopic properties of ginkgolides and bilobalide)

IT 33570-04-6, Bilobalide

RL: BSU (Biological study, unclassified); BIOL (Biological study) (phys., chromatog. and spectroscopic properties of ginkgolides and bilobalide)

OS.CITING REF COUNT: 49 THERE ARE 49 CAPLUS RECORDS THAT CITE THIS

RECORD (49 CITINGS)

REFERENCE COUNT: 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 26 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2005:507012 HCAPLUS Full-text

DOCUMENT NUMBER: 143:353291

TITLE: Extraction of terpene lactone from Ginkgo biloba

leaves

INVENTOR(S): Dai, Baixiong; Gong, Ting; Qian, Jun

PATENT ASSIGNEE(S): Sanjiangyuan Pharmaceutical Co., Ltd., Suizhou City,

Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, No pp.

given

CODEN: CNXXEV

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1530363	A	20040922	CN 2003-119744	20030311
CN 1301988	С	20070228		

PRIORITY APPLN. INFO.: CN 2003-119744 20030311

The title extraction process includes: (1) pulverizing Ginkgo biloba leaves, (2) extracting the powders by ethanol at 75-85ÅC, (3) concentrating the extract, (4) adding water into the extract and filtrating, (5) loading the filtrate on a macroporous resin chromatog. column and eluting it by ethanol, (6) concentrating the eluate and extracting it by Et acetate, and (7) concentrating the extract and drying to obtain the product. The product can be used for treating senile dementia, cardiovascular diseases and cerebrovascular diseases. This process is low cost, low environment

pollution, and is suitable for industrial production

IC ICM C07D311-30

ICS A61P025-28; A61P009-10

CC 63-4 (Pharmaceuticals)

IT Cardiovascular system, disease

Ginkgo biloba

Human

Liquid chromatography Solvent extraction

(extraction of terpene lactone from Ginkgo biloba leaves)

IT 15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C 15291-77-7P, Ginkgolide B 33570-04-6P, Bilobalide

RL: PUR (Purification or recovery); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(extraction of terpene lactone from Ginkgo biloba leaves)

L35 ANSWER 27 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2005:451255 HCAPLUS $\underline{\text{Full-text}}$

DOCUMENT NUMBER: 142:487413

TITLE: Separation of ginkgolides and bilobalide from Ginkgo

biloba using column chromatography

INVENTOR(S): Nakanishi, Koji; Jaracz, Stanislav; Malik, Shahid;

Ishii, Hideki; Dzyuba, Sergei V.

PATENT ASSIGNEE(S): The Trustees of Columbia University In the City of New

York, USA

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.		KIND DATE			APPLICATION NO.						DATE							
WO 2005046829 WO 2005046829			A2 20050526 A3 20051110			,	WO 2	004-	JS37	20041109								
	WO	2005	0468	29		А3		2005	TIIO									
		W:	ΑE,	ΑG,	ΑL,	ΑM,	ΑT,	ΑU,	ΑZ,	ΒA,	BB,	ВG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
			NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
			ΤJ,	TM,	TN,	TR,	ΤΤ,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
		RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
			ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
			EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	ΙΤ,	LU,	MC,	NL,	PL,	PT,	RO,
			SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	${ m ML}$,	MR,
			ΝE,	SN,	TD,	TG												
	US	2008	0108	837		A1		2008	0508		US 2	007-	5791	62		2	0070	905
PRIO	RITY	APP	LN.	INFO	.:						US 2	003-	5198	40P		P 2	0031	112
										,	WO 2	004-1	JS37	412	,	W 2	0041	109

OTHER SOURCE(S): MARPAT 142:487413

The subject invention provides a method for separating a terpene trilactone AΒ from Ginkgo biloba plant material or from an extract of Ginkgo biloba comprising a mixture of terpene trilactones. The process comprises the steps of: (a) subjecting the Ginkgo biloba plant material or the extract to column chromatog, with an appropriate solvent system to produce at least a first fraction containing the terpene trilactone bilobalide, a second fraction eluted after the first fraction containing the terpene trilactones ginkgolide A and ginkgolide B, and a third fraction eluted after the second fraction containing at least a preponderance of the terpene trilactones ginkgolide C and ginkgolide J; and (b) alkylating the terpene trilactone ginkgolide B of the second fraction so as to produce a first mixture including terpene trilactone ginkgolide A and alkylated terpene trilactone ginkgolide B; or alkylating the terpene trilactone ginkgolide C of the third fraction so as produce a second mixture including terpene trilactone ginkgolide J and alkylated terpene trilactone ginkgolide C, so as to thereby isolate a terpene trilactone. For example, the enriched extract of Ginkgo biloba (4.0 g) in min. amount of Et acetate was loaded on silica gel (100 g) column. The column was slowly eluted with Et acetate/hexanes solvent mixts. The fraction collected at 45% Et acetate/hexanes contained bilobalide (0.4 g). The fractions collected at 50% Et acetate/hexanes contained small amts. of impure bilobalide and ginkgolide A then mixture ginkgolide A/ginkgolide B. fractions collected at 55% Et acetate/hexanes contained ginkgolide A/ginkgolide B (1.1 g). The fractions collected at 60% Et acetate/hexanes contained mixture of ginkgolide $C/ginkgolide\ J\ (0.4\ g)$ with small amts. of ginkgolide A and ginkgolide B. To a ginkolide mixture (1.08 g, ginkgolide B 25% weight/weight, ginkgolide A 74% weight/weight) was added potassium carbonate 879 mg, DMF 11 mL, benzyl bromide 756 mL. The mixture was stirred and quenched with 1M HCl (18 mL) and solution was extracted with Et acetate and dried with magnesium sulfate. The product mixture was suspended in chloroform (10 mL), filtered to obtain 605 mg of ginkgolide A as white powder. The filtrate was concentrated and purified by gradient column chromatog. (30 -50 % Et acetate/hexanes) to obtain 326 mg of benzylated ginkgolide B and 134 mg of ginkgolide A. Catalytic hydrogenation of 322 mg of benzylated ginkgolide B yielded 257 mg of ginkolide B.

IC ICM B01D

```
CC
     63-4 (Pharmaceuticals)
     Section cross-reference(s): 30
ST
     terpene lactone benzylation liq chromatog hydrogenolysis; ginkgolide
     bilobalide benzylation liq chromatog hydrogenolysis
     Terpenes, biological studies
ΙΤ
     RL: NPO (Natural product occurrence); PUR (Purification or recovery); THU
     (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP
     (Preparation); USES (Uses)
        (lactones; separation of terpene lactones from Ginkgo
        biloba using column chromatog.)
     Benzylation
ΙT
       Ginkgo biloba
     Hydrogenolysis
      Liquid chromatography
        (separation of ginkgolides and bilobalide from Ginkgo biloba using column
        chromatog.)
ΙT
     15291-76-6P, Ginkgolide C 15291-77-7P, Ginkgolide B
     RL: NPO (Natural product occurrence); PUR (Purification or
     recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
     (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
        (separation of ginkgolides and bilobalide from Ginkgo biloba using column
        chromatog.)
     15291-75-5P, Ginkgolide A
                                 33570-04-6P, Bilobalide
ΙT
     107438-79-9P, Ginkgolide J
     RL: NPO (Natural product occurrence); PUR (Purification or
     recovery); THU (Therapeutic use); BIOL (Biological study); OCCU
     (Occurrence); PREP (Preparation); USES (Uses)
        (separation of ginkgolides and bilobalide from Ginkgo biloba using column
        chromatog.)
     534-17-8, Cesium carbonate 584-08-7, Potassium carbonate
ΙT
     RL: NUU (Other use, unclassified); USES (Uses)
        (separation of ginkgolides and bilobalide from Ginkgo biloba using column
        chromatog.)
     100-39-0, Benzyl bromide 106-95-6, Allyl bromide, reactions
ΙT
     2746-25-0, P-Methoxy-benzylbromide
                                          4392-24-9, Cinnamyl bromide
     17690-16-3, Benzyloxymethyl bromide
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (separation of ginkgolides and bilobalide from Ginkgo biloba using column
        chromatog.)
     170288-58-1P
                   502421-88-7P
                                  852046-13-0P
ΙT
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (separation of ginkgolides and bilobalide from Ginkgo biloba using column
        chromatog.)
OS.CITING REF COUNT:
                               THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
                        1
                               (1 CITINGS)
REFERENCE COUNT:
                         2
                               THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
L35 ANSWER 28 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:
                         2005:391574 HCAPLUS Full-text
DOCUMENT NUMBER:
                         142:459693
TITLE:
                        Chromatography for isolation of high-activity
                        extract of Ginkgo biloba
INVENTOR(S):
                        Hu, Weiwan; Xie, Bijun; Yang, Erning; He, Jingren
PATENT ASSIGNEE(S):
                       Central China University of Agricultural Science,
                        Peop. Rep. China
SOURCE:
                        Faming Zhuanli Shenqing Gongkai Shuomingshu, 13 pp.
                        CODEN: CNXXEV
DOCUMENT TYPE:
```

Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PRIORITY APPLN. INFO.: CN 2002-115533 20020207

Described is extractant for producing high-activity extract of Ginkgo biloba and purification of Ginkgo exts. The extractant contains 0.04-0.2% sulfite or bisulfite (pH 3.5-5.5). The method comprises extracting Ginkgo biloba leaves with the extractant at 30-100° twice, each for 0.5-20 h, purifying on adsorbent resin column with 30-95% lower alc. as eluent, vacuum concentrating at <50°, and drying. The level of ginkgolic acid of Ginkgo biloba extract is detected by HPLC with 0.005-0.05M Ag+-containing methanol -water (70-90:10-30) as mobile phase.

IC ICM C07H017-04

ICS C07H001-08; C07D493-22; C07C065-03; C07C051-48; C07B063-00; A61K035-78; B01D011-04

CC 9-3 (Biochemical Methods)

ST Ginkgo ext purifn chromatog; ginkgolic acid detn HPLC

IT Chromatography

Ginkqo biloba

(chromatog, for isolation of high-activity extract of Ginkgo biloba)

IT Resins

RL: NUU (Other use, unclassified); USES (Uses)
(chromatog. for isolation of high-activity extract of Ginkgo biloba)

IT Proanthocyanidins

RL: ANT (Analyte); ANST (Analytical study) (detection of; chromatog. for isolation of high-activity extract of Ginkgo biloba)

IT Reversed phase HPLC

(for detection of ginkgolic acid; chromatog. for isolation of high-activity extract of Ginkgo biloba)

IT Terpenes, analysis

RL: ANT (Analyte); ANST (Analytical study)
(lactones, detection of; chromatog. for isolation
of high-activity extract of Ginkgo biloba)

IT 67-56-1, Methanol, uses

RL: NUU (Other use, unclassified); USES (Uses)
(chromatog. for isolation of high-activity extract of Ginkgo biloba)

IT 481-46-9, Ginkgetin 16611-84-0 20261-38-5 22910-60-7, Ginkgolic acid 76261-15-9

RL: ANT (Analyte); ANST (Analytical study) (detection of; chromatog. for isolation of high-activity extract of Ginkgo biloba)

IT 64-17-5, Ethanol, uses

RL: NUU (Other use, unclassified); USES (Uses) (in elution buffer; chromatog. for isolation of high-activity extract of Ginkgo biloba)

L35 ANSWER 29 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2005:273104 HCAPLUS Full-text DOCUMENT NUMBER: 142:335147

TITLE: Liquid chromatography/electrospray tandem mass spectrometry of terpenoid lactones in Ginkgo biloba

AUTHOR(S): Sun, Yongkai; Li, Wenkui; Fitzloff, John F.; Van

Breemen, Richard B.

CORPORATE SOURCE: Department of Medicinal Chemistry and Pharmacognosy,

UIC/NIH Center for Botanical Dietary Supplements Research, College of Pharmacy, University of Illinois

at Chicago, Chicago, IL, 60612, USA

SOURCE: Journal of Mass Spectrometry (2005), 40(3), 373-379

CODEN: JMSPFJ; ISSN: 1076-5174

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

Ginkqo biloba (qinkqo) is one of most frequently used botanical dietary AΒ supplements. The bioactive constituents include the terpenoid lactones consisting of bilobalide and the ginkgolides A, B, C and J. A new assay based on high-performance liquid chromatog./electrospray tandem mass spectrometry (LC/MS/MS) was developed for the measurement of the terpenoid lactones in ginkgo products such as leaf powder and exts. Initially, the MS/MS fragmentation pathways of ginkgolides were investigated to identify abundant fragment ions that might be useful for the sensitive and selective detection of ginkgolides and bilobalide during LC/MS/MS. Then, sample preparation and clean-up procedures were streamlined to maximize throughput by taking advantage of the selectivity of LC/MS/MS detection. Analyte recoveries exceeded 90%, the intra-assay and inter-assay relative standard deviations were <5%, the relative error was <8% and the limits of detection and quantification were 3.6-120 and 11-350 fmol, depending on the analyte that was injected on to the LC column. Therefore, this LC/MS/MS assay facilitated the rapid quant. anal. of ginkgolides A, B, C and J and bilobalide in ginkgo dietary supplements with excellent recovery, reproducibity, accuracy and sensitivity.

CC 17-1 (Food and Feed Chemistry)

IT Terpenes, analysis

RL: ANT (Analyte); ANST (Analytical study)
(lactones; terpenoid lactones of Ginkgo biloba
determined by HPLC-ESI-MS-MS)

IT HPLC

(mass spectrometry combined with; terpenoid lactones of Ginkgo biloba determined by HPLC-ESI-MS-MS)

IT Dietary supplements

Ginkgo biloba

(terpenoid lactones of Ginkgo biloba determined by HPLC-ESI-MS-MS)
IT 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7
, Ginkgolide B 33570-04-6, Bilobalide 107438-79-9, Ginkgolide J
RL: ANT (Analyte); ANST (Analytical study)

(terpenoid lactones of Ginkgo biloba determined by HPLC-ESI-MS-MS) OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS

RECORD (11 CITINGS)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 30 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2004:886401 HCAPLUS Full-text DOCUMENT NUMBER: 142:62866

TITLE: Isolation of ginkgolides A, B, C, J and bilobalide

from G. biloba extracts

AUTHOR(S): Jaracz, Stanislav; Malik, Shahid; Nakanishi, Koji CORPORATE SOURCE: Department of Chemistry, Columbia University, NY,

10027, USA

SOURCE: Phytochemistry (Elsevier) (2004), 65(21), 2897-2902

CODEN: PYTCAS; ISSN: 0031-9422

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English Ginkgolides A, B, C and J, together with bilobalide, are unique terpenoid components of the Ginkgo biloba tree. Due to similar chemical properties, their separation is quite tedious. We have developed an efficient and rapid protocol for separation of individual ginkgolides and bilobalide from G. biloba exts. The procedure takes advantage of enhanced susceptibility of ginkgolides B and C to benzylation and the ease of separation of these products from ginkgolides A and J which do not react. The protocol is applicable to the previously reported enriched exts. prepared from G. biloba leaves. A single chromatog. step prior to benzylation provides bilobalide and mixture of ginkgolides A, B, C, and J. After benzylation, the individual ginkgolides are separated by chromatog. 64-2 (Pharmaceutical Analysis) CC Section cross-reference(s): 30, 63 ST bilobalide ginkgolide Ginkgo benzylation chromatog hydrogenolysis ΙT Ginkgo biloba Liquid chromatography (isolation of ginkgolides and bilobalide from Ginkgo biloba exts. by benzylation, chromatog, and hydrogenolysis) 15291-75-5, Ginkgolide A 33570-04-6, Bilobalide ΙT 107438-79-9, Ginkgolide J RL: ANT (Analyte); ANST (Analytical study) (isolation of ginkgolides and bilobalide from Ginkgo biloba exts. by benzylation, chromatog. and hydrogenolysis) 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B ΙT RL: ANT (Analyte); RCT (Reactant); ANST (Analytical study); RACT (Reactant or reagent) (isolation of ginkgolides and bilobalide from Ginkgo biloba exts. by benzylation, chromatog, and hydrogenolysis) 100-39-0, Benzyl bromide ΙT RL: RCT (Reactant); RACT (Reactant or reagent) (isolation of ginkgolides and bilobalide from Ginkgo biloba exts. by benzylation, chromatog. and hydrogenolysis) 170288-58-1P, 10-O-Benzyl-ginkgolide B 502421-88-7P, ΙT 10-O-Benzyl-ginkgolide C RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (isolation of ginkgolides and bilobalide from Ginkgo biloba exts. by benzylation, chromatog, and hydrogenolysis) OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS) 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L35 ANSWER 31 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2004:485409 HCAPLUS Full-text DOCUMENT NUMBER: 141:179751 TITLE: A Method for Extraction and Quantification of Ginkgo Terpene Trilactones AUTHOR(S): Ding, Chen; Chen, Ergin; Zhou, Weijia; Lindsay, Robert С. CORPORATE SOURCE: Department of Food Science, University of Wisconsin Madison, Madison, WI, 53711, USA SOURCE: Analytical Chemistry (2004), 76(15), 4332-4336 CODEN: ANCHAM; ISSN: 0003-2700 American Chemical Society PUBLISHER: Journal DOCUMENT TYPE:

English

LANGUAGE:

```
AΒ
     A method was developed for the extraction and quantification of pharmacol.
     active terpene trilactones (ginkgolides, bilobalide) from the tissues of
     Ginkgo biloba L. and pharmaceutical ginkgo products by RP-HPLC, based on the
     theory of terpene trilactones ionization. Four ginkgolides (GA, GB, GC, GJ)
     and bilobalide (BB) from both the ginkgo leaves and com. available ginkgo
     exts. were quant. extracted by using this method. The recovery rate of the
     method was 97.5-100% with RSD of 1.2-2.8%. The detection limit was 0.05-0.1
     \mu g, and the linear range was 0.1-12 \mu g. This detection limit represents a
     marked improvement over previously reported methods, suggesting the new method
     is a viable technique for routine anal. of ginkgo terpene trilactones in
     natural and com. samples. The method reported by van Beek et al. in 1991 was
     used as a reference method to monitor the accuracy of extraction and anal. in
     this study. SSI-MS technique was used to identify isolated target components.
     Carbohydrase treatment and solubility of terpene trilactones in various
     solvents were also discussed.
CC
     64-2 (Pharmaceutical Analysis)
ΙΤ
    Mass spectrometry
        (liquid chromatog. combined with; method for extraction and
        quantification of Ginkgo terpene trilactones)
     Liquid chromatography
ΙT
        (mass spectrometry combined with; method for extraction and quantification
        of Ginkgo terpene trilactones)
ΙT
     Extraction
       Ginkgo biloba
     Leaf
       Reversed phase HPLC
        (method for extraction and quantification of Ginkgo terpene trilactones)
ΙT
     Terpenes, analysis
     RL: ANT (Analyte); PUR (Purification or recovery); ANST (Analytical
     study); PREP (Preparation)
        (method for extraction and quantification of Ginkgo terpene
        trilactones)
     15291-75-5P, Ginkgolide A
                               15291-76-6P, Ginkgolide C
ΤТ
     15291-77-7P, Ginkgolide B
                                 33570-04-6P, Bilobalide
     107438-79-9P, Ginkgolide J
     RL: ANT (Analyte); PUR (Purification or recovery); ANST (Analytical
     study); PREP (Preparation)
        (method for extraction and quantification of Ginkgo terpene
        trilactones)
OS.CITING REF COUNT:
                               THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
                               (6 CITINGS)
REFERENCE COUNT:
                        12
                               THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
L35 ANSWER 32 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN
                         2004:401393 HCAPLUS Full-text
ACCESSION NUMBER:
DOCUMENT NUMBER:
                         141:301561
                         Rapid determination of terpene lactones in Ginkgo
TITLE:
                         biloba commercial products by HPLC with evaporative
                         light-scattering detection
AUTHOR(S):
                        Herring, Tim
CORPORATE SOURCE:
                        Alltech Associates, Inc., State College, PA, 16801,
                        USA
                        LCGC North America (2004), 22(5), 456-462
SOURCE:
                        CODEN: LNACBH; ISSN: 1527-5949
                        Advanstar Communications, Inc.
PUBLISHER:
DOCUMENT TYPE:
                        Journal
                        English
LANGUAGE:
```

A rapid, sensitive, and reproducible HPLC gradient method was developed for the measurement of ginkgolides A, B, C, and J, along with bilobalide, in a G.

AΒ

biloba com. product. The separation was achieved in <14 min, by using a H2O-MeOH-CF3CO2H mobile phase and an evaporative light-scattering detector. No sample clean-up procedures were used with the methanol extraction of the G. biloba dietary supplement. The detection limit is <125 ng on-column for each terpene lactone on a reversed-phase C18 column. Both intra- and interday reproducibility were evaluated. Four brands of standardized Ginkgo biloba herbal supplements were assessed for their terpene lactone content. This method is applicable for analyzing a G. biloba dietary supplement in capsule, tablet, or liquid forms. CC 64-2 (Pharmaceutical Analysis) Section cross-reference(s): 17 terpene lactone detn Ginkgo HPLC light scattering; liq chromatog terpene ST lactone detn Ginkgo ΙT Dietary supplements Ginkgo biloba HPLC (determination of terpene lactones in Ginkgo biloba com. products by HPLC with evaporative light-scattering detection) Terpenes, analysis ΙT RL: ANT (Analyte); ANST (Analytical study) (lactones; determination of terpene lactones in Ginkgo biloba com. products by HPLC with evaporative light-scattering detection) 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C , Ginkgolide B 107438-79-9, Ginkgolide J RL: ANT (Analyte); ANST (Analytical study) (determination of terpene lactones in Ginkgo biloba com. products by HPLC with evaporative light-scattering detection) THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD OS.CITING REF COUNT: 7 (7 CITINGS) REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L35 ANSWER 33 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN 2003:724195 HCAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: 140:81993 Quality and quantity analysis of terpene lactones from TITLE: Ginkgo biloba leaves by GC-MS AUTHOR(S): Tang, Hongfang; Zheng, Ziqiang; Zhu, Xiaoyu; Mao, Lizhen CORPORATE SOURCE: Zhejiang Academy of Medical Science, Hangzhou, 310013, Peop. Rep. China SOURCE: Zhongcaoyao (2003), 34(3), 214-217 CODEN: CTYAD8; ISSN: 0253-2670 PUBLISHER: Zhongcaoyao Zazhi Bianjibu DOCUMENT TYPE: Journal LANGUAGE: Chinese AΒ The capillary GC-MS anal. method for identification and determination of ginkgolide A, B, C and bilobalide (GA, GB, GC, and BB) in Ginkgo biloba L. leaves was presented. The leave samples were extracted in ultrasonic bath with ethanol-water (20:80). The extract was purified by liquid-liquid extraction with Et acetate followed by solid-phase extraction on a column mixed with acid Al2O3, activated C, and celite. The terpenes were trimethylsilylated by bis(trimethylsilyl)trifluoroacetamide (BSTFA) (with 1% chlorotrimethylsilane (TMCS)) at 100° for 60 min and determined by GC-MS with HP-5 MS capillary column in the selected-ion monitoring mode. The intense fragment ions were chosen as monitoring ions for quant. anal. Cholesterol was

CC

ΙT

TΤ

ST ΙΤ

ΤТ

used as an internal standard Column temperature gradient: initial temperature 180° maintained 1 min, and then increased at 20° min-1 to 260° , and finally at 2° min-1 up to 300° maintained 2 min. The retention times of GA, GB, GC, and BB were 13.7,14.3,15.3 and 6.8 min, the major fragmentation ions (monitoring) were at m/z 537, 625, 713, and 455 (299), the average recoveries of GA, GB, GC and BB were 102.0, 99.4, 96.0, and 96.3%, RSD 0.54, 2.4, 1.98, and 2.43%, resp. The method was repeatable, specific, accurate, and easy to operate, and suitable for quality and quantity anal. of terpene lactones from G. biloba leaves. 63-4 (Pharmaceuticals) Gas chromatography Ginkgo biloba Mass spectrometry (terpene lactones in Ginkgo biloba leaves) 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7 , Ginkgolide B 33570-04-6, Bilobalide RL: NPO (Natural product occurrence); BIOL (Biological study); OCCU (Occurrence) (terpene lactones in Ginkgo biloba leaves) OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS) L35 ANSWER 34 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2003:608626 HCAPLUS Full-text DOCUMENT NUMBER: 139:185402 TITLE: Ginkgo preparations AUTHOR(S): Kressmann, Sabine CORPORATE SOURCE: Pharmakologisches Institut fuer Naturwissenschaftler, Frankfurt am Main, D-60439, Germany Deutsche Apotheker Zeitung (2003), 143(18), SOURCE: 61-66,69-73 CODEN: DAZEA2; ISSN: 0011-9857 Deutscher Apotheker Verlag PUBLISHER: DOCUMENT TYPE: Journal; General Review LANGUAGE: German A review is given on the pharmaceutical quality of Ginkgo biloba-containing prepns. from the US American market. The content of flavone glycosides, terpene lactones, and ginkgolic acid varied considerable. The bioavailability is discussed. 63-0 (Pharmaceuticals) Section cross-reference(s): 64 review Ginkgo flavone glycoside terpene lactone ginkgolic acid chromatog Terpenes, analysis RL: ANT (Analyte); ANST (Analytical study) (lactones; pharmaceutical quality of Gingko prepns.) Chromatography Ginkgo biloba Quality control (pharmaceutical quality of Gingko prepns.) OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS) REFERENCE COUNT: THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS 4 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L35 ANSWER 35 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2003:598252 HCAPLUS Full-text DOCUMENT NUMBER: 140:70227 Liquid chromatography/atmospheric pressure chemical TITLE: ionization ion trap mass spectrometry of terpene

lactones in plasma of animals

Nizal Chandrakumar 10/579,162 AUTHOR(S): Mauri, Pierluigi; Minoggio, Markus; Iemoli, Loredana; Rossoni, Giuseppe; Morazzoni, Paolo; Bombardelli, Ezio; Pietta, Piergiorgio CORPORATE SOURCE: Istituto Tecnologie Biomediche-CNR, Segrate, Milan, 20090, Italy SOURCE: Journal of Pharmaceutical and Biomedical Analysis (2003), 32(4-5), 633-639CODEN: JPBADA; ISSN: 0731-7085 PUBLISHER: Elsevier Science B.V. DOCUMENT TYPE: Journal LANGUAGE: English Liquid chromatog./atmospheric pressure chemical ionization ion trap mass AΒ spectrometry (LC/APCI-ITMS) was applied to evaluate the bioavailability of two different forms (free and complexed with soy phospholipids) of pure bilobalide and ginkgolide B in rats after acute administration. The same technique was used to measure the levels of ginkgolide A, B and bilobalide in plasma of quinea pigs fed Ginkgo biloba extract enriched in terpene lactones after chronic administration. The ratio RP/RA increased two to four times after the administration in the phytosomic form, where RP and RA represent the percentage ratio between the concentration of each terpene lactone in plasma and in the administered form, resp. CC 1-2 (Pharmacology) Section cross-reference(s): 11, 63 liquidchromatog atm pressure chem ionization iontrap massspectrometry ST Ginkqo plasma; bilobalide qinkqolide phospholipid complex pharmacokinetics bronchodilator bioavailability airway inflammation Bronchodilators ΙT Drug bioavailability Ion trap mass spectrometry Liquid chromatography (LC APCI ITMS of Ginkgo terpene lactones in plasma) ΙΤ Ginkgo biloba (ginkgoterpene enriched extract; LC APCI ITMS of Ginkgo terpene lactones in plasma) Terpenes, biological studies ΤТ RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PKT (Pharmacokinetics); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses) (lactones; LC APCI ITMS of Ginkgo terpene lactones in plasma) 15291-75-5P, Ginkgolide A 15291-77-7DP, Ginkgolide B, ΙΤ complexed with soy phospholipids 15291-77-79, Ginkgolide B 33570-04-6DP, Bilobalide, complexed with soy phospholipids 33570-04-6P, Bilobalide RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PKT (Pharmacokinetics); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (LC APCI ITMS of Ginkgo terpene lactones in plasma) OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS) REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L35 ANSWER 36 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN

2003:118417 HCAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: 138:150364

TITLE:

Method for isolating terpene trilactones (ginkgolides, bilobalide) from leaves and pharmaceutical powders of

Ginkgo biloba

INVENTOR(S): Lichtblau, Dirk; Berova, Nina; Berger, John;

Nakanishi, Koji

PATENT ASSIGNEE(S): The Trustees of Columbia University in the City of New

York, USA

SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S.

Ser. No. 903049, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030031736	A1	20030213	US 2002-194089	20020711
US 6590109	B2	20030708		
AT 343393	T	20061115	AT 2002-748132	20020711
US 20040077883	A1	20040422	US 2003-615346	20030707
US 6844451	B2	20050118		
US 20050136136	A1	20050623	US 2005-36409	20050114
PRIORITY APPLN. INFO.:			US 2001-903049	B2 20010711
			US 2002-194089	A1 20020711
			US 2003-615346	A1 20030707

AB A method of isolating terpene trilactones from Ginkgo biloba plant material or extract comprising the steps of suspending the plant material or extract in either water or an aqueous solution of an oxidation reagent; extracting the terpene trilactones using an acceptable extraction agent; separating the organic layer from the aqueous layer; washing the organic layer with an acceptable aqueous salt or hydroxide solution, which may be an alkaline solution; and drying the organic layer to form a dried extract containing terpene trilactones. Further purification by treatment with or filtration over activated charcoal, by treatment with or filtration over alumina and by recrystn. with an acceptable solvent or solvent mixture leads to exts. with a content of terpene trilactones higher than 50%. Unwanted levels of ginkgolic acids are reduced to acceptable levels by reversed phase chromatog.

IC ICM C07D311-78

ICS C07D498-14; A61K035-78

INCL 424752000; 549280000

CC 11-1 (Plant Biochemistry)

Section cross-reference(s): 63

IT Ginkgo biloba

and

(extraction of terpene trilactones (ginkgolides, bilobalide) from leaves

pharmaceutical powders of Ginkgo biloba)

IT Reversed phase chromatography

(for isolating terpene trilactones (ginkgolides, bilobalide) from Ginkgo biloba)

IT Terpenes, biological studies

RL: NPO (Natural product occurrence); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)

(lactones; extraction of terpene trilactones

(ginkgolides, bilobalide) from leaves and pharmaceutical powders of Ginkgo biloba)

IT Extraction

(of terpene trilactones (ginkgolides, bilobalide) from leaves and pharmaceutical powders of Ginkgo biloba)

IT 15291-75-5P, Ginkgolide A 15291-76-6P, Ginkgolide C 15291-77-7P, Ginkgolide B 33570-04-6P, Bilobalide 107438-79-9P, Ginkgolide J

RL: NPO (Natural product occurrence); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)

(extraction of terpene trilactores (ginkgolides, bilobalide) from leaves and pharmaceutical powders of Ginkgo biloba)

IT 64-19-7, Acetic acid, reactions 144-55-8, Sodium bicarbonate, reactions 497-19-8, Sodium carbonate, reactions 584-08-7, Potassium carbonate 1310-58-3, Potassium hydroxide, reactions 1310-73-2, Sodium hydroxide, reactions 7647-01-0, Hydrochloric acid, reactions 7664-38-2, Phosphoric acid, reactions 7664-93-9, Sulfuric acid, reactions 7697-37-2, Nitric acid, reactions 7722-84-1, Hydrogen peroxide, reactions 7757-83-7, Sodium sulfite 7772-98-7, Sodium thiosulfate 12125-02-9, Ammonium chloride, reactions 16721-80-5, Sodium hydrosulfide

RL: RGT (Reagent); RACT (Reactant or reagent)

(extraction of terpene trilactones (ginkgolides, bilobalide) from leaves

and

pharmaceutical powders of Ginkgo biloba)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L35 ANSWER 37 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2003:57921 HCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 138:112404

TITLE: Method for isolating terpene trilactones (ginkgolides,

bilobalide) from leaves and pharmaceutical powders of

Ginkgo biloba

INVENTOR(S): Litchblau, Dirk Andreas; Berger, John; Berova, Nina;

Nakanishi, Koji

PATENT ASSIGNEE(S): The Trustees of Columbia University in the City of New

York, USA

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.				KIND DATE					APPL	ICAT	ION 1	DATE					
WO	2003	0060	40				WO 2002-US22101					20020711					
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	TM,	TN,	TR,	TT,	TZ,
		UA,	UG,	US,	UΖ,	VN,	YU,	ZA,	ZM,	ZW							
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	BG,
		CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	IE,	ΙΤ,	LU,	MC,	NL,
		PT,	SE,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,
		ΝE,	SN,	TD,	ΤG												
CA	2453	467			A1		2003	0123		CA 2	002-	2453	467		2	0020	711
AU	2002	3183	05		A1		2003	0129		AU 2	002-	3183	05		2	0020	711
EP	1416	949			A1		20040	0512		EP 2	002-	7481	32		2	0020	711
EP	1416	949			В1		2006	1025									
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	SK		
AT	3433	93			Τ		2006	1115		AT 2	002-	7481	32		2	0020	711
HK	1065	939			A1		20070	0525		HK 2	004-	1085	87		2	0041	101
ORITY	Y APP	LN.	INFO	. :						US 2	001-	9030	49		A2 2	0010	711

WO 2002-US22101 W 20020711

AB A method of isolating terpene trilactones from Ginkgo biloba plant material or extract comprising the steps of suspending the plant material or extract in either water or an aqueous solution of an oxidation reagent; extracting the terpene trilactones using an acceptable extraction agent; separating the organic layer from the aqueous layer; washing the organic layer with an acceptable aqueous salt or hydroxide solution, which may be an alkaline solution; and drying the organic layer to form a dried extract containing terpene trilactones. Further purification by treatment with or filtration over activated charcoal, by treatment with or filtration over alumina and by recrystn. with an acceptable solvent or solvent mixture leads to exts. with a content of terpene trilactones higher than 50%. Unwanted levels of ginkgolic acids are reduced to acceptable levels by reversed phase chromatog.

IC ICM A61K035-78 ICS C07D307-77

CC 63-4 (Pharmaceuticals)

IT Extraction

Ginkgo biloba

(extraction of terpene trilactones (ginkgolides, bilobalide) from leaves

and

pharmaceutical powders of Ginkgo biloba)

IT Terpenes, biological studies

RL: NPO (Natural product occurrence); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)

(lactones; extraction of terpene trilactones

(ginkgolides, bilobalide) from leaves and pharmaceutical powders of Ginkgo biloba)

IT 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide c 15291-77-7, Ginkgolide B 33570-04-6, Bilobalide 107438-79-9, Ginkgolide j RL: NPO (Natural product occurrence); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses) (extraction of terpene trilactores (ginkgolides, bilobalide) from leaves and pharmaceutical powders of Ginkgo biloba)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 38 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2002:775502 HCAPLUS Full-text

DOCUMENT NUMBER: 138:210425

TITLE: HPLC determination of flavonoids and terpene lactones

in commercial Ginkgo biloba products

AUTHOR(S): Li, Wenkui; Fitzloff, John F.

CORPORATE SOURCE: Functional Foods for Health (FFH) Core Analytical

Laboratory, Program for Collaborative Research in Pharmaceutical Sciences and Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, 60612,

USA

SOURCE: Journal of Liquid Chromatography & Related

Technologies (2002), 25(16), 2501-2514

CODEN: JLCTFC; ISSN: 1082-6076

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

AB Ginkgo biloba products are one of the top ten botanical dietary supplements in the USA. The active constituents include flavonoids and terpene lactones

(ginkgolides and bilobalide). Ginkgo flavonoids were associated with reduced lipid peroxidn. in vascular walls and nerve cells. Ginkgolides are well known to be antagonists of platelet-activating factor (PAF). Usually, enriched ginkgo exts. used for the preparation of ginkgo products are standardized to contain 24% flavonoids and 6% terpene lactones. In the present work, we examined nine com. ginkgo products for the content of total flavonoids and terpene lactones by using high performance liquid chromatog. (HPLC) with UV and evaporative light scattering detection (ELSD), resp. The methods are reliable and sensitive with detection limits of 2 ng for flavonoids on column with HPLC-UV and 20-35 ng for terpene lactones on column with HPLC-ELSD. The results show that most of the com. ginkgo products tested contain flavonoids and terpene lactones as claimed on the label.

CC 64-2 (Pharmaceutical Analysis)

ST flavonoid terpene lactone detn HPLC; liq chromatog detn flavonoid terpene lactone

IT Ginkgo biloba

HPLC

(determination of flavonoids and terpene lactones in com. Ginkgo biloba by HPLC)

IT 117-39-5, Quercetin 480-19-3, Isorhamnetin 520-18-3, Kaempferol 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B 33570-04-6, Bilobalide 107438-79-9, Ginkgolide J RL: ANT (Analyte); ANST (Analytical study)

(determination of flavonoids and terpene lactones in com. Ginkgo biloba by HPLC)

OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS

RECORD (15 CITINGS)

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 39 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2002:713329 HCAPLUS Full-text

DOCUMENT NUMBER: 137:389076

TITLE: Efficient Extraction of Ginkgolides and Bilobalide

from Ginkgo biloba Leaves

AUTHOR(S): Lichtblau, Dirk; Berger, John M.; Nakanishi, Koji CORPORATE SOURCE: Department of Chemistry, Columbia University, New

York, NY, 10027, USA

SOURCE: Journal of Natural Products (2002), 65(10), 1501-1504

CODEN: JNPRDF; ISSN: 0163-3864

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

An efficient and rapid protocol has been developed for extracting ginkgolides and bilobalide (terpene trilactones) from Ginkgo biloba leaves. The procedure takes advantage of the extraordinary stability of the terpene trilactone structure to a variety of chemical treatments, especially oxidation, despite the presence of multiple oxygen functions. The protocol involves boiling the aqueous extract of leaves with dilute hydrogen peroxide, extraction with Et acetate, washing with basic solns., and charcoal filtration to yield an offwhite powder, terpene trilactone content 60-70%. It is likely that the hydrogen peroxide treatment degrades the undesired leaf constituents that lead to intense emulsification during extns. Further reversed-phase chromatog. of the exts. with polymeric resins removes the undesirable ginkgolic acids to amts. less than 10 ppm. The exts. are suited for pure terpene trilactone preparation, enrichment of terpene trilactone content in nutraceuticals, and prepns. of low-flavonoid/high-terpene trilactone controls in medicinal studies. The four ginkgolides (ginkgolides A, B, C, J) and bilobalide isolated from the extract were identical in all respects with authentic specimens.

```
CC
     63-4 (Pharmaceuticals)
     Section cross-reference(s): 11
ΙT
    Extraction
      Ginkgo biloba
     Oxidation
        (efficient extraction of ginkgolides and bilobalide from Ginkgo biloba
        leaves)
     Triterpenes
TΤ
     RL: NPO (Natural product occurrence); PEP (Physical, engineering or
     chemical process); PYP (Physical process); BIOL (Biological study); OCCU
     (Occurrence); PROC (Process)
        (lactones; efficient extraction of ginkgolides and bilobalide from
        Ginkgo biloba leaves)
OS.CITING REF COUNT:
                         20
                               THERE ARE 20 CAPLUS RECORDS THAT CITE THIS
                               RECORD (20 CITINGS)
REFERENCE COUNT:
                         33
                               THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
L35 ANSWER 40 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:
                         2001:658748 HCAPLUS Full-text
DOCUMENT NUMBER:
                         136:74753
                        Analysis of terpenelactones in Ginkgo biloba by high
TITLE:
                        performance liquid chromatography and evaporative
                        light scattering detection
                        Ganzera, Markus; Zhao, Jianping; Khan, Ikhlas A.
AUTHOR(S):
                        National Center for Natural Products Research,
CORPORATE SOURCE:
                        Research Institute of Pharmaceutical Sciences, The
                        University of Mississippi, University, MS, 38677, USA
SOURCE:
                        Chemical & Pharmaceutical Bulletin (2001), 49(9),
                         1170-1173
                        CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER:
                        Pharmaceutical Society of Japan
DOCUMENT TYPE:
                        Journal
LANGUAGE:
                        English
     A reversed phase HPLC method permitting the determination of 5 terpenelactones
     in Ginkgo biloba, without the need of any sample preparation is presented in
     this paper. The compds. were successfully separated within 25 min by using a
     C-12 column, an evaporative light scattering (ELS) detector and a mobile phase
     comprising of ammonium acetate buffer, methanol and isobutanol. All
     terpenelactones were detectable at concns. as low as 20.3 \mug/mL. The anal. of
     G. biloba market products showed remarkable variations in the lactone content,
     and more than 2 fold differences in the suggested daily doses of the total
     lactones, from 8.84 mg to 18.28 mg, resp.
     64-2 (Pharmaceutical Analysis)
CC
    terpene lactone detn HPLC Ginkgo biloba; liq chromatog detn terpenelactone
ST
ΙT
    Ginkgo biloba
      HPLC
        (anal. of terpenelactones in Ginkgo biloba by high performance liquid
        chromatog. and evaporative light scattering detection)
     Terpenes, analysis
TΤ
     RL: ANT (Analyte); ANST (Analytical study)
        (lactones; anal. of terpenelactones in Ginkgo
       biloba by high performance liquid chromatog, and evaporative
        light scattering detection)
     15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7
     , Ginkgolide B 33570-04-6, Bilobalide 107438-79-9, Ginkgolide J
     RL: ANT (Analyte); ANST (Analytical study)
        (anal. of terpenelactones in Ginkgo biloba by high
        performance liquid chromatog, and evaporative light scattering
       detection)
```

OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS

RECORD (25 CITINGS)

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 41 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2001:571842 HCAPLUS Full-text

DOCUMENT NUMBER: 135:376882

TITLE: Assay of terpene lactones in Ginkgo biloba leaves by

RP-HPLC- ELSD

AUTHOR(S): Yan, Yuzhen; Xie, Peishan

CORPORATE SOURCE: Guangzhou Institute for Drug Control, Canton, 510160,

Peop. Rep. China

SOURCE: Yaowu Fenxi Zazhi (2001), 21(3), 173-176

CODEN: YFZADL; ISSN: 0254-1793

PUBLISHER: Yaowu Fenxi Zazhi Bianji Weiyuanhui

DOCUMENT TYPE: Journal LANGUAGE: Chinese

AB Ginkgolide A, B, C and bilobalide in Ginkgo biloba leaves were determined simultaneously by RP-HPLC-ELSD. Methanolic exts. (10%) of the leaves were cleaned up by solid phase extraction via polyamide cartridge and silica gel cartridge successively and the sample solns. were prepared RP-HPLC anal. was carried out on a C18 column with MeOH-H2O as mobile phase, eluted in gradient mode, detected by evaporated light scattering detector. The key step for getting precise data was pre-treatment of the leaves extract through normal phase SPE cartridge and the poor linear response of ELSD could be compensated by multilevel calibration and logarithm calcn. The G. biloba leaves obtained from different area, different growth years and different collection seasons were determined and the contents of ginkgolide A, B, C and bilobalide in G. biloba leaves were different. It was significant for the quality control of the herbal medicine.

CC 64-2 (Pharmaceutical Analysis)

ST terpene lactone detn Ginkgo HPLC; HPLC light scattering terpene detn; liq chromatog terpene lactone detn

IT Ginkgo biloba

Plant analysis

Reversed phase HPLC

(determination of terpene lactones in Ginkgo biloba leaves by RP-HPLC-ELSD)

IT Terpenes, analysis

RL: ANT (Analyte); ANST (Analytical study)

(lactones; determination of terpene lactones in Ginkgo

biloba leaves by RP-HPLC-ELSD)

IT Liquid chromatographic detectors

(light-scattering; determination of terpene lactones in Ginkgo biloba leaves by

RP-HPLC-ELSD)

IT 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7

, Ginkgolide B 33570-04-6, Bilobalide

RL: ANT (Analyte); ANST (Analytical study)

(determination of terpene lactones in Ginkgo biloba leaves by RP-HPLC-ELSD)

L35 ANSWER 42 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2001:473178 HCAPLUS Full-text

DOCUMENT NUMBER: 135:266581

TITLE: Liquid chromatography/atmospheric pressure chemical

ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L.

extracts

AUTHOR(S): Mauri, Pierluigi; Simonetti, Paolo; Gardana, Claudio;

Minoggio, Markus; Morazzoni, Paolo; Bombardelli, Ezio;

Pietta, Piergiorgio

CORPORATE SOURCE: Istituto Tecnologie Biomediche Avanzate - CNR, Milan,

20090, Italy

SOURCE: Rapid Communications in Mass Spectrometry (2001),

15(12), 929-934

CODEN: RCMSEF; ISSN: 0951-4198

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB Liquid chromatog./atmospheric pressure chemical ionization mass spectrometry (LC/APCI-ITMS) was applied to evaluate the levels of ginkgolides A and B and bilobalide in plasma of volunteers after administration of Ginkgo biloba exts. in free (Ginkgoselect) or phospholipid complex (Ginkgoselect Phytosome) forms, providing 9.6 mg of total terpene lactones. The maximum plasma concns., Cmax, of total ginkgolides A, B and bilobalide were 85.0 and 181.8 μg/mL for Ginkgoselect and Ginkgoselect Phytosome, resp. The Cmax values were reached at 120 min for the free form and at 180-240 min for the phospholipid complex form. In both cases, the mean elimination half-life of each terpene lactone was in the range 120-180 min. Due to its sensitivity (.apprx.1 ng/mL) and specificity, LC/APCI-ITMS proved to be a very powerful tool for pharmacokinetic studies of these phytochems.

CC 1-1 (Pharmacology)

IT Chemical ionization mass spectrometry

(atmospheric-pressure; liquid chromatog./atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. exts.)

IT Ginkgo biloba

HPLC

(liquid chromatog./atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with $Ginkgo\ biloba\ L.\ exts.)$

IT Blood analysis

(plasma; liquid chromatog./atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. exts.)

IT Lactones

DOCUMENT NUMBER:

RL: ANT (Analyte); ANST (Analytical study)

(terpene; liquid chromatog./atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. exts.)

IT 15291-75-5, Ginkgolide A 15291-77-7, Ginkgolide B
33570-04-6, Bilobalide

RL: ANT (Analyte); ANST (Analytical study)

(liquid chromatog./atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. exts.)

OS.CITING REF COUNT: 33 THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (33 CITINGS)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 43 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2001:405494 HCAPLUS <u>Full-text</u>

TITLE: Selective dissolution and one step separation of

terpene trilactones in Ginkgo leaf extracts for GC-FID

determination

AUTHOR(S): Lang, Q.; Yak, Hwa Kwang; Wai, C. M.

135:200547

CORPORATE SOURCE: Department of Chemistry, University of Idaho, Moscow,

ID, 83844-2343, USA

SOURCE: Talanta (2001), 54(4), 673-680

CODEN: TLNTA2; ISSN: 0039-9140

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

Durder ultrasonication, the Ginkgo terpene trilactones, ginkgolides and bilobalide, in Ginkgo exts. can be selectively dissolved in 10% aqueous NaH2PO4 solution at a temperature of 50-60° and separated from the solution by extraction with a mixture of EtOAc/THF in a capped vial. After derivatization, these terpene trilactones were quantified by using GC-FID. This method had a detection limit of 10 ng, and the RSD was 6%. Twelve com. GBE products in powder, liquid, tablet and capsule forms were analyzed. The total time required for analyzing these samples from sample preparation to final data processing was <6 h, and the total organic solvent consumption was <40 mL. This procedure is a simple, fast, safe, and effective method for all types of Ginkgo biloba exts. including the "complex" or "advanced" formulations.

CC 64-2 (Pharmaceutical Analysis) Section cross-reference(s): 63

ST terpene trilactone detn Ginkgo gas chromatog

IT Gas chromatography Ginkgo biloba

(dissoln. and separation of terpene trilactones in Ginkgo exts. for GC-FID determination)

IT Terpenes, analysis

RL: ANT (Analyte); PRP (Properties); ANST (Analytical study) (lactones; dissoln. and separation of terpene trilactones in Ginkgo leaf exts. for GC-FID determination)

IT 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7

, Ginkgolide B 107438-79-9, Ginkgolide J

RL: ANT (Analyte); PRP (Properties); ANST (Analytical study) (dissoln. and separation of terpene trilactores in Ginkgo exts. for GC-FID determination)

TOT GC FID decelminacion

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD

(8 CITINGS)

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 44 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2001:58319 HCAPLUS Full-text

DOCUMENT NUMBER: 134:262980

TITLE: The application of a novel adsorbent in rapid sample

clean-up of ginkgolides and bilobalide in extracts of

Ginkgo biloba leaves

AUTHOR(S): Xu, Mingcheng; Xu, Mancai; Shi, Zuoqing; Liu, Juxiang;

Shi, Rongfu; He, Binglin

CORPORATE SOURCE: The State Key Laboratory of Functional Polymeric

Materials for Adsorption and Separation, Institute of Polymer Chemistry, Nankai University, Tianjin, 300071,

Peop. Rep. China

SOURCE: Chinese Journal of Reactive Polymers (2000), 9(1),

60-66

CODEN: CJRPEH; ISSN: 1004-7646

PUBLISHER: Nankai University, Institute of Polymer Chemistry

DOCUMENT TYPE: Journal LANGUAGE: English

AB A rapid method has been developed for rapid sample clean-up in the determination of the pharmacol. active terpenoid including ginkgolide A, B, C and bilobalide in ginkgo biloba leaves exts. (GBE). The exts. are dissolved

in 7% of ethanol aqueous solution and then purified by a highly selective polymeric adsorbent solid-phase chromatog. column. After being concentrated, the separated terpenoids with no phenolic disturbance are determined by high-performance liquid chromatog. on a Nova-Pak C18 column with methanol-water (30:70) as effluent and refractive index detection. The recovery of the method is about 95% and the new method saves more time than the conventional two-column purification method.

CC 9-3 (Biochemical Methods)

Section cross-reference(s): 11

IT Chromatography

(adsorbents; application of a novel adsorbent in rapid sample clean-up in exts. of Ginkgo biloba leaves)

IT Ginkgo biloba

HPLC stationary phases

Hydrogen bond

(application of a novel adsorbent in rapid sample clean-up in exts. of Ginkgo biloba leaves)

IT Adsorbents

(chromatog.; application of a novel adsorbent in rapid sample clean-up in exts. of Ginkgo biloba leaves)

IT Terpenes, biological studies

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(lactones; application of a novel adsorbent in rapid sample

clean-up in exts. of Ginkgo biloba leaves)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 45 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2000:775495 HCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 134:9446

TITLE: Separation and isolation of terpene lactones from Ginkgo biloba L. by direct high performance liquid

chromatography

AUTHOR(S): Tang, Yuping; Lou, Fengchang

CORPORATE SOURCE: China Pharmaceutical University, Nanjing, 210038,

Peop. Rep. China

SOURCE: Journal of Liquid Chromatography & Related

Technologies (2000), 23(18), 2897-2900

CODEN: JLCTFC; ISSN: 1082-6076

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

AB Isolation of terpene lactones, i.e., Bilobalide, Ginkgolides A, B, C and J in pure form from Ginkgo biloba leaves by a preparative high performance liquid chromatog, procedure was described.

CC 64-3 (Pharmaceutical Analysis)

IT Ginkgo biloba

HPLC

(separation and isolation of terpene lactones from Ginkgo biloba L. by direct high performance liquid chromatog.)

IT Terpenes, analysis

RL: ANT (Analyte); ANST (Analytical study)

(separation and isolation of terpene lactones from Ginkgo biloba

L. by direct high performance liquid chromatog.)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD

(2 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 46 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2000:766968 HCAPLUS Full-text DOCUMENT NUMBER: 134:53282 Rapid analysis of terpene lactones in extract of TITLE: Ginkgo biloba L. by high performance liquid chromatography Wang, Hai-feng; Ju, Xing-rong AUTHOR(S): Anal. and Test centre of Cereal, Oil and Foodstuffs, CORPORATE SOURCE: Nanjing Institute of Economics, Nanjing, 210003, Peop. Rep. China Sepu (2000), 18(5), 394-397 SOURCE: CODEN: SEPUER; ISSN: 1000-8713 PUBLISHER: Kexue Chubanshe DOCUMENT TYPE: Journal LANGUAGE: English A new rapid anal. method was developed for the quantification of terpene lactones (bilobalide (BB) and ginkgolide A,B,C,J) in extract of Ginkgo biloba L. (EGb) using a liquid-liquid solvent extraction procedure followed by high performance liquid chromatog. EGb was dissolved in 30% ethanol and extracted with ether. After evaporation, the residue was then determined by HPLC on a C18 column with methanol-water-orthophosphoric acid (25:75:0.1, V/V) as eluent and refractive index (RI) detection. Results showed that the excellent sample clean-up procedure is more simple and specific, and saves more time (less than 20 min) than any other methods that have been reported, and also leads to high recoveries (>99.0%) and low RSDs (<2.0%). The reproducible method is regarded to be very useful for evaluating the quality of extract of Ginkgo biloba L. 9-3 (Biochemical Methods) CC Section cross-reference(s): 11, 30 Ginkqo terpene lactone bilobalide qinkqolide HPLC; liq chromatoq Ginkqo terpene lactone bilobalide ginkgolide Terpenes, analysis ΙΤ RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence) (lactones; rapid anal. of terpene lactones in extract of Ginkgo biloba L. by high performance liquid chromatog.) ΙT Extraction Ginkgo biloba HPLC Plant analysis (rapid anal. of terpene lactones in extract of Ginkgo biloba L. by high performance liquid chromatog.) 15291-76-6, Ginkgolide C 15291-77-7 15291-75-5, Ginkgolide A , Ginkgolide B 33570-04-6, Bilobalide 107438-79-9, Ginkgolide J RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence) (rapid anal. of terpene lactones in extract of Ginkgo biloba L. by high performance liquid chromatog.) OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS) REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L35 ANSWER 47 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2000:316563 HCAPLUS Full-text DOCUMENT NUMBER: 133:125364

High-performance liquid chromatographic

determination methods of terpene lactones from Ginkgo

TITLE:

biloba

AUTHOR(S): Lu, Ding-qiang; Chen, Jun

CORPORATE SOURCE: School of Biological and Environmental Engineering,

Jiangsu University of Science and Technology,

Zhenjiang, 212013, Peop. Rep. China

SOURCE: Jiangsu Ligong Daxue Xuebao (2000), 21(2), 22-26

CODEN: JLDXFT; ISSN: 1007-1741

PUBLISHER: Jiangsu Ligong Daxue Xuebao Bianjishi

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Chinese

AB A review with 21 refs. Ginkgolides and bilobalide are the main components with benefic clin. efficacy in Ginkgo biloba leaf exts. and Ginkgo prepns. So the qual. and quant. analyses in determining ginkgolides and bilobalide are important. At present the reverse-phase high-performance liquid chromatog. (HPLC) methods are more suitable and popular. According to different detectors, the HPLC methods are divided into three divisions: HPLC-UV, HPLC-refractive index (RI), HPLC-evaporated light scattering detection (ELSD) and HPLC-Mass spectrometry (MS). The review and comparison of the published HPLC methods, and the clean-up procedures of sample are given.

CC 64-0 (Pharmaceutical Analysis)

IT Ginkgo biloba

HPLC

(high-performance liquid chromatog. determination methods of terpene lactones from Ginkqo biloba)

IT Terpenes, analysis

RL: ANT (Analyte); ANST (Analytical study)

(lactones; high-performance liquid chromatog. determination methods of terpene lactones from Ginkgo biloba)

IT 33570-04-6, Bilobalide

RL: ANT (Analyte); ANST (Analytical study)

(high-performance liquid chromatog. determination methods of terpene lactones from Ginkqo biloba)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L35 ANSWER 48 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2000:222468 HCAPLUS Full-text

DOCUMENT NUMBER: 133:55457

TITLE: Determination of five kinds of ginkgolides in Ginkgo

biloba leaves extract by reversed-phase high

performance liquid chromatography

AUTHOR(S): Zhang, Jian; Pan, Jian; Xie, Huiming; Yang, Zhiyi; Hu,

Xueqiao; Yanq, Ke

CORPORATE SOURCE: Institute of Bi-mechanical & Electrical Engineering,

Hefei University of Technology, Hefei, 230069, Peop.

Rep. China

SOURCE: Fenxi Huaxue (2000), 28(1), 53-56

CODEN: FHHHDT; ISSN: 0253-3820

PUBLISHER: Zhongquo Huaxuehui "Fenxi Huaxue" Bianji Weiyuanhui

DOCUMENT TYPE: Journal LANGUAGE: Chinese

AB In this paper, five kinds of ginkgolides (A, B, C, J, BB) in Ginkgo biloba leaves extract was determined by reversed-phase high performance liquid chromatog. at the first time. The Waters Symmetry-C18 column (3.9 mm x 150 mm, 5 μ m) and column temperature was 30°, 24% (V/V) methanol as mobile phase and detector was refractometer (model: waters 410, sensitivity: 1024). The calibration curve was linear in the range of 0.02.apprx.0.40 g/L, r = 0.9814.apprx.0.9934; recovery: 93.2% .apprx. 97.4% and RSD: 1.27% .apprx. 2.68%, different ginkgolides determination limit from 2.07 to 3.98 mg/L. This

```
method is sensitive, reproducible and easy to operate. The condition of
     column can be enlarging for preparing-scale high performance liquid chromatog.
CC
     9-3 (Biochemical Methods)
     Section cross-reference(s): 11, 64
     detn ginkgolide Ginkgo biloba leaf; reversed phase high performance liq
ST
     chromatog
ΙT
     Ginkgo biloba
     Leaf
       Reversed phase HPLC
        (determination of five kinds of ginkgolides in Ginkgo biloba leaves extract
by
        reversed-phase high performance liquid chromatog.)
ΙT
     Terpenes, analysis
     RL: ANT (Analyte); ANST (Analytical study)
        (lactones; determination of five kinds of ginkgolides in Ginkgo
        biloba leaves extract by reversed-phase high performance liquid
        chromatog.)
     15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C
                                                           15291-77-7,
ΤТ
     Ginkgolide B 33570-04-6 107438-79-9, Ginkgolide J
     RL: ANT (Analyte); ANST (Analytical study)
        (determination of five kinds of ginkgolides in Ginkgo biloba leaves extract
by
        reversed-phase high performance liquid chromatog.)
                               THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
OS.CITING REF COUNT:
                         4
                               (4 CITINGS)
L35 ANSWER 49 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:
                         2000:12273 HCAPLUS Full-text
DOCUMENT NUMBER:
                         132:227524
TITLE:
                        Liquid chromatography/electrospray mass spectrometry
                         of bioactive terpenoids in Ginkgo biloba L.
AUTHOR(S):
                         Mauri, Pierluigi; Migliazza, Barbara; Pietta,
                         Piergiorgio
                         ITBA/CNR, Milan, 20090, Italy
CORPORATE SOURCE:
                         Journal of Mass Spectrometry (1999), 34(12), 1361-1367
SOURCE:
                        CODEN: JMSPFJ; ISSN: 1076-5174
PUBLISHER:
                         John Wiley & Sons Ltd.
                         Journal
DOCUMENT TYPE:
LANGUAGE:
                         English
     Standardized exts. of G. biloba leaves are mainly used in the treatment of
     peripheral and cerebral circulation disorders, and also as a remedy against
     asthma, coughs, bladder inflammation, blenorrhagia and alc. abuse. The leaf
     exts. contain biflavones, flavonol glycosides and terpene lactones. This
     paper reports a method based on liquid chromatog. coupled with electrospray
     mass spectrometry for the anal. of terpenoids in G. biloba exts. This method
     allows the rapid isocratic separation of underivatized ginkgolides (A, B, C
     and J) and bilobalide at very low levels (10 pg on the column) and their
     quant. detection by external standardization with relative standard deviations
     of 3 and 5% for intra- and inter-day analyses, resp.
CC
     64-2 (Pharmaceutical Analysis)
     liq chromatog mass spectrometry terpenoid Ginkgo; HPLC mass spectrometry
     terpenoid detection Ginkgo; ginkgolide detection Ginkgo chromatog mass
     spectrometry; electrospray mass spectrometry Ginkgo terpenoid
     Glycosides
ΙT
     RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
     unclassified); ANST (Analytical study); BIOL (Biological study); OCCU
        (flavonoid; liquid chromatog./electrospray mass spectrometry of
        bioactive terpenoids in Ginkgo biloba exts..)
ΙT
     Terpenes, analysis
```

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence) (lactones; liquid chromatog./electrospray mass spectrometry of bioactive terpenoids in Ginkgo biloba exts..) ΙT Mass spectrometry Mass spectrometry (liquid chromatog, combined with; liquid chromatog ./electrospray mass spectrometry of bioactive terpenoids in Ginkgo biloba exts..) Electrospray ionization mass spectrometry ΙT Ginkgo biloba HPLC (liquid chromatog./electrospray mass spectrometry of bioactive terpenoids in Ginkgo biloba exts..) RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence) (liquid chromatog./electrospray mass spectrometry of bioactive terpenoids in Ginkgo biloba exts..) Liquid chromatography ΙT Liquid chromatography (mass spectrometry combined with; liquid chromatog ./electrospray mass spectrometry of bioactive terpenoids in Ginkgo biloba exts..) 153-18-4, Quercetin 3-0-rutinoside 604-80-8, Isorhamnetin 3-0-rutinoside ΙT 15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7, Ginkgolide B 17650-84-9, Kaempferol 3-O-rutinoside 32453-37-5 32690-74-7 33570-04-6, Bilobalide 107190-70-5 107190-71-6 107438-79-9, Ginkgolide J 175089-93-7 261353-22-4 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence) (liquid chromatog./electrospray mass spectrometry of bioactive terpenoids in Ginkgo biloba exts..) OS.CITING REF COUNT: 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS) THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 20 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L35 ANSWER 50 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 1999:334416 HCAPLUS Full-text DOCUMENT NUMBER: 131:134473 TITLE: An Extraction Method for Determination of Ginkgolides and Bilobalide in Ginkgo Leaf Extracts AUTHOR(S): Lang, Qingyong; Wai, C. M. CORPORATE SOURCE: Department of Chemistry, University of Idaho, Moscow, ID, 83844, USA SOURCE: Analytical Chemistry (1999), 71(14), 2929-2933 CODEN: ANCHAM; ISSN: 0003-2700 PUBLISHER: American Chemical Society DOCUMENT TYPE: Journal LANGUAGE: English On the basis of reversible ionization and intramol. esterification, ginkgolides can be effectively removed from Ginkgo extract products or from Ginkgo leaves with boiling water containing 0.1% Na2HPO4 at pH 8 followed by extraction of the aqueous phase with methylene chloride at pH 5. Bilobalide was quant. removed from these samples by boiling water followed by the same liquid/liquid extraction After derivatization with

```
bis(trimethylsilyl)acetamide, these lactone terpenoids were readily quantified
     using GC-FID with baseline separation Using the proposed procedure, 6
     different com. Ginkgo biloba products were analyzed, and significant
     differences in their ginkgolide contents were observed
CC
     63-4 (Pharmaceuticals)
     Section cross-reference(s): 9, 64
ST
     ginkgolide extn Ginkgo gas chromatog
    Extraction
TΤ
      Gas chromatography
       Ginkgo biloba
     Plant analysis
        (extraction method for determination of ginkgolides and bilobalide in
Ginkgo leaf
       exts.)
    Diterpenes
ΙT
      Diterpenes
     RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
     unclassified); PEP (Physical, engineering or chemical process); ANST
     (Analytical study); BIOL (Biological study); OCCU (Occurrence); PROC
     (Process)
        (lactones; extraction method for determination of ginkgolides and
        bilobalide in Ginkgo leaf exts.)
OS.CITING REF COUNT:
                         24
                               THERE ARE 24 CAPLUS RECORDS THAT CITE THIS
                               RECORD (24 CITINGS)
                               THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
REFERENCE COUNT:
                         19
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
L35 ANSWER 51 OF 51 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:
                        1998:794528 HCAPLUS Full-text
DOCUMENT NUMBER:
                         130:57289
TITLE:
                         Determination of terpene lactones in extract of Ginkgo
                         biloba L. by TLC scanning
AUTHOR(S):
                         Tang, Yuping; Lou, Fengchang; Zheng, Weiping
CORPORATE SOURCE:
                        China Pharmaceutical University, Nanjing, 210008,
                        Peop. Rep. China
                        Yaowu Fenxi Zazhi (1998), 18(5), 305-307
SOURCE:
                         CODEN: YFZADL; ISSN: 0254-1793
PUBLISHER:
                         Yaowu Fenxi Zazhi Bianji Weiyuanhui
DOCUMENT TYPE:
                         Journal
LANGUAGE:
                         Chinese
     The content determination of ginkgolides A, B, C and bilobalide in extract of
AΒ
     G. biloba L. leaves by a TLC scanning method was studied. A methanol solution
     of the ethanol extract of Ginkgo leaves was dispersed on a silica gel GF254-
     0.5% sodium CM-cellulose plate using acetoacetic acid-toluene-acetone as the
     dispersing agent to a distance of 16 cm. The fluorescence was observed under
     365 nm UV light. The method is simple, rapid, accurate, reproducible and of
     wide linear range.
CC
     64-2 (Pharmaceutical Analysis)
     Section cross-reference(s): 11
TΤ
    Ginkgo biloba
     Plant analysis
       TLC (thin layer chromatography)
        (determination of terpene lactones in Ginkgo biloba exts. by TLC scanning
        method)
     Terpenes, analysis
ΙT
     RL: ANT (Analyte); ANST (Analytical study)
        (lactones; determination of terpene lactones in Ginkgo
        biloba exts. by TLC scanning method)
     15291-75-5, Ginkgolide A 15291-76-6, Ginkgolide C 15291-77-7
ΤТ
     , Ginkgolide B 33570-04-6, Bilobalide
```

RL: ANT (Analyte); ANST (Analytical study) (determination of terpene lactones in Ginkgo biloba exts. by TLC scanning method) OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS) => d his ful (FILE 'HOME' ENTERED AT 16:46:19 ON 27 OCT 2009) FILE 'CAPLUS' ENTERED AT 16:46:25 ON 27 OCT 2009 E US2007-579162/APPS 1 SEA SPE=ON ABB=ON PLU=ON US2007-579162/AP T.1 SEL RN FILE 'REGISTRY' ENTERED AT 16:46:37 ON 27 OCT 2009 L214 SEA SPE=ON ABB=ON PLU=ON (100-39-0/BI OR 106-95-6/BI OR 107438-79-9/BI OR 15291-75-5/BI OR 15291-76-6/BI OR 15291-77-7/ BI OR 170288-58-1/BI OR 17690-16-3/BI OR 2746-25-0/BI OR 33570-04-6/BI OR 4392-24-9/BI OR 502421-88-7/BI OR 534-17-8/BI OR 584-08-7/BI) L3 1 SEA SPE=ON ABB=ON PLU=ON 852046-13-0/BI 15 SEA SPE=ON ABB=ON PLU=ON L2 OR L3 L4FILE 'CAPLUS' ENTERED AT 16:46:49 ON 27 OCT 2009 1 SEA SPE=ON ABB=ON PLU=ON L4 AND L1 L_5 D IALL HITSTR FILE 'STNGUIDE' ENTERED AT 16:47:42 ON 27 OCT 2009 FILE 'REGISTRY' ENTERED AT 16:47:47 ON 27 OCT 2009 E TERPENE TRILACTONE/CN FILE 'STNGUIDE' ENTERED AT 16:48:22 ON 27 OCT 2009 FILE 'CAPLUS' ENTERED AT 16:53:43 ON 27 OCT 2009 E GINGKO BILOBA/CT E GINKO BILOBA/CT E GINKGO BILOBA/CT E E3+ALL FILE 'HCAPLUS' ENTERED AT 16:54:54 ON 27 OCT 2009 L6 4569 SEA SPE=ON ABB=ON PLU=ON GINKGO BILOBA+PFT.NT/CT E TERPENES+ALL/CT 2201 SEA SPE=ON ABB=ON PLU=ON TERPENES+PFT,NT/CT(L)?LACTON? L7184 SEA SPE=ON ABB=ON PLU=ON L7 AND L6 $\Gamma8$ E SEPARATION+ALL/CT L9 1075549 SEA SPE=ON ABB=ON PLU=ON SEPARATION+PFT,NT/CT L10 83 SEA SPE=ON ABB=ON PLU=ON L9 AND L8 L11 1 SEA SPE=ON ABB=ON PLU=ON L10 AND L1 D SCA 49 SEA SPE=ON ABB=ON PLU=ON L10 AND ?CHROMATOG?

FILE 'STNGUIDE' ENTERED AT 16:59:29 ON 27 OCT 2009

L12

FILE 'HCAPLUS' ENTERED AT 17:11:22 ON 27 OCT 2009

FILE 'REGISTRY' ENTERED AT 17:11:24 ON 27 OCT 2009 E GINKGOLIDE A/CN

	Wizar Chandrakumar 10/3/3,102
L13	1 SEA SPE=ON ABB=ON PLU=ON "GINKGOLIDE A"/CN E GINKGOLIDE B/CN
L14	1 SEA SPE=ON ABB=ON PLU=ON "GINKGOLIDE B"/CN E GINKGOLIDE C/CN
L15	1 SEA SPE=ON ABB=ON PLU=ON "GINKGOLIDE C"/CN E GINKGOLIDE J/CN
L16	1 SEA SPE=ON ABB=ON PLU=ON "GINKGOLIDE J"/CN
L17	4 SEA SPE=ON ABB=ON PLU=ON (L13 OR L14 OR L15 OR L16)
шт,	SEL RN
L18	
пто	OR 15291-76-6/CRN OR 15291-77-7/CRN)
L19	
птэ	12 SEA SPE-ON ADD-ON PLO-ON LI/OR LIO
	FILE 'HCAPLUS' ENTERED AT 17:13:33 ON 27 OCT 2009
L20	97 SEA SPE=ON ABB=ON PLU=ON L19(L)PUR/RL
L21	
ш∠т	I SEA SIE-ON ABB-ON I BO-ON BZO AND BI
	FILE 'REGISTRY' ENTERED AT 17:13:50 ON 27 OCT 2009
	E CK203/MF
	E K2CO3/MF
L22	1 SEA SPE=ON ABB=ON PLU=ON L4 AND K/ELS
1122	D SCA
	SEL RN
L23	
1125	E DIMETHYL FORMAMIDE/CN
	E DIMETHYLFORMAMIDE/CN
L24	1 SEA SPE=ON ABB=ON PLU=ON DIMETHYLFORMAMIDE/CN
D2 4	D SCA
L25	0 SEA SPE=ON ABB=ON PLU=ON L24 AND L4
пи	SEL RN L24
L26	
L27	0 SEA SPE=ON ABB=ON PLU=ON L26 AND L4
П2 /	E BENZYL BROMIDE/CN
L28	1 SEA SPE=ON ABB=ON PLU=ON "BENZYL BROMIDE"/CN
120	D SCA
	SEL RN
L29	118 SEA SPE=ON ABB=ON PLU=ON L28 OR 100-39-0/CRN
227	TIO DELI DIE ON TED ON TED ON TEO ON TOO OF ON
	FILE 'HCAPLUS' ENTERED AT 17:19:59 ON 27 OCT 2009
L30	117 SEA SPE=ON ABB=ON PLU=ON L20 OR L19(L)(?ISOLAT? OR ?PURIF?)
100	III DELI DIE ON TED ON TED ON ELO ON ELO (I) (.100EII. ON .10NII.)
L31	4 SEA SPE=ON ABB=ON PLU=ON L30 AND (L23 OR L26 OR L29)
L32	1 SEA SPE=ON ABB=ON PLU=ON L1 AND L31
L33	40 SEA SPE=ON ABB=ON PLU=ON L30 AND ?CHROMATOG?
L34	4 SEA SPE=ON ABB=ON PLU=ON L31 AND L33
L35	51 SEA SPE=ON ABB=ON PLU=ON L34 OR L12
	FILE 'HCAPLUS' ENTERED AT 17:21:49 ON 27 OCT 2009
	D QUE L35
	D L35 IBIB ABS HITIND TOT